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Modeling and Estimation for the Renal System 
Benjamin J. Czerwin 
 
Understanding how a therapy will impact the injured kidney before being administered 
would be an asset to the clinical world. The work in this thesis advances the field of 
mathematical modeling of the kidneys to aid in this cause. The objectives of this work are 
threefold: 1) to develop and personalize a model to specific patients in different diseased states, 
via parameter estimation, in order to test therapeutic trajectories, 2) to use parameter estimation 
to understand the cause of different kidney diseases, differentiate between potential kidney 
diseases, and facilitate targeted therapies, and 3) to push forward the understanding of kidney 
physiology via physiology-based mathematical modeling techniques. To accomplish these 
objectives, we have developed two models of the kidneys: 1) a broad, steady-state, closed-loop 
model of the entire kidney with human physiologic parameters, and 2) a detailed, dynamic model 
of the proximal tubule, an important part of kidney, with rat physiologic parameters. To readily 
aid physicians, a human model would easily fit into the clinical workflow. Since there is a lack 
of invasive human renal data for validation and parameter estimation, we employ a minimal 
modeling approach. However, to aid in deeper understanding of renal function for future 
applications, targeted therapy testing, and potentially replace invasive measures, we develop a 
more detailed model. The development of such a model requires invasive data for validation and 
parameter estimation, and hence we model for rodents, where such invasive data are more 
readily available.  
 
 
The kidneys are composed of approximately one million functional units known as 
nephrons. The glomerular filtration rate (GFR) is the rate at which the kidney filters blood at the 
start of the nephron. This filtration rate is highly regulated via several control mechanisms and 
needs to be maintained within a small range in order to maintain a proper water and electrolyte 
balance. Hence, fluctuations of GFR are indicative of overall kidney health. In developing the 
human kidney model, we also sought to understand the relationship between blood pressure and 
GFR since many therapies affect blood pressure and subsequently GFR. This model describes 
steady-state conditions of the entire kidney, including renal autoregulation. Model validation is 
performed with experimental data from healthy subjects and severely hypertensive patients. The 
baseline model’s GFR simulation for normotensive and the manually tuned model’s GFR 
simulation for hypertensive intensive care unit patients had low root mean squared errors 
(RMSE) of 13.5 mL/min and 5 mL/min, respectively. These values are both lower than the error 
of 18 mL/min in GFR estimates, reported in previous studies. It has been shown that vascular 
resistance and renal autoregulation parameters are altered in severely hypertensive stages, and 
hence, a sensitivity analysis is conducted to investigate how changes in these parameters affect 
GFR. The results of the sensitivity analysis reinforce the fact that vascular resistance is inversely 
related to GFR and show that changes to either vascular resistance or renal autoregulation cause 
a significant change in sodium concentration in the descending limb of Henle. This is an 
important conclusion as it quantifies the mapping between hypertension parameters and two 
important kidney states, GFR and sodium urine levels. 
Glomerulonephritis is one of the two major intra-renal kidney diseases, characterized as a 
breakdown at the site of the glomerulus that affects GFR and subsequently other portions of the 
nephron. This disease accounts for 15% of all kidney injuries and one-fourth of end-stage renal 
 
 
disease patients. The human kidney model is used to estimate renal parameters of patients with 
glomerulonephritis. The model is an implicit system and in developing an optimization algorithm 
to use for parameter estimation, we modify in a novel way, the Levenberg-Marquardt 
optimization using the implicit function theorem in order to calculate the Jacobian and Hessian 
matrices needed. We further adapt the optimization algorithm to work for constrained 
optimization since our parameter values must be physiologically feasible within a certain range. 
The parameter estimation method we use is a three-step process: 1) manually adjusting 
parameters for the hypertension comorbidity, 2) iteratively estimating parameters that vary from 
person to person using no-kidney-injury (NKI) data, and 3) iteratively estimating parameters that 
are affected by glomerulonephritis using labeled diseased data. Such a process generates a model 
that is personalized to each given patient. This patient-specific model can then be used to 
simulate and evaluate outcomes of potential therapies (e.g., vasodilators) on the model in lieu of 
the patient, and observe how alterations in blood pressure or sodium level affect renal function. 
Parameter estimation in the presence of glomerulonephritis is a challenging task due to the 
complexity of the kidney physiology and the number of parameters to estimate. This is further 
complicated by comorbidities such as hypertension, cardiac arrythmia, and valvular disease, 
because they alter kidney physiology and hence, increase the number of parameters to estimate. 
We chose to focus on hypertension since it is very prevalent in hospitals and intensive care units. 
It was found that over all patients, average model estimates of GFR and urine output rate (UO) 
were within 9.2 mL/min and 0.71 mL/min for NKI data. These results are expectedly better than 
those achieved from the non-personalized model since the parameters are now specific to each 
patient. The results also demonstrate our ability to non-invasively estimate GFR with less error 
than the 18 mL/min currently possible. The estimations were validated by ensuring that the 
 
 
estimated parameter values were physiologically sound and matched the literature in terms of 
expected values for different demographic groups. 
It is vital for a properly functioning kidney to maintain solute transport throughout the 
nephron. Kidney diseases in the nephron can manifest themselves via the solute transport 
mechanisms. To understand how these diseases affect the kidney and to simulate transporter-
targeting therapies, we have developed a detailed model, starting from the human model 
previously developed, of one portion of the kidneys, the proximal tubule. The proximal tubule is 
the site of the most active transport within the nephron and the target for several therapies. Our 
goal is to study and understand the dynamic behavior of the proximal tubule when solute 
transporters breakdown and to investigate treatment therapies targeting certain solute 
transporters. The proposed model is dynamic and includes several solutes’ transport 
mechanisms, with parameters for rats. We chose to investigate diabetic nephropathy and the 
associated sodium-transporter alteration (knockout) therapy. Diabetic nephropathy is 
characterized as kidney damage due to diabetes and affects 30% of diabetics. In terms of 
reducing hyperfiltration, a potential cause of diabetic nephropathy where an overabundance of 
solutes and fluid are filtered at the glomerulus, the model demonstrates that knockout of this 
transporter results in a reduction in sodium and chloride reabsorptions in the proximal tubule, 
thereby preventing hyperfiltration. Further, we conclude that vital flows for maintaining kidney 
homeostasis, fluid and ammonium reabsorptions, are corrected to healthy values by a 50% 
knockout (impairment) of the sodium-hydrogen transporter. 
Next, we use the dynamic model to detect different diseased states of the proximal tubule 
transporters. We have accomplished this task by using Bayesian estimation to estimate 
transporter density parameters (a metric for kidney health) using measured signals from the 
 
 
proximal tubule. This approach is validated with experimental rat data, while further 
investigations are conducted into the performance of the estimation in the presence of varied 
input signals, signal resolutions, and noise levels. Estimation accuracy within 20% of true 
transporter density and within 4% of true fluid and solute reabsorption was achieved for all 
combinations of diseased transporters. We concluded that including chloride and bicarbonate 
concentrations improved estimation accuracy, whereas including formic acid did not. This is an 
important conclusion as it can help physicians determine which blood tests to order for 
diagnosing kidney disease; to our knowledge, this is a first. It was also found that sodium and 
glucose proximal tubule concentrations are most affected by changes in the sodium-hydrogen 
and sodium-bicarbonate transporters. This conclusion provides insight into the interplay between 
solute transporter density and sodium and glucose concentrations in the proximal tubule. Such 
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Chapter 1: Introduction & Physiology Overview 
1.1 Introduction 
The kidneys are a vital organ for survival in all vertebrates. Malfunction of this closely 
regulated organ can have disastrous consequences. The kidneys can be subjected to several 
diseases of local origin including the necrosis of portions of the kidney. Further, several diseases 
of the heart and lungs can have secondary effects on the kidneys [1], [2]. This is evidenced by 
the fact that over 30% of patients in the intensive care unit (ICU) subsequently develop kidney 
complications [3]. Furthermore, therapies for the  heart and lung diseases may negatively affect 
the kidneys [2]. According to Goyal et al. [4], “AKI [Acute Kidney Injury] is one of the most 
clinically impactful diseases since it affects patient management to a great extent in terms of the 
treatment options for their primary disease.” With the use of the physiology-based models 
developed in this work, a further understanding of kidney physiology can be obtained. In 
conjunction, these models, via parameter estimation, can be used to determine and differentiate 
potential kidney diseases for a specific patient. Finally, with these models, therapy scenarios can 
be tested before administration to patients. 
The main functions of the kidneys can be summarized by the following list [5]: 
1. Regulation of water and electrolyte balance 
2. Excretion of metabolic waste 
3. Excretion of bioactive substances (hormones, drugs, etc.) 
4. Regulation of arterial blood pressure 
5. Regulation of red blood cell production 




7. Gluconeogenesis (glucose generation) 
The kidneys filter the entire blood supply approximately 40 times per day. This process filters 
approximately 120 mL of blood per minute. In large part, around 99% of filtrate is returned to 
the blood supply after initial filtration. 
 Local diseases that can affect the kidneys can be divided into three categories, prerenal, 
intrarenal, and postrenal [6]. Prerenal diseases are characterized by affects to renal perfusion. 
Postrenal diseases typically include obstructions to the collecting system. Intrarenal diseases can 
largely be subdivided into two categories, glomerulonephritis and tubular necrosis. 
Glomerulonephritis diseases are those that predominantly affect the glomerulus (the first site of 
filtration in the kidney). Tubular necrosis is the death of cells in the tubules of the kidneys that 
can have dramatic effects on fluid and solute reabsorption. 
 As mentioned above, the kidneys can also be affected by adjacent organ diseases. An 
important example of this is the lung-kidney crosstalk which describes the acid-base balance that 
is pivotal to maintain in the body. This balance is achieved by the lungs and kidneys, and 
disruptions to one of these organs can dramatically affect the other [1]. Another example 
includes heart disease, which affects blood pressure and hence renal perfusion [2]. 
In recent years, kidney health and physiology has begun to receive more attention. 
Nephrologists have started to explore the use of biomarkers from blood tests to preemptively 
detect kidney disease [7]. Along with this, guidelines to diagnosis kidney injury are continually 
being updated with the most recent update to the Kidney Disease: Improving Global Outcomes 
(KDIGO) guidelines occurring in 2012 [8]. In large part, kidney disease diagnosis, especially in 
the ICU, utilizes these guidelines, which take into account patient demographics, urine output, 




to the late indicators used as inputs. The outputs of the guidelines are also nonspecific in the 
sense that they cannot differentiate between the type of renal disease. And, serum creatinine in 
particular, can vary greatly between demographics and, though adjustments are included in the 
guidelines, can be an unreliable determinant of GFR and kidney health [9]. 
One of the goals of this work is to offer another method, that can be used in conjunction 
with current techniques, leveraged by nephrologists, to save the lives of kidney disease patients. 
This method is physiology-based modeling. Physiology-based modeling is the process of 
developing equations describing a physiological system where the equations are derived from 
physical principals and phenomena. Unlike machine learning or statistical approaches to 
modeling, in physiology-based modeling, all equation parameters represent real, physical 
qualities of the system. This characteristic of the parameters allows us to describe diseases via 
changes to these parameters. It also allows us to detect the presence of diseases via altered 
parameters. 
Physiology-based models comprise several continuity equations that make use of the 
conservation of mass principal and other constraint equations. In developing these models, we 
consider several spatial locations throughout the kidney that we subsequently discretize based on 
function and call nodes. At each of these spatial locations/nodes, we are interested in hydraulic 
pressure and flow, solute concentrations and flows, and electrical voltages. Therefore, at each 
node the model will have values for all of these variables. For a functional understanding of the 
kidneys, and unlike a real patient, where invasive variable measurement is not always an option, 
a model can provide values for these variables. This allows us to look deep into the kidney 
without the need for invasive measurements. For instance, the variable that is often considered to 




cannot be measured directly. Currently, this variable is estimated based on demographics and 
serum creatinine blood levels. However, with the model, we can in fact directly observe the 
output value of GFR. 
In order to simulate any model, we need to feed the model a set of inputs and a current set 
of parameter values. From the simulation, we are presented with a set of outputs. Therefore, the 
outputs of the model can change either due to input changes or parameter changes. Typically, 
other organ diseases will alter inputs (e.g., blood perfusion) and parameters of the kidney. 
Kidney specific diseases will manifest as changes to only kidney parameters such as co-
transporter coefficients. From person to person, there are physical differences between kidneys. 
For instance, the number of nephrons (functional unit of the kidneys) is variable between people, 
ranging from 100,000 to 1,350,000  nephrons per kidney [10]. Similarly, with age there is a 
natural sclerosis of the tubules and this will also differ from person to person [11]. Hence, for a 
model to represent an individual person, parameter values would need to be changed to 
correspond to that individual. With a physiology-based model, this is possible through manual 
parameter tuning or parameter estimation techniques. The parameter estimation of a 
physiological model utilizes known or measured inputs and outputs for a particular patient to 
estimate that patient’s parameter values. Essentially, this is the process of finding suitable values 
for the parameters that create a mapping from inputs to outputs. This represents the main 
motivation for this work, that is, the development of a kidney model and process that can be 
personalized to patients. This is a step toward personalized medicine. 
In the current state of medicine, physiological model-based applications are few and far 
between. However, the incorporation of such a model fits nicely. As described in Fig. 1.1, such a 




can then be interpreted by a physician to determine the next steps in that patients’ care. For 
instance, a physician would now have access to model generated GFR values, and estimated 
parameters. As will be seen in Chapter 5, specialized solute transporter parameter values in the 
proximal tubule can be estimated to differentiate between potential diseases affecting this region. 
A physician can use these values to rule out potential diseases affecting the kidneys. Therapy 
testing is another way to utilize physiologic models. As described above, often, therapies that 
combat heart disease may have negative impacts on kidney function. The physiological models 
developed here allow for therapy administration to the model to observe outputs before actual 
administration to patients. This allows physicians to determine if certain therapies will negatively 
impact the kidneys or determine the level by which the therapy should be administered to reduce 
negative impacts on the kidneys. This is described, for example, by administration of 
vasodilators to patients with high blood pressure. This reduction in blood pressure will begin to 
affect GFR and kidney health almost immediately. As will be investigated, the optimal blood 
pressure to maintain healthy kidney function can be determined via the model. This is only 





Fig. 1.1: A high-level schematic showing the workflow of a physician. The addition to the 
current workflow, using the work done in this thesis (dotted box) is included when a 
physiological model is available. 
The evidence and motivation for a physiology-based kidney model is overwhelming and 
scientists since the early 1980s have begun to develop more and more powerful models of the 
kidneys. Perhaps the father of kidney modeling, Dr. Alan Weinstein has forged the path into 
kidney modeling culminating to his work thusly in [12]. Other scientists, Drs. Anita Layton and  
Aurélie Edwards have continued to advance this field and summarized, in great detail, many of 
the modeling techniques that have been used, in a textbook [13]. In our work, we continue the 
advancement of kidney modeling by developing a steady-state human kidney model that is 
developed with attention to avoid the potential issue of overfitting and while considering the 















differences from person to person. We developed this model as a minimal model since the 
available invasive data for humans is scarce. This model is then personalized to specific patients 
via parameter estimation. This allows the model to be incorporated into physician workflows as 
described above. In addition, a highly detailed, lumped proximal tubule model that addresses 
some of the simulation issues associated with a differential-algebraic equation and analyzes a 
previously proposed diabetic therapy, is then developed. Further, we utilize this model to 
investigate how parameter estimation can be used to differentiate potential tubular diseases and 
test hypothetical therapies. 
The other main motivation for this work is to further understand the kidney physiology as 
a whole. Namely, with the development of these models, we can view inside the kidney. We can 
observe how variables respond to changing inputs and parameter values. This type of 
understanding is gained through scenario testing and sensitivity analyses. In scenario testing, we 
can alter input parameter values and simulate the model to observe how pressures, 
concentrations, and flows respond in the nephron. Therapies can be simulated via scenario 
testing as well, where the parameter and input changes due to the therapy are administered to the 
model. This can lead to the development of therapies that may impact certain model variables in 
unpredictable ways. In sensitivity analyses, we alter parameter values and observe how the 
model responds.  This type of analysis allows for observing relative impact of parameter values 
on variables. In Chapter 2, we investigate how changing feedback gains and vascular resistances 
(both parameters that characterize the system) affects GFR and sodium concentrations 
throughout the nephron. We are able to draw and verify conclusions that are hitherto not possible 




1.2 Thesis Organization 
The structure of the thesis is as follows: 
Chapter 1 is an introduction providing the motivation and importance for this research. It also 
describes the scope of this work and provides a physiological overview of how the kidneys 
function. 
Chapter 2 details the derivation of a steady-state, closed-loop human kidney model. The model 
is validated against human data from the literature and from publicly available databases. Model 
outputs are studied under the influence of changing inputs and parameter values. 
Chapter 3 uses the model developed in Chapter 2, to explore how parameter estimation can be 
used to personalize the model to diseased patients. The model and parameter estimation 
technique are validated against real patient data and through robustness testing. 
Chapter 4 provides a detailed derivation of a rigorous dynamic proximal tubule kidney model 
with rodent parameters. This model is then analyzed through the lens of a potential therapy 
technique to mitigate hyper-reabsorption for diabetics. Further, analysis into how to solve and 
determine stability for this differential-algebraic set of equations comprising the model is 
conducted. 
Chapter 5 uses the model developed in Chapter 4, to investigate how tubule transporter 
parameter estimation can be utilized. Bayesian estimation technique is developed and employed 
to determine tubule transporter parameter values (and hence presence of a disease). Validation is 
done on rat data. Further, we determine which measurement signals are needed to successfully 
differentiate between tubule transporter diseases.  
Chapter 6 concludes the dissertation and discusses further research that can be conducted based 




1.3 Physiology Overview 
Here we present a brief overview of the kidney physiology. As previously mentioned, the 
main function of the kidneys is to regulate water and electrolyte balance [5]. This function is 
vital for survival. The kidneys, much like the lungs, comprises several smaller functional units 
working in unison to achieve an end goal. For the kidneys, these functional units are called 
nephrons. Nephrons are tubules, of varying lengths, dimensions, permeabilities, and filtration 
coefficients. An anatomical layout of a nephron can be seen in Fig. 1.2. Throughout the nephron, 
the balances of solutes and fluids are maintained. A human kidney comprises approximately one 





Fig. 1.2: Nephron anatomy schematic. 
Upon entering the kidney, the renal artery bifurcates several times until it forms 
glomeruli (one glomerulus per nephron). These glomeruli primarily employ ultrafiltration 
(filtration based on solute size) on entering fluid and solutes to form filtrate in Bowman’s space. 
The filtrate (plasma composed of the fluid and solutes that passed through the glomeruli) will be 
reabsorbed back into the blood in large part (or completely) by the nephron before reaching the 
ureters. The non-reabsorbed fluids or solutes will move axially through the nephron to be 




















Fig. 1.3: Flow of fluid and solute through the kidney. Renal blood flow begins from the green 
block, is filtered at the yellow block, and ends at one of the two red blocks. Arrows indicate 
the allowable direction of flow. In the nephron, flow to the interstitial fluid is known as 
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There is an exchange of solutes and blood between the nephron and the capillaries that 
wrap around the tubules. These blood vessels carry the unfiltered fluid and solutes from the 
glomerulus. Solutes and fluids must pass through the interstitial fluid bathing the tubules and 
capillaries in order to move between the tubules and capillaries. Approximately 67% of the fluid 
and 65% of the sodium filtered from the glomerulus is returned to the blood in the first segment 
of the nephron alone  [5], [14]. 
Each segment of the nephron is shown in Fig. 1.3. This first segment of the nephron is 
known as the proximal tubule. The proximal tubule comprises a convoluted and a straight 
portion. Fluid and sodium are reabsorbed in essentially equal parts in this section, deemed the 
glomerulotubular balance. From the proximal tubule, filtrate moves to the loop of Henle. The 
loop of Henle can be further subdivided into the thin descending, thin ascending, and thick 
ascending portions. The descending portion of the loop of Henle is said to be impermeable to 
solute transverse transport and therefore only fluid is exchanged between this segment and the 
interstitial fluid. The ascending portions of the loop of Henle are impermeable to fluid transport 
but permit solute reabsorption. This difference between both segments allows for a highly 
concentrated urine to be formed deep within the kidney in the loop of Henle. Following the loop 
of Henle is the distal convoluted tubule. From here, several nephrons are reunited via the 
collecting ducts which further drain into larger collecting ducts until finally forming the renal 
calyx and then ureters to be transported to the bladder. Reabsorption in the distal tubules and 
collecting ducts is variable and based on the physiological state of the body. 
There are two predominant types of nephrons: superficial (cortical) and juxtamedullary. 
Superficial nephrons have a shorter loop of Henle which penetrate only to the cortical region of 




to the center of the kidney. Superficial nephrons comprise approximately 85% of the nephrons in 
humans [22]. 
In Fig. 1.4, we see a block diagram of renal autoregulation, as well as the specific 
membranes by which solutes and fluids must traverse at the glomerulus and nephron. Glomerular 
filtration occurs across three distinct membranes, the fenestration level, the basement membrane, 
and the pedicels. The fenestration level is purely filtration based on size as these fenestrations are 
pores in the glomerular endothelium. The gel-like basement membrane is the least understood 
membrane, but generally the agreed upon main function is to restrict small proteins from passing 
via an electrical selectivity process. Generally speaking, no proteins should be filtered out by the 
glomerulus. The final method of filtration are the podocytes or foot process that are interleaved, 
with tiny slits that employ ultrafiltration. 
Renal function is a highly controlled mechanism, one with several active concurrent 
control loops. We begin with the myogenic response. This mechanism uses the smooth muscles 
of the afferent arteriole to sense the pressure and subsequently change the resistance through the 
afferent arteriole via constriction or dilation. The function of the myogenic response, along with 
many of the other feedback mechanisms, is to control the flow of blood into the glomerulus and 
hence maintain a healthy glomerular filtration rate (GFR). 
The tubuloglomerular feedback mechanism accomplishes the same goal via a sensor in 
the distal convoluted tubule. Here, the macula densa cells sense the salt concentration at this part 
of the nephron. These cells, via the specialized JG (juxtaglomerular) cells that surround the 
afferent arteriole will be used to stimulate the afferent arteriole to dilate or constrict depending 
on the salt levels. Essentially, a change in GFR will eventually alter the salt levels in the distal 




The most intricate renal autoregulation method is the renin-angiotensin mechanism. This 
feedback involves several organs with a direct effect on the kidneys. In general, the kidneys 
release renin which reacts with angiotensin that is produced by the liver and circulating 
throughout the body. These reactants create angiotensin I. ACE inhibitors in the blood stream 
will react with angiotensin I to form angiotensin II. Angiotensin II stimulates the adrenal glands 
that then releases aldosterone. Both the angiotensin II and the aldosterone have the effect of 
altering mean arterial pressure (MAP) and hence directly affecting renal perfusion. This 
feedback mechanism will again alter the GFR via the change in renal perfusion. The beginning 
of this process is the release of renin by the kidneys. The renin levels in the blood are controlled 
by the kidneys and stimulation or inhibition of the release of renin is a direct function of the JG 
cells. Hence, these JG cells are both the sensor for the renin-angiotensin mechanism and 
tubuloglomerular feedback. 
The final main control mechanism of the kidney is neural feedback. This feedback is not 
directly controlled by the kidneys; however, it has a direct effect on the kidneys. As blood 
pressure changes in the body, there will be a neural response brought on by the baroreceptors 
that sense blood pressure, to constrict or dilate the vasculature in the body. This will directly 
affect all the renal vasculature including, most importantly, the afferent arteriole that will directly 
affect GFR. 
These control mechanisms, along with the specialized nature of each segment allow for 
the kidneys to maintain the fluid and electrolyte balance within the body, in a tightly controlled 
range. While there are natural state fluctuations in the body (e.g., exercise, sleep, etc.), the 




breaks down, then we see how the system responds in order to compensate. A breakdown of a 





Fig. 1.4: Block diagram describing the main four renal autoregulation mechanisms: the 
myogenic mechanism, tubuloglomerular feedback, the renin-angiotensin mechanism, and 
neural feedback. This diagram also includes the membranes and mechanisms of filtration for 
the glomerulus and nephrons. PG is the glomerular pressure, RA is the afferent arteriole 



































































































































Chapter 2: Human Closed-Loop Kidney Model - Development, 
Validation, & Analysis of Filtration Rate 
2.1 Introduction 
Organ diseases altering blood pressure directly affect kidney function, since the renal 
artery is the blood supplier of the kidneys. The kidneys are a vital organ, whose main functions 
are to regulate water and electrolyte balance, and to excrete metabolic waste and bioactive 
substances [5]. Determining an appropriate mean arterial pressure (MAP) for renal perfusion and 
glomerular filtration rate (GFR) is significant for a doctor administering therapy [15]. This 
represents the first step in one of our primary objectives for this work, which would potentially 
allow physicians to test therapies and alterations on a physiological model before doing so on a 
patient. Once this model is developed and validated (this chapter), it will subsequently be 
personalized in Chapter 3: 
There are several human models of the kidney [16][17][18][19] . A few of them have 
been developed based on adjustments of rat models [16][17][18]. Rat models are typically the 
starting point for kidney modeling since invasive rat data is widely available and rat renal 
physiology is similar to human renal physiology. Further, the more complex a model, the greater 
the number of parameters that are needed. Models [16][17][18], are developed using partial 
differential equations and algebraic constraint equations. For humans, these models adapt rat 
vessel dimensions to those of humans and then adjust certain transporter density parameters to 
match desired human outputs. The complex transport phenomena that characterize the kidneys 
are described via many parameters (coefficients) in transport equations. With increasing 




approach to ensure we are only using the necessary parameters to capture the structure of the 
system without including parameters that cannot be validated. 
Moss et al. [20] use a lumped parameter approach to dynamically model salt and fluid for 
an entire rat kidney that reduces the number of parameters, but it is naturally not suitable for 
human applications. Hallow et al. [18] modeled hyperabsorption in human diabetic kidneys, 
focusing only on water and sodium transport. This model assumes negligible pressure drop 
across the glomerulus, limiting the modeling of glomerular filtration. Another model from 
Hallow and Gebremichael [21], describes the development of what they deem a core model, one 
that can be used as a starting point for different studies and modeling endeavors. Their model is 
similar to [18] in its use of physiologic parameters and modeling techniques, but may suffer from 
possible overfitting due to a large number of parameters, 20 of which were simply tuned to make 
the data fit their model. In this work, however, we have used a minimal number of parameters to 
capture the relationship between mean arterial pressure and GFR. This was done to 1) avoid 
potential overfitting and 2) due to the fact that invasive human measurements are needed to 
validate internal states of the kidney are not widely available. Uttamsingh et al. [19] uses a 
piecewise linear function adapted from a dog to model GFR as MAP changes in humans. 
However, this approach is prohibitive in simulating impaired feedback and its effect on GFR. 
Other models, as also mentioned in [7], are phenomenological models, which suffer from the 
inability to determine which specific mechanistic segments of the kidneys have changed. The 
parameters of a physiological model, on the other hand, when estimated, indicate specific kidney 
insults, as diseases are represented by parameter alterations. Currently, the MDRD (Modification 
of Diet in Renal Disease) is the method most used clinically in estimating GFR, as described in 




most notably its inaccuracy when GFR is above 60 mL/min/1.73m2, where it is expressed as mL 
per min per square meter of body surface area. Therefore, in normal kidney function, this 
equation is not reliable, and often labs simply report GFR above 60 mL/min/1.73m2 as normal. 
Further, this equation has no predictive capabilities since the inputs to this equation (age, sex, 
race, and creatinine) are not described functionally as related to blood pressure or other variables. 
Another commonly used equation for estimating GFR is CKD-EPI (Chronic Kidney Disease 
Epidemiology Collaboration). This equation is largely cited as being more accurate than the 
MDRD equation [23]. However, with identical inputs, it has similar drawbacks in predicting 
GFR as the MDRD equation. 
We develop a human kidney model that uses a minimal set of adjustable parameters 
while still capturing the essential physiology and avoids overfitting. Our steady-state, closed-
loop (i.e., with feedback signaling the afferent arteriole to dilate or constrict) model is a set of 
algebraic equations produced by lumping several spatial locations together, thus minimizing our 
equation set and parameters needed to run the model. In our model, we have several unknown 
hydraulic resistance values along the nephron that are needed for simulation.  We use 
constrained trust-region optimization to validate the feasibility of the hydraulic resistance 
parameter values throughout the nephron by ensuring that the dimensions estimated via the 
optimization are physiologically sound. We calculate a pressure at the glomerulus, removing the 
negligible pressure drop assumption across the glomerulus. In doing so, we are able to determine 
GFR while  making use of the Starling equation [5]. The model is validated against real human 
data collected from ICU patients [24] and published studies [25]. This model can aid in renal 
therapy via generation of a GFR-MAP relation and simulation of impaired feedback and 




following chapter, using a Levenberg-Marquardt optimization parameter estimation technique, to 
determine the optimal therapy for an individual patient. 
2.2 Methods 
In this section, we will first describe some model assumptions, then the formulation of 
model equations, parameters, and finally the physiological feedback mechanisms. Recall, we use 
a first-principle, physiologic approach to modeling in order to understand the inner workings of 
the system via physiological parameters. The equations of motion (derived in the sections to 
follow) are a nonlinear algebraic system of equations comprising (2.1) – (2.12), are based on 
kidney physiology, and are derived via continuity equations. The complete system of equations 
can be seen in 2.2.5 and is solved with Newton’s method in MATLAB®. 
With the aim of assessing the relation between blood pressure and GFR, we model the 
movement of fluid throughout the kidney. The flow of fluid throughout the kidney can be altered 
by tubuloglomerular feedback (TGF), which is a function of sodium concentration in the distal 
tubule. Hence, since we model TGF, we also model the movement of sodium throughout the 
nephron to be able to compute sodium concentrations in the distal tubule. 
To accomplish this modeling task, the kidney is discretized into several spatial locations 
(nodes) based on physiological reabsorption similarities between nodes. A schematic of the 
considered spatial nodes, a linear graph [26], for a single nephron is shown in Fig. 2.1. with 
arrows leading to node $ representing the reabsorption paths. Each node is characterized by a 
hydraulic pressure and a sodium concentration. Fluid and sodium flow between nodes with 
positive flows are indicated by the arrows in the figure. Similarly, to a linear graph, we can use 
this node schematic to help derive the equations of motion. A single nephron is modeled first and 




flow, GFR, and urine output. At each node, a mass conservation equation is developed, 
describing the steady-state physics of the hydraulic pressure and sodium concentration at that 
node. 
 
Fig. 2.1: Kidney node schematic. Arrow directions indicate positive flow. 
For healthy simulation (baseline) we use the following typical model input values: a 
mean arterial pressure (MAP) of 90 mmHg, a ureter pressure of 0 mmHg, a venous pressure of 3 
mmHg, and a venous sodium concentration of 140 mEq/L. We also assume that one tenth of the 
cardiac output (CO) enters each kidney [5], with one two-millionth of this flow entering each 
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and flowing into the pre-afferent arteriole node * in Fig. 2.1 [5]. Finally, we ensure that the sum 
of total kidney urine flow and total kidney venous return must equal total kidney plasma flow. 
2.2.1 Hydraulic Modeling 
Fluid moves axially (through the vessels) due to a hydraulic pressure gradient. This flow 
is determined by the hydraulic resistance parameter. The hydraulic resistance is a function of 
fluid material property and vessel thickness. The flow of water between arbitrary nodes + and , 





where / is hydraulic pressure at node + or ,, 1!"#  is hydraulic resistance from node + to ,, and 
-!"#  is hydraulic flow from + to ,. 
Glomerular filtration modeling has consisted of either considering many capillaries in 
parallel or lumping the entire set of capillaries into one compartment and assuming that pressure 
and resistance drops across the glomerulus are negligible [28]. We calculate a pressure at the 
glomerulus, thereby assuming there is a pressure drop across the glomerulus. We assume 
negligible resistance along the glomerulus itself due to the large number of capillaries in parallel 
(effectively reducing resistance to a negligible number). At the second and third nodes of Fig. 
2.1, the glomerular filtration (between nodes 3 and 4) is modeled via the Starling equation as 
seen in (2.2) below, since here there is an oncotic pressure due to the proteins in the blood. This 
equation is equivalent to hydraulic fluid flow (where the glomerular filtration coefficient is 
included in the resistance term 1$%# ), with an added term for the oncotic pressures, 5. This 
oncotic pressure is due to proteins that are not filtered at the glomerulus and remain in the blood 
vessels and therefore we assume a reflection coefficient of unity for this oncotic pressure. The 





& = /$ − /% − 5$%1$%#
. (2.2) 
A typical value of the oncotic pressure between the glomerulus and Bowman’s space is 5$% =
30 mmHg [27] is used. The remaining fluid flow equations are derived from  (2.2) when there 
are no proteins separated by a membrane. 
In subsequent nodes, fluid is reabsorbed in the bloodstream along the nephron from the 
proximal tubule (6), thin descending limb of Henle (7), and the distal tubule (8) as shown in 
Fig. 2.1 by the arrows going into node $. We follow the assumption that the cellular walls of the 
thick ascending limb of Henle (node 9) are impermeable to water and therefore no fluid is 
reabsorbed from 9. We define a reabsorption fraction at each node where fluid is reabsorbed, as 
a percentage of the incoming axial flow. This transverse reabsorption fluid flow from an 
arbitrary node , back to the veins, $, is therefore described by 
 -"'( = :"# ⋅ -!"# , (2.3) 
where :"# is the fluid reabsorption fraction at node ,, and -!"#  is the axial flow (along the 
nephron) into node , from node +. The reabsorption fractions of 6 and 8 are nearly constant, 
regardless of fluid flow, in healthy cases, as described by [19]. For node 6, a constant value of 
0.75 is used for the reabsorption fraction due to the glomerulotubular balance, where 
reabsorption fractions of fluid and sodium are approximately equal and invariant to GFR. For 8, 
a constant value of 0.95 is used for the reabsorption fraction, which changes with antidiuretic 
hormone levels, but not with fluid flow, into 8. A constant antidiuretic hormone level 
corresponding to a 0.95 reabsorption fraction of water from node 8 was used. [19]. For node 7, 
the reabsorption fraction is an inverse function of fluid flow into 7 given by [19] as 




2.2.2 Sodium Modeling 
As previously mentioned, we model sodium in the nephron in order to model TGF. Since 
sodium is freely filtered at the glomerulus, we assume that the sodium concentration at 
Bowman’s space (node	4) and at the renal veins (node $) are equal. 
Axial flow of sodium along the tubule is due to advection, which is the movement of 
solutes by bulk fluid flow. Advective flow between nodes + and , is modeled via this equation, 
 ?!"+ = -!"# ⋅ @!,- (2.5) 
where @!,- is the sodium concentration at node + and -!"#  is the hydraulic flow between nodes + 
and ,. 
Sodium reabsorption flow is modeled similarly to fluid reabsorption, in that we define 
reabsorption fractions for each node along the nephron. The transverse flow of sodium from an 
arbitrary node , back to the veins, $, is therefore described by 
 ?"'( = :",- ⋅ ?!"+ , (2.6) 
where :",- is the sodium reabsorption fraction at node ,. The cellular walls at the thin ascending 
limb of Henle (node 7) are impermeable to sodium and therefore the reabsorption fraction there 
is zero. For node 6, we again use 0.75, as fluid and sodium are reabsorbed at almost one to one 
ratio. According to [19], the reabsorption fraction at the thick ascending limb of Henle (node 9) 
is approximately invariant to the flow into node 9 and approximately equal to 0.80 and as such 
:.,- = 0.8. At node 8, the reabsorption fraction is determined by another renal feedback 
mechanism, the renin-angiotensin mechanism where the sodium reabsorption fraction is 
modulated by aldosterone blood levels, as outlined by Uttamsingh et al. [19]. This is given by an 






1 + C/01!"# 20.04
+ 0.7316. (2.7) 
2.2.3 Parameter Estimation: Hydraulic Resistance 
Axial fluid flows are characterized by hydraulic resistances. Hydraulic resistances of the 
axial flows are calculated via two methods. Method 1 uses the Poiseuille equation assuming 





where D is fluid viscosity, and E ̅and  :̅ are the average length and radii of nodes + and ,, 
respectively. Given the variability in human nephron dimensions, even between neighboring 
nephrons, calculating resistances via Method 1 may not yield resistances that achieve 
physiologically accurate pressures throughout the nephron. For instance, small changes in radius 
will produce large changes in resistance, as the radius is raised to the fourth power in (2.8). By 
assuming healthy pressures, a GFR of 120 mL/min [27], healthy reabsorption fractions as 
discussed above, and a resistance from 3 to 4 of 1$%# = 100 s/mL/mmHg, the hydraulic 
resistances can also be calculated directly from the continuity equations (conservation of mass), 
which defines Method 2. The resistances via Methods 1 and 2 ought to be identical, naturally. 
We then use optimization techniques (described below) to find feasible dimensions (lengths and 
radii) of the vessels. Subsequent resistances could then be calculated using (2.8). These 
dimensions found via the optimization iteratively solving the system of equation should be 
within a physiologically feasible range. 
In Method 2, all axial hydraulic resistances (including those along the tubule, excluding 
1$%# ) were calculated using a set of physiologically reasonable pressures that are given in Table 




the ascending and descending myogenic feedback mechanisms, and hence 16$#  varies with 
pressure. The 16$#  calculated from the equations is after feedback modulation. The baseline value 
of 16$# , in the absence of feedback, was estimated from [29] to be 17# = 2.78 × 108 
s/mL/mmHg. 
Table 2.1: Pressure Values Used in Resistance Calculation. 
Node H (mmHg) Notes 
* 77 Estimated within feasible range 
3 55 Given from [27] 
I 17 Estimated from [5] 
4 15 Given from [27] 
6 10 
Pressure from 6 to 8 decreases along tubule 





Our goal is to determine feasible scaling factors of the lengths and radii that will be used 
to calculate resistances via Method 1. These calculated resistances will then be used in 
simulation using baseline parameters, outputting the prescribed pressures. The iterative 
constrained optimization technique minimized the sum of the squares of the difference between 
resistances estimated from Method 1 (which uses the scaling factors to calculate resistance) and 
Method 2 (which are the true resistances) by estimating the scaling factors. Baseline dimensions 
were taken from Layton and Layton [16]. These scaling factors (outputs of the optimization) are 
nondimensional constants multiplying baseline lengths and radii, bound to a range between 0.7 
to 1.2, with an initial value of 1. This range represents varying nephron sizes in humans [30].  
The optimization results in Table 2.2 show a feasible solution, with a possible local 
minimum. In this problem, we were more interested in feasibility (satisfying constraints) rather 




These optimized parameters (scaling factors) are then used to calculate resistances, assuming 
Poiseuille flow with (2.8), which will induce feasible pressures throughout the system at a 
healthy MAP = 90 mmHg. 
Table 2.2: Resistance Parameter Estimation Results. Lengths and radii from the literature and 
the optimization algorithm are in cm. The literature values of the dimensions are also 
presented and given such that the value from the literature multiplied by the scaling is the 
optimized value. Resistances assuming Poiseuille flow calculated from values in the 
literature [16] before and after optimization (s/mL/mmHg) are also shown. 
Node 
Lengths Radii 
Branch Poiseuille Resistance 
Optimized 
Resistance Literature 
[16] Optimized Scaling 
Literature 
[16] Optimized Scaling 
! 1.7	 2.0024	 1.178	 0.0019	 0.0013	 0.707	 ,! 1.06 × 10! 5.00 × 10! 
0 0.32	 0.3838	 1.199	 0.0013	 0.0009	 0.702	 !0 2.51 × 10! 12.0 × 10! 
1 1	 0.7	 0.700	 0.0013	 0.0013	 0.982	 01 3.77 × 10! 6.15 × 10! 
2 2	 2.3947	 1.197	 0.0010	 0.0011	 1.116	 12 14.0 × 10! 12.3 × 10! 
 
The resulting resistances in Table 2.2 are, in some instances, much larger than those 
estimated from the original dimensions. However, since all lengths and radii are bounded 
between 0.7 and 1.2 times their original values, they still represent plausible resistances for a 
human. The average percent error between resistances calculated from continuity equations 
versus those calculated from optimization is 5.2 × 1028% indicating a good fit between the 
optimized values. Using the resistances in Table 2.2, we arrive at accurate pressures throughout 
the system that match the prescribed pressures in Table 2.1. 
In addition to finding the resistances via optimization, we needed to find the hydraulic 
resistance from the heart (node N) to the pre-afferent arteriole (node *) for simulations where 
MAP is varied, since we could no longer use a predefined renal plasma flow, because this flow 
varies with MAP. A pressure drop from the heart (node N) to node * was set to 13 mmHg in 




MAP of 90 mmHg, the resistance from heart to pre-afferent arterioles (196# ) was calculated to be 
2.58 × 108 s/mL/mmHg by rearranging (2.1) to solve for the resistance. 
2.2.4 Feedback Mechanisms 
Since patient measurements typically occur at intervals longer than the transient response 
of the kidney, we are only interested in GFR after this transient response. As such, we adopt the 
steady-state feedback equations of [32], implemented by [33]. They included tubuloglomerular 
feedback (TGF) and descending and ascending myogenic feedback mechanisms. A feedback 
diagram is presented in Fig. 2.2. As shown, all feedback mechanisms share a common actuator 
that is the afferent arteriole muscles that change 16$#  by constricting or dilating. 
 
Fig. 2.2: Feedback diagram for tubuloglomerular feedback and descending and ascending 
myogenic mechanisms. Model inputs include mean arterial pressure, ureter pressure, venous 
pressure and sodium concentration. 
However, each controller has a different sensed input (located in the feedback paths in 
Fig. 2.2). TGF (2.10) senses @.,- and imposes an additional resistance 1:$;#  on the baseline 
resistance of 16$# , denoted by 17#, as @.,- decreases. The descending myogenic mechanism (MD) 
senses pre-afferent arteriole pressure and imposes an additional resistance 1<.#  when this 
































increases, linearly with pre-afferent pressure, as the vessel continues to constrict. The ascending 
myogenic mechanism (MA) senses afferent arteriole resistances (determined by the descending 
myogenic mechanism and TGF, since MD is a function of TGF) and imposes yet another 
resistance 1<6# , as shown in (2.12). The total resistance is hence given by the combined additive 
effect of all feedback mechanisms as  







1<.# = 0.5 ⋅ O17# + 1$@# + 1:$;# P ⋅ Q
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67 − 1R ⋅ N(/6 − 67)	










where	1$@# 	is the hydraulic resistance from glomerulus to post-efferent arteriole and N(/6 − 67) 
is the Heaviside function that is 0 when /6 is below 67 mmHg and 1 otherwise. It can be seen 
that (2.12) is a function of 1<.#  and subsequently 1:$;#  as well. Equations (2.10) – (2.12) are 
multiplied by a feedback gain. When these gains are zeros, the system is open loop. For a healthy 
person, these gains are ones. 
2.2.5 Summary of Equations 
Considering each node in the system, we can write the continuity equations for both fluid 
and sodium. Beginning with fluid, we have the following equations, 




+ 3U1/W = 0 (2.13) 
6 /A − /B1AB#
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+ 3U1/W = 0 (2.20) 
where W is the number of nephrons, : are the reabsorption fraction parameters defined earlier, 
and all other variables and parameters follow the notation in the previous equations. The fluid 
flows, GFR (glomerular filtration rate), UO (urine output), and -6$  are defined as, 
 3U1 = W ⋅
/A − /J + 5JA
1JA#
 (2.21) 
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where N is the Heaviside function and \ are feedback specific parameters defined in (2.10)-
(2.12). Recall that the fluid flow -6$  is flow from the pre-afferent arteriole to the glomerulus and 




into (2.1). And hence, we see /H and @E appear in (2.23) since they are the feedback inputs for 
the descending myogenic, ascending myogenic, and TGF. 
For all nodes concerning sodium, we have the following equations, 
Node Continuity Equation  
6 










































Note that since we are assuming sodium concentration at Bowman’s space is equivalent to 
venous sodium concentration (a physiologically sound assumption since sodium is freely 
filtered), we only require equations for the four nephron component nodes in order to solve for 
all sodium concentration values. 
2.3 Results & Discussion 
2.3.1 Model Validation 
The model is validated against real patient data as well as other models in the literature. 
As will be detailed in the results below, we first compare our model outputs to the model outputs 




MAP to those of five intensive care unit patients with diagnoses unlikely to impact kidney 
function. Finally, we compare the same GFR vs. MAP curve to the data from 20 patients (across 
a large range of ages) reported in [25] over a two-hour study. None of these patients had clinical 
evidence of primary renal disease. 
We simulated the model under healthy conditions at MAP = 90 mmHg (/! in (2.1) for 
the continuity equation at node *) for healthy cases and solve for all pressures, flows, and 
sodium concentrations at and between the nodes in Fig. 2.1. Sodium concentrations along the 
tubule were compared to Layton and Layton’s continuous steady-state model [16] in Fig. 2.3a. 
As shown, the values are close in magnitude. This is a good indication that the concentrations of 
sodium in the tubule are physiologically sound. Of note, our model lumps the distal tubule and 
collecting duct into one node as also seen in [19], and therefore we see, in Fig. 2.3a, our sodium 
concentration at 8 slightly differ from [16]. However, we observed little impact of the length of 
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Fig. 2.3: Model sodium concentration values along the tubule compared to [16] and over 
varied MAP inputs ranging from 54 to 180 mmHg. 
Flow values of fluid and sodium between several nodes are compared to Uttamsingh et 
al. [19] in Table 2.3, with percent differences reported. Our baseline (no parameter alterations) 
simulation results indicate good matching to those of Uttamsingh et al., with an average percent 
difference of 7.7%. Our model explicitly includes resistances and pressures and uses the Starling 
equation, rather than the piecewise linear function used by Uttamsingh et al., for calculation of 
GFR via (2.2), allowing us to simulate impaired feedback and observe subsequent changes in 
GFR, as presented in 2.3.2. 
Table 2.3: Model output flows. 
Fluid flows in mL/min. 
Branch Uttamsingh et al. [19] Model % Difference 
34 125	 115.47 7.62 
67 31.25	 28.87 7.62 
8J 1	 0.850 15.1 
6$ 93.75	 86.61 7.62 
7$ 10.55	 10.43 1.12 
8$ 19.7	 17.56	 10.9 
(a) 
Sodium flows in mL/min. 
Branch Uttamsingh et al. [19] Model % Difference 
67 4.44 4.04 8.97 
98 0.89 0.50 9.26 
6$ 13.3 12.1 8.83 
9$ 3.55 3.23 8.91 
8$ 0.76 0.75 0.52 
(b) 
 
After validating our model against other models, we then varied MAP over the range of 
54 to 180 mmHg in increments of 10% of the baseline (90 mmHg). The effect of MAP on 




also rises as given by (2.1). The increased RPF decreases fluid reabsorption from 7 since the 
reabsorption fraction and fluid flow into node 7 are inversely related, as described in (2.4). 
Therefore, @),- decreases as MAP increases, especially since sodium mass does not change in 7 
either, due to the impermeability of the tubule to sodium at this location.  
At node 8, sodium concentration increases with MAP. This is due to the inverse 
relationship between sodium reabsorption and sodium flow into 8 as described in (2.7). This is 
expected, since TGF increases afferent arteriole resistance to decrease RPF and GFR when @.,- 
is high. 
GFR was also analyzed during a variation of MAP as shown in Fig. 2.4a. A spline 
interpolation was inserted between simulation points to generate a continuous curve. A healthy 
GFR range of 90 to 120 mL/min is highlighted between two horizontal dotted lines. Additional 
simulations are shown where different feedback mechanisms were disabled in Fig. 2.4a. As can 
be seen in the open loop system (dashed line with open square markers), after 85 mmHg, GFR is 
already beyond the healthy limit of 120 mL/min (now in the region of hyperfiltration) and 
climbs rapidly (almost linearly) as MAP increases. The descending (solid line with open square 
markers) and ascending myogenic mechanism are effectively inactive below MAP = 80 mmHg 
and beyond this point, they begin to increase 16$#  continually as MAP increases. This increase in 
16$#  decreases GFR for a given MAP. TGF (dotted line with open square markers) becomes less 
effective, saturating to a maximum 1:$;#  value beyond which increased MAP values are no 
longer controlled by this mechanism, as shown by the line’s change in slope with sufficiently 
large MAP. The ascending myogenic response is not simulated without the descending myogenic 
response and TGF, as 1<6#  would be zero without the TGF. The descending myogenic response 




line with no markers) for GFR as MAP changes and our curve (solid line with markers, with all 
feedback mechanisms enabled) match very well between 80 and 100 mmHg, the agreed-upon 
healthy range of MAP. The ascending myogenic mechanism has the effect of decreasing GFR 
with increased MAP beyond 80 mmHg, as demonstrated in [32]. As such, including the 
ascending myogenic mechanism causes the GFR vs. MAP curve to flatten or increase GFR much 
less for further MAP increases. This is an important component for regulating and maintaining 
GFR for individuals. 
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Fig. 2.4: Glomerular filtration rate plotted as input MAP is varied: (a) under varying 
controllers active and compared to Uttamsingh et al. [19] simulation, (b) compared to 
Massachusetts’ ICU hospi’al's patient data [24], and (c) in slightly and severely hypertensive 
cases as compared to real human data from Almeida et al. [25]. RMSE is root mean squared 
error. Descending myogenic mechanism (MD), ascending myogenic mechanism 
(MA), tubuloglomerular feedback (TGF) 
 
We next compared model-computed GFR to the GFR calculated using patient data from 
the MIMIC database [24] and utilizing the widely used Modification of Diet in Renal Disease 
(MDRD) formula [34] after removing the GFR normalization by patient body surface area. 
MIMIC was chosen since it is a large and a diverse population database. It is also widely used in 
the research community and easily accessible. The database also includes multiple measurements 
from a single patient, at different times and for different MAP values, rather than aggregated or 
averaged population data only. This type of time-series data is needed to validate model outputs 
for a single patient, having multiple inputs. All ICU stays are considered separately – even if the 
stay is a readmission of the same patient. Because we modeled a healthy individual, we want to 
first validate on healthy patients. Since most patients in the MIMIC ICU data are critically ill, we 
sought to find relatively healthier patients, i.e., those with no acute or chronic kidney problems, 
and then filter out those with other kidney, heart, or severe illnesses that could impact kidney 





Fig. 2.5: Patient inclusion criteria from MIMIC database. After removing patients with 
insufficient data for calculating a KDIGO (Kidney Disease Improving Global Outcomes) 
stage of 0, indicating no acute kidney injury, we had a set of 12,666 unique ICU stay IDs 
(identification number for each stay). Patients were further filtered from the database by 
retaining only those meeting the following criteria: patients who have height and weight 
records in order to remove GFR body surface area normalization in the data (419 remaining), 
patients who have not undergone surgery during a stay, which may affect GFR (293 
remaining), patients who have not passed away during a stay (146 remaining), patients 
without diseases such as diabetes, cancer, pancreatitis, etc. (127 remaining), patients with 
diagnoses that would most likely not affect kidney function (5 remaining). 
From the remaining patients, we have a total of 10 ten points for validation. These data 
points span a large MAP range and will hence validate the model for low and high MAP values. 
Four of the patients remaining were male. The mean age was 34.2, with standard deviation of 
15.5. The mean BMI (body mass index) was 21.4, with standard deviation 4.9. The diagnoses 
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were altered mental status, diaphragmatic injury, and abnormal head CT. It is important to note 
that all patients were under the age of 60, and patients, with the exception of one, were within a 
healthy BMI (body-mass-index) of 18.5 and 24.9. These two observations are important, as age 
can greatly affect GFR, generally diminishing with age, and a large BMI will result in a larger 
GFR than for a similar patient with a lower BMI since the MDRD equation, for calculating GFR, 
is normalized by body surface area, whereas our model outputs are not. 
The associated blood pressure and GFR measurements were plotted for these ICU stay 
IDs against the simulated curve that can be seen in Fig. 2.4b above. Several patients had more 
than one measurement of blood pressure and GFR, hence we see more than 5 data points, even 
though we had only 5 patients. The data does not fit our curve perfectly, as is expected without 
manual fitting or model fine-tuning, but it does show the general shape and magnitude of our 
curve. GFR can be altered by many factors that are not captured in the general model and 
therefore a more personalized model with parameters reflecting each patient would better fit the 
data for each patient. We observe an RMSE (root mean squared error) of all the data of 13.5 
mL/min. This is a reasonable number considering the data is from 5 unique ICU stay IDs and 
there are healthy variations between patients in general due to natural variations in parameter 
values. We note also that the data fits the curve reasonably well in regions where feedback is not 
active (below MAP = 80 mmHg) and areas where feedback is active (above MAP = 80 mmHg). 
This gives credence to the model when fitting low pressure MAP input data where renal 
autoregulation is largely inactive. It also shows that the model can fit high pressure MAP input 
data where renal autoregulation is vital for maintaining GFR. 
The purpose of this validation against real patient data is to ensure that the model is able 




cannot expect to claim overarching statistical conclusions on the model fit to patient data. 
However, we can claim the model is capable of describing this relationship within a reasonable 
range (15 mL/min GFR RMSE). Patient parameters can vary greatly from person to person as 
seen in [10], [35], and [36], describing the changes in nephron number, glomerular resistance, 
and renal autoregulation based on patient demographics alone. It is important to note that the 
validation data using healthy kidneys would correspond to normal parameters values, and this 
would be the first validation step, while altered parameters correspond to diseased kidneys. As 
such, a personalized patient-to-model fit would require parameter adjustment, even for healthy 
patients. As BMI increases, parameters in the model will change. This is due to the link between 
obesity and structural changes to the kidney that can cause decreased glomerular resistance and 
tubular flow in the loop of Henle [11], [37]. In the Analysis section we will observe how 
changing parameter values affects the model outputs. The current model can only describe 
certain clinical conditions. To address others, we would need to change several parameters to 
reflect healthy or diseased states of the patient. These parameters include aldosterone and 
antidiuretic hormone levels, glomerulotubular balance, reabsorption fractions, glomerular 
filtration resistances, and/or resistances. Several of these parameters, for instance, will change for 
diseases such as tubular necrosis or glomerulonephritis as described in [38]. 
We investigated the effect of administration of vasodilators in patients where there is a 
need to reduce MAP without negatively affecting GFR. We used real patient data from [25], 
where slightly and severely hypertensive patients were administered a stepwise infusion of 
sodium nitroprusside (SNP) to target acute blood pressure reductions. The slightly hypertensive 
patient group consisted of four men and six women with a mean age of 41.7±3.8 years (16-55 




a mean age of 38.5±4.3 years (15-58 range). We simulate SNP infusions as a change (reduction) 
in MAP. We plotted the collected data versus our model results in Fig. 2.4c. In the case of slight 
hypertension (dotted error bar line), our model (solid line), without any adjustment to vascular 
resistances or feedback gains, fits the data well with an RMSE of 4.2 mL/min. To model severe 
hypertension, a sixfold increase of all vascular resistances (196# , 16$# , 1$@# , and 1@'# ), 
corresponding to a decrease in vascular radii by 0.55 times, was used. Almeida et al. [25] notes 
that the measurements of the severely hypertensive patients suggest that their feedback 
mechanisms are affected. Impaired feedback was then modeled by a decrease in feedback gains 
(multiplication by 0.5) in all three feedback mechanisms described in (2.9). After adjustments to 
vascular resistances and feedback gains, the model (dotted line) accurately represents the 
severely hypertensive patient GFR data (dashed error bar line) with an RMSE of 2.6 mL/min, 
shown in Fig. 2.4c. In the case where vascular resistances are increased and feedback is not 
modulated (dashed line), the slope of the curve is nearly identical to the baseline curve, but the 
GFR values are too low to match the patient data having only an RMSE of 19.9 mL/min. This is 
expected as the feedback mechanisms affect the slope of the GFR vs. MAP curve mostly. 
Feedback has a dampening effect on GFR as MAP changes, flattening the curve with increased 
feedback modulation as can be seen in Fig. 2.4a. This reinforces the hypothesis of Almeida et al. 
[25] that the feedback is impaired in severe hypertension, since here the model more closely 
matches severely hypertensive data after feedback modulation (Fig. 2.4c). 
2.3.2 Model Analysis 
We then conducted a sensitivity analysis to study how GFR and sodium concentration 
along the tubule are affected when vascular resistances and feedback gains are altered. Over a 




we simulated the system over a range of MAP values. We also varied feedback gains over a 
range of 0 to 2 for the same MAP range, independently, simulating instances where feedback is 
altered, such as in hypertension. Results of varied vascular resistances and feedback gains are in 
Fig. 2.6, where a is a gain by which the vascular resistances or feedback gains were altered. For 
Fig. 2.6a and Fig. 2.6b, observing GFR, the dotted lines are individual simulations, and the solid 
lines delineate the region covered by the simulations. 
 
(a) 
60 80 100 120 140 160 180





































60 80 100 120 140 160 180

































































Fig. 2.6: Sensitivity analysis results varying vascular resistance and feedback gains while 
monitoring GFR and sodium concentrations in the nephron. (a) GFR vs. MAP as vascular 
resistance is scaled by !. (b) GFR vs. MAP as feedback responses are scaled by !. (c) Sodium 
concentration along the nephron as vascular resistance is scaled by !. (d) Sodium 
concentration along the nephron as feedback gains are scaled by !. 
We studied this increase in vascular resistance specifically for the case of hypertension 
[39], where vascular resistance is increased from the baseline value to 8 times this value. The 
vascular resistances alter the curve such that GFR decreases with increasing vascular resistance 
as seen in Fig. 2.6a. A similar relationship was described by [40], where it was shown that 
increasing vascular resistances decrease the GFR. We see in Fig. 2.6b that feedback gains have a 
dramatic effect on the slope of GFR as MAP changes. This makes sense since impaired feedback 
will not effectively control high MAP values and thus GFR will rise more with MAP. In the 
































(modulated by the feedback) is severely decreased, as also seen in Fig. 2.4a. This reinforces the 
importance of feedback to maintain GFR during high MAP periods. Overall, GFR is more 
sensitive to impaired feedback as compared to changes in vascular resistances as seen by the 
larger changes in GFR from equivalent changes to vascular resistances or feedback gains in Fig. 
2.6a and Fig. 2.6b. This is an important fact to note since this implies that diseases or therapies 
that alter renal autoregulation, as opposed to vascular resistance, will impact GFR more. 
We also studied how the sodium concentration, along the tubule, is affected by changes 
in vascular resistances and feedback gains, specifically at MAP = 90 mmHg. Typically, sodium 
concentration is not measured in the nephron, hence the importance of this study. Results can be 
seen in Fig. 2.6c and Fig. 2.6d. The largest impacted sodium concentrations occur in the 
descending limb of Henle in response to changed vascular resistances and feedback gains. 
Sodium concentration in the distal tubule is also largely affected by feedback gain changes via 
TGF so it makes sense that sodium concentration would vary significantly in the same direction 
as this change. This noninvasive observation from the simulation is important because sodium is 
pivotal in maintaining the fluid-electrolyte balance in the body. 
As the vascular resistance increases, @),- (concentration of sodium in the 7 node) 
increases as well, Fig. 2.6c. This is due to a decrease in fluid flow into 7 and a subsequent 
increase in fluid reabsorption at 7, as expected – see (2.4). This increased fluid reabsorption, in 
turn, increases the sodium concentration at node 7. A similar, but less pronounced, effect can be 
seen when the feedback gains are increased due to the subsequent increase in 16$# , as described 
by (2.9), which lowers the GFR and decreases reabsorption from the node. Again, the model 
shows that alterations in sodium concentration throughout the nephron will trigger TGF and 




Given a decrease in feedback gains, @.,- rises, due to the TGF response no longer 
effectively maintaining GFR. Impaired feedback decreases 16$#  and therefore fluid and sodium 
flow into 8 increases, Fig. 2.6d. This subsequently decreases the reabsorption of sodium in 8 
and therefore raises @.,-. This effect, shown via the model simulation, can be responsible for 
increases in urine output and hence, an important cause of increased urine output for physicians 
to consider. 
2.4 Conclusion 
We have developed a closed-loop, nonlinear, steady-state, algebraic human kidney model 
with 30 parameters, [with resistance values verified using known pressure values. This chapter 
brings us one step closer to personalizing a human kidney model that can be used by physicians 
to test therapies. This model was validated to ensure it is capable of matching human data, 
including in hypertensive states. Validation against other models in the literature and ICU patient 
GFR data, for critically ill patients without kidney injury, using normal kidney function 
parameters, has shown good matching with a 13.5 mL/min root mean squared error (RMSE). We 
further validated our model against a diseased case of hypertension where sodium nitroprusside 
was administered to reduce blood pressure. For mild hypertension, the baseline model accurately 
reproduced GFR (glomerular filtration rate) as MAP (mean arterial pressure) changed. For 
severe hypertension, we increased vascular resistance and impaired feedback. From here, the 
model parameters were frozen and would change only in personalization. The subsequent 
simulations showed good results compared to the data, RMSE of 4.2 and 2.6 mL/min for slightly 
and severely hypertensive patients respectively. 
The model was also analyzed to further the understanding of renal physiology that is now 




and feedback. We examined how GFR changed in response to these changes and noted that 
feedback had a dramatic effect on the slope of the GFR vs. MAP curve, due to the inability for 
the feedback to correct GFR with increasing MAP. As described in [40], we saw an inverse 
relationship between vascular resistance and GFR. We studied sodium concentrations along the 
tubule in response to these parameter changes because these values along the nephron are 
typically not measured for humans and therefore, the model can provide insights through 
simulation. We noted a significant change in sodium concentration in the descending limb of 
Henle, since fluid reabsorption is greatly affected by changes in GFR, shown in the sensitivity 
analysis to be largely affected by both vascular resistance and feedback. This is an important 
conclusion as it quantifies the mapping between hypertension parameters and two important 
kidney states, GFR and sodium urine levels.  
In the subsequent chapter, we will personalize the model for glomerulonephritis patients 
via parameter estimation techniques. This will enable forecasting of variables in specific patients 





Chapter 3: Human Closed-Loop Kidney Model - Parameter 
Estimation in Healthy & Diseased States 
3.1 Introduction 
The power of a mathematical model describing organ systems is fully realized when the 
model is personalized to an individual patient and can subsequently be used to predict the 
patient’s outputs given known inputs. For the kidneys, predicting patient glomerular filtration 
rate (GFR) and urine output rate (UO) are key in determining the overall health of the kidney as 
evidenced by their use in determining acute kidney injury staging [41]. Therapies that impact 
some of the input variables in the kidneys, including mean arterial blood pressure (MAP) and 
blood sodium levels (Na), will nevertheless impact the GFR and UO. Using our model, we are 
capable of predicting how changes in MAP and Na affect GFR and UO. Further, using 
previously measured inputs and outputs for a particular patient, certain model parameters can be 
personalized for that particular patient, thereby achieving our objective: personalized predictions 
of GFR and UO outputs, given new or hypothetical MAP and Na inputs. 
Several papers have utilized parameter estimation techniques for the kidneys [42]–[46] 
via regular or nonlinear least-squares. These works utilized rat models and focused on estimating 
resistances, capacitances, or transporter parameters for kinetic models of co-transporters. 
Estimations were carried out with healthy data, spontaneously hypertensive data, or data after 
glucose loading. This parameter estimation is done so for the model to fit generic, average rodent 
data. While useful for calculating missing, or difficult to ascertain, parameter values, the models 
are not used for specific rodent (or human) personalization. In [16], the authors manually tune 




physiological differences between rodents and humans. This is done so for average human data 
and not for patient-specific data though, and hence, this is not a personalization of a human 
model. In [18] the authors also use a rodent model and alter parameter values to match generic 
human data. However, the authors tune over twenty parameters, verging on overfitting, and also 
match generic human data. We do not see estimation that uses no-kidney-injury (NKI) data and 
kidney diseased data, in conjunction as we do (3.2.6), for parameter estimation for a specific 
patient. Nor do we see estimation of several parameters simultaneously to fit a specific patient’s 
data. There is a deficit in the literature of parameter estimation using a physiological model for 
the purposes of personalizing that model to a human kidney. 
We begin by imputing patient data collected from the MIMIC database [24] using a linear 
interpolation. From here, we mathematically describe which parameters will be altered for 
healthy (no disease) or NKI individuals and those with glomerulonephritis. A sensitivity analysis 
is conducted to minimize the set of parameters to be estimated for NKI and diseased patients 
such that we estimate parameters that have the greatest impact on GFR and UO. Then, the 
robustness of the parameter estimation method is analyzed to understand the limits of our 
estimations. Finally, the model and parameter estimation technique are used to estimate real 
patient parameters, where we compare model predicted GFR and UO with database recorded 
GFR and UO. We also analyze how patient comorbidities affect the estimation results and 
propose methods for improving the model estimation for certain comorbidities. 
3.2 Methods 
3.2.1 Model Description 
The nonlinear algebraic system of equations for this model comprising (2.13) – (2.27) is 




several spatial locations (nodes) based on physiological similarities characterized by reabsorption 
paths. A schematic of the considered spatial nodes is shown in Fig. 2.1 with arrows leading to 
node $ representing the reabsorption paths. Each node is characterized by both a hydraulic 
pressure and a sodium concentration. Fluid and sodium flow between nodes with positive flows 
defined along the direction of the arrows. A single nephron is modeled in detail and the single 
nephron’s variables are then multiplied by the number of nephrons (two million  [27]) to give an 
indication of the total renal plasma flow, GFR, and urine output. At each node mass conservation 
defines the equations to be solved for pressures and sodium concentrations. 
All variables cannot be solved explicitly in the system of equations. Using the computer 
algebra system in MATLAB®, leveraging substitution of variables into other equations, the 
system can be reduced to the following four equations 
 
iL(66, 6$) = 0, 
iD(66, 6$) = 0, 
3U1 = iO(66, 6$), 





where iL, iD, iO, i5 are functional relations between the variables. From here, (3.1) and (3.2) are 
solved using fsolve in MATLAB®, which solves the system as an optimization problem via 
the trust-region dogleg algorithm. These equations are solved multiple times for several different 
starting points in order to capture multiple solutions. From here, the solution with the lowest 
fsolve cost, that produces valid, positive GFR and UO values when substituted into (3.3) and 
(3.4), is chosen. 
Axial fluid flows are characterized by hydraulic resistances. Hydraulic resistance values 
from 2.2.3 were used. Glomerular resistance was set to a healthy value of 1$%# = 100 
s/mL/mmHg. The baseline value of 16$# , in the absence of feedback, was estimated from [29] to 




13 mmHg in accordance with [31]. With this pressure drop and a baseline cardiac output of 5.5 
L/min at a MAP of 90 mmHg and a zero oncotic pressure, the resistance from heart to pre-
afferent arterioles (196# ) was calculated to be 2.58 × 108 s/mL/mmHg by rearranging (2.1) to 
solve for the resistance. 
3.2.2 Data Imputation 
The data to be used for parameter estimation comes from the MIMIC database [24]. This 
database is a freely accessible critical care collection of approximately 60,000 patient records. 
Within the database is static patient information including age, sex, race, height, weight, ICD-9 
code, and comorbidities. The ICD-9 code for billing was used to determine if a patient was 
diagnosed with glomerulonephritis. Further, for each patient, there exist several measurement 
records of MAP, Na, urine output, and serum creatinine. Urine output divided by time between 
measurements represents urine output rate (UO). GFR cannot be measured directly 
noninvasively, so typically, it is estimated via the MDRD formula [34] after removing the 
equation’s normalization by patient body surface area to achieve GFR units of mL/min. Hence, 
we used all patients with glomerulonephritis ICD-9 codes (who at one point did not have 
glomerulonephritis), height, and weight measurements available. 
The KDIGO (Kidney Disease Improving Global Outcomes) acute kidney injury (AKI) 
stage [41] was used to determine the severity of kidney injury for all patients based on their GFR 
and UO measurements. Patients with stage 0 are considered to have healthy kidneys and have 
NKI (no-kidney-injury). And patients with stages between 1 and 3 are considered to have 
diseased kidneys. 
For each patient, measurements for the inputs and outputs are often not taken at the exact 




gaps between measurements), we imputed the data. The data imputation used for the MIMIC 
data was a linear interpolation between data points. However, we investigated several possible 
methods in order to determine the optimal method for this data. The optimal method was 
determined based on a test that was conducted. The test involved using all data (MAP, Na, GFR, 
UO) and intentionally deleting an additional 10%, 12%, and 15% of the data at random. From 
here, data imputation methods were used to fill in all the missing data, including the intentionally 
deleted data. All data per patient were shifted and scaled to zero mean and a standard deviation 
of one, and the root mean squared error (RMSE) was calculated across all data fields for the 
intentionally deleted data. 
The results for the test with the various data deletion amounts can be seen in Fig. 3.1. 
Here we compared several methods including: PCA (principal component analysis), PPCA 
(probabilistic PCA), PV (previous neighbor interpolation), XV (next neighbor interpolation), NV 
(nearest neighbor interpolation), LR (linear interpolation), TSR (trimmed scores regression), 
KDR (known data regression), KDR-PCR (KDR with principal component regression), PMP 
(projection to the model plane), IA (iterative algorithm), and NIPALS (modified nonlinear 
iterative partial least squares regression algorithm). Details on the algorithms for TSR, KDR, 
KDR-PCT, PMP, IA, and NIPALS can be seen in [47]. There, Folch-Fortuny, Ferrer, and 
Arteaga implement these algorithms in MATLAB® in the MDI (missing data imputation) 
toolbox that was used in this study. Briefly, these methods start by filling the missing positions 
with zeroes, and estimating, after centering, a PCA model. Then, for each incomplete row, an 




































































Fig. 3.1: Root mean squared error (RMSE) of several imputation methods compared for 10%, 
12%, and 15% data deletion. The methods compared were PCA (principal component 
analysis), PPCA (probabilistic PCA), PV (previous neighbor interpolation), XV (next 
neighbor interpolation), NV (nearest neighbor interpolation), LR (linear interpolation), TSR 
(trimmed scores regression), KDR (known data regression), KDR-PCR (KDR with principal 
component regression), PMP (projection to the model plane), IA (iterative algorithm), and 
NIPALS (modified nonlinear iterative partial least squares regression algorithm). 
As can be seen from the results, we first note that the RMSE values are also consistent for 
each algorithm across all deletion percentage cases. We see that PPCA outperforms PCA and 
NIPALS algorithm in all cases, as also seen in [48]. Further, for all cases, we see the lowest 
RMSE with a linear interpolation. While linear interpolation yields the lowest RMSE values, all 
algorithms, with the exception of PCA and NIPALS produce RMSE values below 1.5. As 
described in [47], the TSR, KDR, and KDR-PCR are all algorithmically the same with different 
































3.2.3 Parameters that Change from Person to Person 
Among healthy (no diseased) and no-kidney-injury (NKI) individuals, parameters will 
undoubtedly be different. These differences arise from demographic and comorbidity differences 
between people since parameters in the system characterize a particular person. In a study by 
Almeida et al. [25], it was shown that the vascular resistance increases and feedback declines in 
cases of severe hypertension. Since hypertension is very prevalent (the most of all reported 
comorbidities of the patient data we will use, 75%) in the intensive care unit (ICU), this is a 
necessary comorbidity to consider when modeling the kidneys. 
A person’s age will affect several parameters within the model. For instance, the number 
of nephrons can vary between 100,000 and 1,350,000 for each kidney [10]. From Denic et al. 
[11], we see that the number of nephrons decreases with age. This decrease in nephron number 
with increased age is due to the increased number of sclerotic (stiffening and dying) nephrons 
that develop with age. Hydraulic vascular resistance will increase as the vasculature becomes 
stiffer. This will also then lead to a decrease in renal perfusion rate as described in [49].The 
glomerular resistance, 1$%# , between the glomerulus and Bowman’s space will also be affected 
by age. From Hoang et al. [50], they suggest that glomerular resistance will decrease with age. 
This decreased resistance with increased age is inferred by Hoang et al. due to structural 
changes, altering the resistance, they observed in the glomerulus membrane with age. Fluid 
reabsorption, according to Kanasaki, Kitada, and Koya [51], is largely unaffected directly by age. 
However, they do report a marked decrease in sodium reabsorption in the proximal tubule for the 
elderly. They do note that this increase is offset by a decrease in sodium reabsorption in the distal 
segments of the nephron leading to no overall change in fluid reabsorption associated with age. 




with age, which agrees with the finding from [51]. Additionally, they describe that, due to thick 
ascending loop of Henle’s diminished response to stimuli in old age, sodium reabsorption 
decreases in the loop of Henle as well. Renal autoregulation is decreased with increased age as 
described by Wei et al. [53] in their study of aging mice. With age, the kidneys are likely to 
hypertrophy (an increase in vasculature/vessel dilation) and subsequently tubule diameters 
increase, as shown by McNamara et al. [54]. This increase will lead to a decrease in tubular 
hydraulic resistance as described by (2.8), the Poiseuille equation where we see the relationship 
between tubular diameter and resistance. 
Height and weight also influence overall nephron number and increases in BMI (body-
mass-index) and decreases in height correspond to decreased nephron number, as suggested by 
[11]. Further, it has been shown through structural changes to the kidney, that obesity (BMI	 >
	30 kg/m2) can lead to a decrease in glomerular resistance by 0.8487 times. According to Tsuboi 
et al. [55] and Tobar et al. [56], renal tubular overload in obesity may stimulate sodium and 
water reabsorption in the proximal tubules. Further, via activation of the renin-angiotensin 
mechanism, sodium reabsorption in the distal tubules will increase in the presence of obesity. As 
described by Hall et al. [37], obesity leads to the physical compression of the kidneys, which 
reduces tubular flow and subsequently increases sodium reabsorption in the loop of Henle . 
Renal autoregulation is also altered with obesity. Monu, Wang, and Ortiz [36] demonstrated that 
the tubuloglomerular feedback mechanism was attenuated due to obesity in mice. Tubular 
hydraulic resistance, a direct function of tubular hypertrophy due to the increase in tubular 
diameter, has been shown to decrease with obesity by [56], [57]. However, [54] reported little 
increase in tubular resistance with respect to increase in body surface area. Cauwenberghs and 




It has been reported that sex also dictates several parameter values for the kidneys. From 
Denic et al. [11], we find that females have a lower nephron number. Remuzzi et al. [35] showed 
a significant reduction in glomerular resistance in male rats as compared to females. Fu et al. 
[59] demonstrated the directly related link between increased testosterone and tubuloglomerular 
feedback mechanism. Veiras et al. [60] further showed the link between testosterone and 
increased fluid and sodium reabsorption. Hypertrophy is also known to be more prevalent in 
males and subsequently the tubular resistance decrease [57] is more prevalent in males. Finally, 
Cauwenberghs and Kuznetsova [58] reference an overall increase in vascular resistance for 
females dictated by a more pronounced decrease in renal perfusion. 
Hughson et al. [61] have shown that there is no significant relationship between nephron 
number and race. However, as per the MDRD equation for GFR, we expect increased glomerular 
resistance in people of Black race (African, African American, Black Caribbean, etc.) as opposed 
to non-Black race (American Indian, Alaska Native, Asian, Native Hawaiian, Other Pacific 
Islander, white, etc.). Weder, Gleiberman, and Sachdeva [62] reported little decrease in proximal 
tubule sodium reabsorption for Black people, while Bochud et al. [63] showed a decrease in 
sodium reabsorption in the proximal tubule, but an increase in the distal tubule, with an overall 
increase in sodium reabsorption. Bankir, Perucca, and Weinberger [64] reported an increase in 
overall fluid reabsorption for Black people, which they speculate could be due to hotter climates 
requiring the need to retain water. Hoy et al. [57] note that overall glomerular size is, on average, 
larger in Black people and therefore tubular resistance is lower. Finally, Weinberger, Fineberg, 




3.2.4 Parameters that Change with Glomerulonephritis 
In the presence of glomerulonephritis (GN), several changes can be seen throughout the 
kidney, as diseases like GN are characterized by changes in parameters in the model. As 
glomerulonephritis worsens, nephron death is inevitable and consequently, the number of 
nephrons diminishes with increasing severity of the disease [38]. Through experiments with rats, 
Maddox et al. [66] showed that the glomerular resistance decreases with increasing severity. 
Juncos [67] describes how, with increasing GN severity, sodium reabsorption in the distal tubule 
can change from 1.9 to 2.9 times the baseline value (up to a limit such that more sodium is 
reabsorbed than available), leading to observable sodium retention. This increase in sodium 
distal reabsorption is due to glomerulonephritis induced activation of the renin-angiotensin 
mechanism. However, sodium reabsorption in the proximal tubule and loop of Henle remains 
largely unaffected. Finally, due to hypertrophy changes from the glomerulonephritis, Maddox et 
al. [66] reported that afferent and efferent arteriole resistances are altered between 0.88 and 1.21 
times their baseline values. 
3.2.5 Sensitivity Analysis 
In order to better understand which parameters should be estimated for hypertensive, 
NKI, and GN patients, we conducted a sensitivity analysis where we varied the normalized 
scaling parameters between 0 and 1 and recorded the resulting varied outputs. This analysis was 
repeated several times for MAP and Na inputs over the range of 50 to 170 mmHg and 100 to 170 
mmol, respectively. We calculated a Σ value to quantify how sensitive a particular variable, i, is 
to a change in a particular parameter, \, based on the change of both the parameter and variable 
value from their baseline values, as 






The parameters listed in Table 3.1 are those perturbed/altered during this analysis and those 
known to change from person to person or during disease, as previously discussed. Herein, “All” 
or “all” fluid or sodium reabsorptions refers to the collective group of all reabsorption parameters 
throughout all nodes (modeled nephron locations), which will be altered together by applying the 
same scaling factor to all respective reabsorption fractions. After calculating Σ associated with 
one output and a parameter-change, over the complete range of inputs, the results were averaged 
together to produce a single Σ value for each output and parameter pair. The results of the 
sensitivty values for GFR and UO separately are presented in Fig. 3.2. 
Table 3.1: Sensitivity analysis parameters. All fluid and sodium reabsorption scalings 
multiply all reabsorption fractions for fluid and sodium, respectively. 
Parameter Abbreviations 
Number of nephrons No. Neph. 
Glomerular resistance Glom. Res. 
Distal tubule sodium reabsorption Dis. Na. Reab. 
Feedback Fdbk 
All fluid reabsorption Fluid Reab. 
All sodium reabsorption Na Reab. 
Afferent and efferent arteriole resistances Aff/Eff Res. 
Tubular resistance Axial Res. 






Fig. 3.2: Sensitivities of GFR and UO in response to several parameter changes, averaged over 
varied input ranges. 
We see most prominently that UO is most affected by all fluid reabsorption. This is 
expected since the highly variable fluid reabsorption in the distal segment, affected by the 
concentrations of antidiuretic hormone in the body, can have a dramatic effect on UO in times of 
water conservation. Further, fluid flow into the distal segment is a direct result of the fluid 
reabsorption in the neighboring parts of the nephron. It is also reported that GFR is most affected 
by sodium reabsorption, primarily in the proximal tubule and loop of Henle. Sodium 
concentrations have a direct impact on GFR via TGF given by (2.10). Since sodium 























































(2.10), it is expected that altering this reabsorption fraction will therefore alter the effectiveness 
of TGF and hence alter the GFR. 
Considering now the average sensitivities of both GFR and UO to a parameter change, 
the next most sensitive parameter is glomerular resistance. It is expected that a large sensitivity 
value would be calculated, since this resistance directly impacts GFR in (2.1). The number of 
nephrons has the next highest sensitivity value. This also makes sense as the GFR and UO are 
calculated by multiplying the single nephron GFR and UO by the total number of nephrons. 
Since the number of nephrons is very variable from person to person, this is an important 
parameter that can have a significant influence on GFR and UO. The next most influential 
parameter on these variables is the axial hydraulic resistance through the tubules. Unsurprisingly 
this parameter has a large influence on GFR and UO since fluid flow through the nephron is 
directly related to GFR and UO. 
From this study, we sought to finalize the parameters to estimate for hypertensive, NKI, 
and GN patients. Since feedback and vascular resistance have low impact on GFR and UO 
compared to the other parameters, these parameters make good candidates for manually tuning 
for hypertensive patients, where they are reported to be affected [25]. Hence, in the estimation 
for NKI and GN parameters, we first manually tune the feedback and vascular resistance values 
based on whether or not a patient is hypertensive. This method of adjusting feedback and 
vascular resistance values in the case of hypertension, in [68], has been shown to be effective in 
tuning the model to fit hypertensive patient GFR within 2.6 mL/min. It was also determined, 
based on the sensitivity values of GFR and UO in response to several parameter changes, that 
fluid and sodium reabsorption, glomerular resistance, the number of nephrons, and tubule axial 




most important to estimate in order to be able to effectively fit the model response to a real 
patient response. 
3.2.6 Parameter Estimation Method 
The condensed number of parameters to be estimated for NKI patients, as determined by 
the physiology literature and confirmed via sensitivity analysis, is number of nephrons, 
glomerular resistance, total (all) fluid reabsorption, total (all) sodium reabsorption, and tubular 
resistance. For glomerulonephritis (GN) patients, this set is number of nephrons, glomerular 
resistance, distal sodium reabsorption, and afferent/efferent arteriole resistance. For hypertensive 
patients (regardless of NKI or GN), the set is vascular resistance and renal autoregulation. This 
list of parameters is also shown below in Table 3.2. 
Table 3.2: Parameters to estimate for NKI (no-kidney-injury) and GN (glomerulonephritis). 
Parameters manually set for hypertension (HTN). 
 NKI GN HTN 
Number of Nephrons ✓ ✓  
Glomerular Resistance ✓ ✓  
All Fluid Reabsorption ✓   
All Sodium Reabsorption ✓   
Tubular Resistance ✓   
Distal Sodium Reabsorption  ✓  
Afferent/Efferent Resistance  ✓  
Feedback   ✓ 
Vascular Resistance   ✓ 
 
Rather than estimate the parameter values directly, we instead estimate the scaling factor 
multiplying each parameter. This is done for better performance so that the magnitude of one 
parameter is not favored over another. These scaling factors are also bounded within 
physiological limits, to be discussed. As described in [69], this greatly improves the optimization 




parameter values affected in cases of hypertension by either using the baseline values of [1, 1] 
(normotensive) or [0.5, 6] (hypertensive) for feedback and vascular resistance, respectively, [68]. 
This is done by increasing vascular resistance and decreasing renal autoregulation in cases of 
hypertension. From here, using the available NKI patient data (AKI stage 0), we will estimate the 
NKI parameters using the algorithm described in 3.2.7. The estimated values for nephron number 
and glomerular resistance become new estimation upper limits for the GN parameter estimation 
now since GN patients values for these two parameters will not return to their baseline values if 
the patient is healthy again. Using the parameters estimated during the times of NKI (all fluid 
reabsorption, all sodium reabsorption, and tubular resistance) are held constant for the GN 
patients, we estimate the GN parameters. This process of estimating certain parameters using 
NKI data before estimating the GN parameters we call pre-tuning. Essentially, we use our 
physiological knowledge to estimate parameters that will not necessarily change due to a present 
condition of glomerulonephritis, but that do vary from patient to patient and hence can be 
estimated during NKI. This allows us to tune more parameters for a given patient accurately by 
only estimating a subset of parameters at a time, depending on the patient’s state. This is 
juxtaposed to the non-tuned case where all GN parameter values would be estimated using the 
diseased data outright without first estimating certain parameter values for NKI data. To ensure a 
physiologically feasible range for the parameters, limits for the afferent/efferent resistances are 
applied such that these parameters are bound within the range reported in the literature of 0.88 
and 1.21 in both pre-tuned and non-tuned cases [66]. Finally, the set of GN parameters is 
estimated using the GN data (AKI stage 1, 2, and 3). 
We compare the estimation performance in several different scenarios: with and without 




estimation), pre-tuning NKI parameters using data from AKI stages 0-3 (healthy and diseased) 
vs. using only data from AKI stage 0 (healthy only), and including or excluding the all fluid 
reabsorption parameter in the set of GN parameters. To discern which estimates are the best, we 
compare the average GFR and UO RMSE (root mean squared error) values for all simulations. 
We ensure that the parameter values achieved via estimation are within the physiologically 
expected bounds, and finally, we compute and compare the *pq (Akaike information criterion) 
score, summarized nicely in [70] by Burnham and Anderson and described in a bit more detail 
below.  
The *pq also belongs to a family of information metrics that includes the 4pq (Bayesian 
information criteria) and Up* (Fisher information approximation). These metrics all fit into the 
minimum description length (MDL) framework. Each tries to find the balance between model fit 
and model complexity such that the model is specific enough to estimate the observed data and 
generalizable enough not to be capturing the noise of the signals. The *pq is an estimator of out-
of-sample prediction error and relative quality of statistical models for a given set of data. It also 
penalizes models for including too many parameters and potentially overfitting the data. 
Generally speaking, the lower the *pq value, the better the model. After estimating model 
parameters, we compute the corrected *pq, which accounts for sample sizes that are small. Non-
corrected *pq converges to the corrected *pq value as the sample size gets large, so [70] 
recommends always using the corrected *pq score. This formula is 
 *pq = Wlog(uvD) + 29 + 29
(9 + 1)
W − 9 − 1 , 
(3.6) 
where 9 is the number of parameters plus 1, W is the number of data points, and uvD is the mean 




We then calculate Δ*pq as the difference between the *pq scores and the minimum *pq 
score of all the models we are comparing. Burnham and Anderson [70] provide rough guidelines 
for interpreting Δ*pq values recommending that Δ*pq values above 10 indicate that a model 
with lower *pq is better. This implies that when comparing Δ*pq values between models, we 
can confidently conclude that those with Δ*pq values above 10 should not be used because they 
are overfitting the data, according to this metric. 
To further evaluate estimation performance, we compare the errors in the model outputs 
to the GFR and UO data and report RMSE values. In current practice, GFR can only be 
calculated based on serum creatinine measurements taken at a given moment. This calculation of 
GFR has been reported to have error of as much as 18 mL/min [71]. The GFR MDRD 
calculation is also less accurate for values above 60 mL/min [72]. Further, the GFR values 
calculated using the MDRD equation versus the CKD-EPI equations are often in disagreement. 
With this limitation of the GFR calculations to which we will compare our estimation in mind, 
we expect our model’s estimates to provide a GFR with RMSE under 18 mL/min for all GFR 
values. Since oliguria (the production of abnormally low urine amounts and a sign of kidney 
injury) is defined as UO less than 1 mL/min, we expect to see the estimation of UO with RMSE 
under 1 mL/min. Beyond this, the simplest model for any set of data is simply the average. In 
that case, the standard deviation of the data would represent the RMSE threshold for this simple, 
average model. Hence, we also expect our model estimation results to have errors well below the 
standard deviation of the data. Finally, our estimation results should also have parameter values 
that make physiological sense. Since reducing the RMSE at the cost of infeasible parameters 




3.2.7 Parameter Estimation Algorithm 
In order to estimate the model’s parameters, given a set of input and output 
measurements from a patient, we seek to minimize the sum of squared errors between model 
outputs and database outputs. This error is minimized over the set of adjustable parameters, 
determined by the disease and AKI stage of each patient. Since each parameter is physiologically 
bounded within a certain range, we consider constrained optimization. Further, since our outputs, 
GFR and UO, cannot be solved explicitly via our system of equations, we employ implicit 
constrained optimization. 
The derivation for the optimization will continue for a single output in an unconstrained 
and implicit system, and then modifications will be made to account for these changes. To 
guarantee local convergence we use constrained Levenberg-Marquardt optimization and an 
Armijo line search, and to guarantee global convergence we then implement the projected 
gradient optimization [73] when these methods fail to converge. In an effort to avoid the local 
minima due to the nonlinear nature of the system, we use a multi-start algorithm which will 
optimize the parameter values of several slightly different starting points, wherein we then 
choose the parameter values with the lowest cost [69]. Specifically, we begin by exhaustively 
evaluating the cost for 10% incremental changes to all combinations of scalings to be estimated. 
Then, we choose the three scaling value combinations that produce the smallest cost. These three 
scaling value combinations are then used as the starting points for the estimations. After 
convergence, we remove duplicates (two or more parameter sets having the same values after 
convergence), and then choose the set of scaling values with the lowest cost that also have 




The parameter estimation method used for this work was a multi-start constrained 
Levenberg-Marquardt optimization for an implicit system for local convergence and projected 
gradient for global convergence. This method was chosen, not necessarily for the speed of 
solving, but for the performance on similar systems, as well as the ease with which we could 
adapt unconstrained optimizations to be constrained. 
Villaverde et al. [69] conducted several experiments to determine the ideal method of 
optimization for kinetic biological systems by defining a metric known as efficiency (a balance 
between accuracy and time). They initially concluded that gradient-based local searches 
outperform gradient-free local searches. They also concluded that hybrid algorithms which 
leverage global and local algorithms are more efficient than purely global or local searches. 
Further, they concluded that a multi-start method can be sufficient for finding the global 
minimum. This reinforces the importance of simulating our parameter estimation several times 
for different starting points to avoid local minima. It was also concluded in [69] that Levenberg-
Marquardt for nonlinear least squares performs efficiently for most problems when compared to 
interior-point algorithm and the gradient-free based dynamic hill climb algorithm. 
Ozyildirim and Kiran [74] in their work, compared gradient descent, conjugate descent, 
Broyden–Fletcher–Goldfarb–Shanno (BFGS), and Levenberg-Marquardt for several machine 
learning parameter estimation simulations. They concluded that, while not the fastest, given the 
same starting conditions, the Levenberg-Marquardt algorithm converged the most accurately. 
The derivation for the estimation algorithm used for all versions of the model is now 
presented. Given : outputs w = OxL, … , xP , … , x(P with z observable outputs, { inputs | =




 	w = Ä(|, ~). (3.7) 
For a single response system, such that x = w, and with W measurements of the system, we look 








= ÑWÑ = (Ö − wÜ)W(Ö − wÜ)
= ÖWÖ − áÖWwÜ + wÜWwÜ, 
(3.8) 
where Ö is a vector of W measurements of the output and wÜ is a vector of W model outputs. This is 
done iteratively since the system is nonlinear. This method can be modified to include a 
weighting matrix à. 
The Levenberg-Marquardt algorithm is a balance between the gradient descent method 
and the Gauss-Newton method. For the gradient descent method, we use the negative gradient of 
the cost function with respect to the parameters in order to update ~. This gradient is given by 
 â
â~ Ç(~) = −2(Ö − wÜ)
W â
â~wÜ = −2(Ö − wÜ)
Wä, (3.9) 
where ä = äX
YZ  is the Jacobian of wÜ with respect to ~. Therefore, for gradient descent, we have 
 Åã[\ = aä](Ö − wÜ), (3.10) 
where a determines the step size along the search direction of Åã[\, added to ~. For Gauss-
Newton method, we use a Taylor series to approximate the function after the parameters have 
been updated by Å~[^, given by 
 wÜO|, ~ + Å~[^P = wÜ(|, ~) + äÅ~[^ = wÜ + äÅ~[^. (3.11) 
The new cost function is given by 
 ÇO~ + Å~[^P = Ö
WÖ − áÖWOwÜ + äÅ~[^P + OwÜ + äÅ~[^P
WOwÜ + äÅ~[^P





We can therefore find the value of Å~[^ that minimizes the cost function by finding where the 




ÇO~ + Å~[^P = 0, (3.13) 
 −2(Ö − wÜ)Wä + 2Å~[^W äWä = 0. (3.14) 
Therefore, Å~[^ is given from the normal equation 
 (äWä)Å~[^ = äW(Ö − wÜ), (3.15) 
as 
 Å~[^ = (äWä)2LäW(Ö − wÜ) = äa(Ö − wÜ), (3.16) 
where äa is the pseudoinverse of ä. For the Levenberg-Marquardt algorithm, we adaptively 
switch between both methods for parameter updates Å~bc, as determined by a damping 
parameter å and the positive definite scaling matrix ç:ç. This is given by 
 Å~bc = (äWä + åç:ç)2LäW(Ö − wÜ). (3.17) 
Here a larger å value corresponds to a favoring for gradient descent and a smaller value 
corresponds to a favoring for Gauss-Newton. This allows the algorithm to take larger steps 
initially and iteratively update å to favor Gauss-Newton to accelerate towards the local minimum 
when close. For each successful step, the value of å is decreased, and for unsuccessful steps, å is 
increased. We use a delayed gratification approach, described in [75], where the value of å is 
decreased by 5 times for unsuccessful steps, and increased by only 1.5 times for successful steps. 
Transtrum and Sethna [75], also propose defining ç:ç as the largest values of ä:ä yet 
encountered, as a compromise between two common techniques that define ç:ç as either ä:ä or 




The Armijo line search iteratively reduces the step along the search direction in an effort 
to reduce the cost. This search is only conducted if the Levenberg-Marquardt step fails to reduce 
the cost by a certain amount, and if the search direction is in a descent direction. A descent 
direction is defined as one where 
 è ââ~ Ç(~)ê
:
Å~bc ≤ −í‖Å~bc‖R, (3.18) 
for parameters of the optimization í > 0 and \ > 1. 
In our kidney model we cannot explicitly solve for GFR and UO in the form of (3.7), and 
as such we have 
 î = ï(w, |, ~). (3.19) 
Therefore, we need to approximate the values for ä using the implicit function theorem as 
described by Sachs [76]. Given a system of the form in (3.19), a Jacobian of ï with respect to 
(w, |, ~) that exists and is continuous, and a Jacobian of ï with respect to w, äYd, evaluated at 
(w, |, ~) that is of rank :, then this guarantees the existence of a set of : functions Ä, which are 
unique, continuous, and differentiable within some neighborhood of (w, |, ~) given by w =





The ñth row (for ñth model output) of äX
e  corresponds to the óth row (for the óth measurement of 
xvP) of äX




For the multi-response case, with , observable outputs (sensors), for each output, we 
stack the vectors and matrices such that Ö = òÖf, … , Ög, … , Öhô
W, wÜ = òwÜf, … , wÜg, … , wÜhô
W, and 
ä = òäf, , … äg… , ähô
W, and redefine the Levenberg-Marquardt equation as  
 Å~bc = (äWä + åé)2LäW(Ö − wÜ). (3.21) 
Finally, since the parameters are physiologically bounded such that they cannot be 
negative and must be within a reasonable scaling, we consider constrained optimization and 
make further adjustments to the optimization. Our parameter bounds are all simple box 
constraints and therefore, utilizing the constrained Levenberg-Marquardt algorithm described in 
[73] will satisfy local convergence and is easily implemented. Here we solve the for Å~bc from 
(3.21) as we normally would and then restrict the values of Å~bc to be within physiological 
constraints. For global convergence and for Levenberg-Marquardt and line search steps that do 
not reduce the cost by a sufficient amount, we implement a projected gradient step [73]. Here we 
search for the maximum value ö = {úi|E = 0,1,2, … } that satisfies a simple descent condition 
given by 





where u and ú are parameters of the optimization. 
To further improve the speed and accuracy of the optimization, we employ geodesic 
acceleration. This addition essentially includes a second order correction for the approximation 
of the cost function in (3.8). The full derivation of this method can be found in [75]. The 
derivation leaves us with two terms for calculating the parameter shift,  
 Åã = Åãf + Å~j, (3.23) 




 Å~j = −
1
2 (ä
:ä + åç:ç)2Lä:Çkk, (3.24) 
where Ç′′ is the second directional derivative of the cost. This derivative is approximated by 
 Çkk ≈ 2ℎ `
Ç(~ + Åãf) − Ç(~)
ℎ − äÅãfb, (3.25) 
where ℎ is the approximate derivative step size, with a value of 0.1 working reasonable well 




≤ a, (3.26) 
for some a < 1. This inequality ensures that the now second order sequence used to approximate 
the cost converges with successively smaller terms in the Taylor series. 
To stop the algorithm, we have both stopping conditions and convergence criteria. 
Stopping conditions include stopping when: 1) å values are above a certain value (1010), 2) a 
maximum number of optimization steps is reached (1000), 3) the maximum parameter shift is 
below a certain threshold (10-5), or 4) Levenberg-Marquardt, line search, or projected gradient 
could not successfully step. To claim convergence, there are three possible criteria: 1) the cost is 
reduced below a certain value (10-4), 2) the gradient of the cost is reduced below a certain value 
(10-3), or 3) the angle between the residual vector and the tangent plane is minimized (10-2). This 
last criteria is described in [75], as a geometric interpretation of the least-squares problem and 
can be quantified by  
 cos• =
|¶:Ñ|
|Ñ| , (3.27) 
where the angle • is to be minimized below some quantity such as the recommended 10-3, and 
¶: is the projection operator into the tangent plane. This matrix ¶: is determined by 




3.2.8 Hessian Calculation 
In adding the geodesic acceleration modifier to the Levenberg-Marquardt routine, we 
approximate the second directional derivative by (3.25). However, we can calculate this exactly 
if we first calculate the Hessian of the cost function. To calculate the Hessian of the cost 
function, we can differentiate the Jacobian of the cost function with respect to ~, such that ßXl  is 
a \ × \ matrix with an arbitrary element given by 






We can use (3.9) to then write 




wÜb = −2 ®®m
(Ö − wÜ): ⋅ ®®n




via the product rule. From here, 








































































































































In approximations of the Hessian, the second matrix in (3.33) is set to zero, since the residuals 
and derivatives will be approximately zero near the solution. To solve for ßXl  exactly though, we 









xvV is easily found with two derivatives of iq with respect to m and n, evaluated at |V 
and ~. However, for an implicit system, we do not have an explicit expression for iq. We know, 
based on (3.20), how to calculate the óth row of äX
YZ , using the ≤th row, corresponding to iq, from 
äX
e , evaluated at wS, |S, and ~. We can differentiate äX
e , elementwise, with respect to m. Then, by 
using the element in the ≤th row and zth column of the : × \ matrix, âäX











The elementwise derivative of r
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Therefore, we can calculate (3.37) and use the (≤, z)th element to evaluate (3.34), for all 
combinations of mixed partials. Finally, we evaluate (3.33) to calculate the Hessian. For (3.37), 
we have two new terms not previously evaluated, in finding the Jacobian of the cost,	âäed/âm 
and âäXd/âm. Using the chain rule, in (3.20), for an arbitrary element of âäed/âm and âäXd/âm, 

































In order to evaluate the elements in (3.38) and (3.39), we need to calculate ®Ä/®m. Since we are 
dealing with an implicit system, in order to calculate this, we use the expression for äX
e  in (3.20). 
The öth column of äX
e  is equivalent to ®Ä/®m in (3.38) and (3.39). Or more succinctly, ®Ä/®m =
äp*



















































; with ®~/®m equal 




Reiterating, we calculate all elements in (3.40) and (3.41) for a given m, which are then 
used to evaluate (3.37). The (≤, z)th element of â?X





iq. This term is 





evaluated at wÜV, |V, and ~. Once all the elements of the second matrix in (3.33) are calculated, 
for all combos of m and n, then we are readily able to calculate the Hessian. 
Generalizing this evaluation of the cost function Hessian for multivariate systems is fairly 
straightforward. The dimensions of the Hessian are still \ × \ and the expression is given by 
(3.33). The Jacobian matrix äX
YZ  is augmented to ,W × \ where , is the number of observable 
outputs. Without loss of generality, it is assumed that the observable outputs are the first , 








. For the remainder of the Hessian evaluation 
in (3.33), we need to adjust (3.34). This is done similarly such that Ñ =
[(ÖL − wÜL): ⋯ (Ö" − wÜ"):]: and wÜ = [(wÜL): ⋯ (wÜ"):]:. 
3.3 Results & Discussion 
3.3.1 Parameter Estimation Method Validation 
For a sanity check of the algorithm implementation, we used model generated data and 
estimated the glomerular resistance value, while holding all other parameter values at their 
baseline value. The global minimum can be visually discerned from a plot of the cost function as 
the parameter changes. We estimated the parameter value for several starting points within the 
bound for this parameter. The true global minimum is found at 2. The cost function is shown in 
Fig. 3.3. We note that in simulation, regardless of the starting point with respect to the global 




the estimation is in fact converging towards a minimum as it should. The estimation 
implementation was also checked for two parameter, three parameter, four parameter, and five 
parameter estimations with model generated data. In all cases, the true minimum was found. 
Estimation took longer when estimating more parameters. Also, when estimating three, four, and 
five parameters, an exhaustive evaluation of the cost function was performed before the 
estimation, as described in the Methods section. This involved evaluating the cost for 10% 
incremental changes of all combinations of scalings to be estimated. Then, the scaling values 
with the lowest cost were used as initial points for the estimation. For the five-parameter (or NKI 
parameter) scaling estimation of the number of nephrons, the glomerular resistance, the fluid 
reabsorption, the sodium reabsorption, and the axial resistance, we generated input and output 
data, using the model, for the following scalings, [1.1,1.2,0.9, 0.9,1.1] respectively. All other 
values were held to their baseline value of 1. After an exhaustive search, three scaling 
combinations with the lowest cost were identified. After running the parameter estimation with 
these three initial value sets, two cases converged to the same final set of values, 
[1.117, 1.186,0.899, 0.898,1.137], with final costs below 1025. From this experiment and 
further testing with the model and optimization method we determined that three starting points 





Fig. 3.3: Plot of the cost function for a model generated data, as only the glomerular resistance 
parameter is varied. The cost considers both the GFR and UO, and the global minimum is 2. 
3.3.2 Hessian Calculation Results 
Typically, the cost function Hessian is approximated as ä:ä. However, given the 
derivation of the cost function Hessian outlined above, we can exactly calculate it. The Hessian 
approximation is derived from (3.32) where, as the parameter values approach the true values, 
the residuals will approach zero. Hence, the Hessian, when near the true parameter values, is 
approximated by ä:ä. As such, as the parameter values approach the true values, we can expect 
the percent difference between the eigenvalues of the approximate and exact Hessians to 
decrease. 


























To ensure that our Hessian calculation was correct, we plotted the absolute differences 
between the true Hessian and the approximate Hessian eigenvalues, as a function of absolute 
distance from the optimization convergence value, for a particular parameter estimation example. 
In Fig. 3.4, we see the results after a parameter estimation for glomerular resistance using model 
generated data with a true global minimum at 2. As can be seen from the figure, as the parameter 
values approach the minimum, the difference between both eigenvalues of the Hessian 
calculation methods approach zero as well. The difference is never truly 0 and this is due to the 
fact that the residuals calculated are never equivalently zero, since the optimization routine will 
declare convergence after a certain cost or angle is achieved. However, we can observe the trend 
that clearly indicates that the error between both Hessians is decreasing as expected. We can also 
thereby quantify the relationship between the difference in Hessian value calculations and 





Fig. 3.4: Hessian error between approximated hessian using only the Jacobian and the true 
Hessian derived in the Methods section. Results are for a model generated data, estimating 
just glomerular resistance scaling with true global minimum at 2. 
3.3.3 Parameter Estimation Robustness 
In order to test the robustness of the model and estimation technique, we studied how 
noise affects the estimation results and how an incorrect parameter adjustment (for hypertension) 
affects the estimation results in both cases of a hypertensive (hypertension positive) patient and 
normotensive (hypertension negative) patient. Noise is an inevitable aspect of signal 
measurement and can also be due to an imperfect model of the real-world system. As such, 
studying how noise will impact the estimation results for NKI and GN patients in important. For 
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MIMIC database. The hypertension parameters were shown to be the least effective in altering 
GFR and UO values and this manual tuning has been shown to perform well in other work [68]. 
However, we sought to understand how incorrect tuning for hypertension would affect 
estimation results for NKI and GN patients. Incorrect tuning for hypertension can occur if the 
hypertension flag in the MIMIC database was incorrect and as a result, we either adjust 
parameters for hypertension in a non-hypertensive patient or fail to adjust parameters for 
hypertension in a hypertensive patient.  
Noise robustness was tested by randomly adding three degrees of uniformly distributed 
noise to the outputs of model generated data with known parameter values. Estimations were 
conducted three times with the results averaged since there is an inherent randomness associated 
with the noise. GFR noise was determined based on a 95% confidence interval in measuring 
serum creatinine (an input into the function for determining GFR). In this case, low GFR noise 
was determined to be 1.3 mL/min [77]. For urine output rate, UO, low noise was determined to 
be 0.04 mL/min [78]. Medium and high noise was classified as the doubling and quadrupling of 
low noise, respectively. The results of this test are shown in Fig. 3.5. This test was conducted for 
parameters that reflect an NKI patient, with values chosen based on the physiology (1.2 times the 
number of nephrons, 1.2 times glomerular resistance, 0.9 times fluid and sodium reabsorption, 
and 1.1 times axial resistance in the tubule), and parameters that reflect a glomerulonephritis 
patient (0.7 times the number of nephrons, 0.5 times glomerular resistance, 0.8 times distal 
sodium reabsorption, and 0.88 afferent and efferent arteriole resistance). We note the similarity 
in Fig. 3.5a and Fig. 3.5b. Noise in both cases will affect the residuals theoretically identically. 
Because of this, we can expect a similar magnitude of root mean squared error (RMSE) values in 




error (MSSE) and hence the cost functions are both quadratic while the GFR and UO RMSE 
functions seem to be linear. 
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Fig. 3.5: Noise robustness testing figures for a NKI patient and for a glomerulonephritis 
patient. Testing was conducted three times for each noise level with results averaged. Data 
was generated from the model with parameters that reflect with the NKI or 
glomerulonephritis state of the patient. GFR noise was 1.3, 2.6, and 5.2 mL/min. UO noise 
was 0.04, 0.08, 0.16 mL/min. 
For the NKI patient data, we can see that with increased noise, the estimation in fact 
performs worse. Specifically, the GFR RMSE was essentially zero with no noise and with 1.3 
mL/min of noise added to the measurement output, this corresponds to a GFR RMSE of 0.68 
mL/min. As noise increased to 5.2 mL/min, the GFR RMSE increased to 2.6 mL/min. It appears 
to be an approximately linear relationship with the doubling of noise. The UO RMSE displays a 















































































similar relationship, where increased measurement noise linearly affected the estimation UO 
RMSE. For the glomerulonephritis patient, we see again that increased noise worsens the 
estimation in terms of RMSE and optimization cost. As in the NKI patient case, generally there 
is a linear relationship between the doubling of noise and GFR and UO RMSE. This implies that 
additional noise does not affect the parameter estimation with diseased data more than the 
parameter estimation with NKI data. The optimization cost changes quadratically as well, as 
expected since it is calculated based on the squares of GFR and UO RMSE. Based on this noise 
robustness analysis, we can expect a linear increase in GFR and UO RMSE with respect to the 
doubling of the noise for the GFR and UO measurements. 
For the hypertensive test, we sought to understand the extent to which estimation error is 
affected by incorrect adjustment of parameters for hypertension, since these parameters are set to 
one of two possible values manually for each patient. In order to test this, we generated two NKI 
and two glomerulonephritis patients, one with hypertension and one without in each group. 
Therefore, for the NKI and glomerulonephritis tests, we have four cases, 1) a true-negative (TN) 
case for a normotensive patient with no hypertension flag and correct normotensive parameters, 
2) a false-positive (FP) case for a normotensive patient with hypertension flag and incorrectly 
assigned hypertension parameters, 3) a true-positive (TP) case for a hypertensive patient with 
hypertension flag and correct hypertensive parameters, and 4) a false-negative (FN) case for a 
hypertensive patient with no hypertension flag and incorrectly assigned normotensive 
parameters. The results from these tests are shown in Fig. 3.6, with an NKI patient in Fig. 3.6a 
and a glomerulonephritis patient in Fig. 3.6b. In general, baseline simulations, with correct 
hypertension parameters, successfully identified the parameter scalings in both cases, true 




respective histogram being equal in value. This result is expected since the model should fit the 
generated data perfectly with correct parameters. Presumably the estimated scalings would be 




























































































































































Fig. 3.6: Hypertension parameter robustness. For the NKI and glomerulonephritis test 
patients, we have four cases, 1) a true-negative (TN) case for a normotensive patient with 
correct normotensive parameters, 2) a false-positive (FP) case for a normotensive patient with 
incorrectly assigned hypertension parameters, 3) a true-positive (TP) case for a hypertensive 
patient with correct hypertensive parameters, and 4) a false-negative (FN) case for a 
hypertensive patient with incorrectly assigned normotensive parameters. 
For the NKI patient in the case of incorrectly assumed hypertension (FP), nephron 
number, glomerular resistance, and axial resistance increased, while sodium reabsorption 
decreased, and fluid reabsorption remained largely unchanged in the estimation. Decreased 
feedback from hypertension will increase GFR at higher MAP and Na pressures. The increased 
vascular resistance will decrease the GFR and UO values. Because of this, the estimation is 
assuming a greater nephron number to counterbalance this decreased GFR. The estimated 
increased glomerular resistance is an attempt by the estimation to modulate the less functional 
autoregulation, by dampening the flow into the proximal tubule that is no longer being controlled 
by the feedback. For the NKI patient in the case of incorrectly assumed normotension (missed 
hypertension) (FN), nephron number and glomerular resistance are both estimated below their 
true values. Sodium reabsorption and axial resistance are estimated above their true values, and 
fluid reabsorption is correctly estimated. For the same reasons as mentioned above, nephron 
number and glomerular resistance estimated values balance the effects of overactive feedback 
and a higher vascular resistance for the patient. The only parameter that is estimated above the 
true value in both cases is the axial resistance. Overall, an increase in this parameter value, will 
lead to a decrease in GFR and UO. This is due to the reduction in flow throughout the nephron. 
For the glomerulonephritis patient in the case of incorrectly assumed hypertension (FP), 
nephron number, distal sodium reabsorption, and a/efferent resistance decreased. Glomerular 
resistance increased in the FP case. Interestingly, unlike the FP NKI case, nephron number here 




afferent/efferent resistance sharply decreased, which will drastically flatten the rise in GFR with 
MAP under the myogenic response threshold. This is no doubt due to the incorrect assumption 
that the feedback has been damped in the FP case. The opposite effect is seen in the FN case. 
Distal sodium reabsorption has a mild direct effect on GFR and UO as it changes. 
In summary from the hypertension parameter robustness, we can expect the following: 
GFR RMSE as high as 2 mL/min and UO RMSE as high as 0.2 mL/min, nephron number as 
high as 10%, glomerular resistance as high as 200%, fluid reabsorption not greatly affected, 
sodium reabsorption as high as 10%, axial resistance as high as 60%, distal sodium reabsorption 
as high as 30%, and afferent/efferent arteriole resistance greater than 200%. 
3.3.4 No-Kidney-Injury Parameter Estimation Validation 
For the 28 available NKI patients that develop GN, we estimated the NKI parameters that 
can be seen in Table 3.3. There was an average of 30 datapoints per patient. The estimation was 
performed over all patients and the average values of each estimated parameter and GFR and UO 
RMSE values were collected. The estimation was performed twice for all patients, once 
estimating the NKI parameters using only the AKI stage 0 data and another time using all 
available patient data (AKI stage 0 – 3). This was done to simulate a scenario of tuning the NKI 
parameters with unlabeled kidney measurement data, as can occur in real-time settings. 
Table 3.3: Average estimated parameters and RMSE values for all 28 patients (30 data points 
per patient average) for NKI parameter estimations. Two models are presented, one using all 
AKI stage 0 data and one using all available data (AKI stage 0 – 3) for each patient. The "#$ 
scores for each model is presented and a %"#$ is computed.  
 AKI Stage 0 Estimates 
AKI Stage 0 – 3 
Estimates 
Number of Nephrons 0.587 0.594 
Glomerular Resistance 0.252 0.222 
All Fluid Reabsorption 0.974 0.970 
All Sodium Reabsorption 0.969 0.948 




GFR RMSE (mL/min) 13.55 13.66 
UO RMSE (mL/min) 0.78 0.65 
*pq 102.8 177.5 
Δ*pq 0 74.7 
 
We note that for both models, the GFR and UO RMSE are approximately 1/5th the 
standard deviation of the data. This is expected because the model should perform better than a 
simple constant model of just the data mean. Further, for both models, the GFR RMSE is less 
than 18 mL/min and UO RMSE is less than 1 mL/min. Therefore, our estimation is performing 
better than the current standard for assessing GFR. 
For the model using only AKI stage 0 data, we note that, with the removal of two 
potential outlier patients lowering the GFR and UO RMSE values, the GFR RMSE value is 
further reduced from 13.55 mL/min to  9.01 mL/min and is lower than the 13.5 GFR RMSE 
value reported in [68], where a generic human model was used to fit healthy patient data. This 
should certainly be the case since the parameters are now being tuned to fit the data more 
accurately. We also see that the scaling factor applied to the number of nephrons is not 
surprisingly less than one, since this parameter varies greatly across all types of people. 
The second model with all the patient data can be used to study how an unlabeled dataset 
(or an unlabeled kidney injury) will influence the estimation results. The number of nephron 
estimates were similar across both sets, and glomerular resistance estimates slightly lower across 
all stages. Tubular resistance was decreased on stage 0 and increased in all stages. This suggests 
that tubular resistance is potentially increased in AKI stage 1 – 3 and hence raising the value for 
AKI stage 0 – 3 estimates. The GFR RMSE was nearly identically with AKI stage 0. UO RMSE 
was surprisingly more accurate in AKI stage 0 – 3 estimates. This implies that the model may be 




would have a lower UO value on average since the kidney is diseased for this data. It also 
suggests measurement bias, where more measurements with more accuracy (less noise) were 
being recorded for AKI patients as opposed to NKI patients. 
According to *pq value, the AKI stage 0 model is far better than the estimation using 
AKI stage 0 – 3  since the difference in AICs is well above 10 [70]. This is not surprising since 
we are using NKI parameters to fit more data, a large portion of which will require tuning 
additional parameters, outside of the NKI parameters, due to AKI stage 1 – 3 and GN. 
To further validate our estimation results, we divide the results, for AKI stage 0 data, by 
different demographic categories including sex, race, age, height, weight, and length of stay 
(LOS). The goal was to look at average results across different demographics to see if they 
match the literature, see section 3.2.3. These results are presented in Fig. 3.7.  
 
Fig. 3.7: Average NKI parameter estimations over all 28 patients using only AKI stage 0 data. 
The estimated parameters were averaged along different demographic dimensions including 
sex, race, age, height, weight, and length of stay (LOS). For sex and race, the number of 
patients in each category is uneven and shown in parenthesis. For age, height, weight, and 
LOS, the patients were split evenly into groups of 14. 
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Considering the difference in patients according to sex, we see that the number of 
nephrons is greater for the male patients as described by [11]. The glomerular resistance is also 
higher for males as reported by [35]. Fluid and sodium reabsorption is also slightly higher for 
males as reported by [60]. Finally, as reported by [57], we see the axial resistance is lower for 
males. When considering race, we note that only 14.3% of the population used in this study were 
Black, and hence statistical conclusions cannot be drawn. In fact, in the group of Black race, 
fluid and sodium reabsorptions, and axial resistances results oppose those expected from 
literature. The literature also says that the number of nephrons should approximately be the same 
across all races, which we do not see here. In terms of age, we do not see the expected decrease 
in number of nephrons with age. However, we do see, as described in [50], a relatively 
constantly fluid and sodium reabsorption with age. Further we see the decrease in axial 
resistance described by [53] that increases with age. For height and weight, [79] reports that 
taller and heavier people will have increased nephron number, which we see here. Further, fluid 
and sodium reabsorption are about the same across individuals ignoring cases of extreme obesity  
[55] and [56]. For length of stay (LOS), the number of nephrons, fluid and sodium reabsorption, 
and tubular resistance are estimated to be approximately the same value, and hence be invariant 
to length of stay. This is expected as there should be no correlation between these parameter 
values and their length of stay in the hospital will classified as NKI. 
Overall, for sex, age, height, weight, and LOS the observed differences in the majority of 
parameter scaling factors across each demographic category aligns with the expected values from 
the literature and gives credence to the estimation results presented. Three trends we have not 
found in the literature but do note from the results include that axial resistance decreases for 




with age. Also, the increased nephron number reported in taller and heavier people may be due to 
compressing of the kidney and the nephrons, which increases the axial resistance. 
3.3.5 Glomerulonephritis Parameter Estimation Validation 
For estimating the GN parameters of the patients, we have an average of 36 data points 
per patient. We employed the estimation methodology described previously under several 
different scenarios or estimation models. The full list of models can be seen in Table 3.4.  




B Pre-tuned – without a/efferent resistance bounds 
C Pre-tuned – without glomerular resistance upper bound 
D Pre-tuned – without number of nephron upper bound 
E Pre-tuned – without upper bounds 
F Pre-tuned – Using pre-tuned parameters from AKI stage 0 – 3 data 
G Pre-tuned – Using pre-tuned parameters from AKI stage 0 – 3 data, 
without a/efferent resistance bounds 
H Not pre-tuned – without afferent/efferent resistance bounds 
I Not pre-tuned 
J Not pre-tuned – with all fluid reabsorption, without a/efferent resistance 
bounds 
K Non-pre-tuned – with all fluid reabsorption 
 
 Model A was conducted as the baseline estimation, as described previously. Model B is 
the same as Model A, but without bounding on afferent/efferent resistance. This was done to see 
if the estimated parameter value is still within physiological bsunds as expected. Models C, D, 
and E are the same as Model A, but each omits different parameter bounding. Models F and G 
use pre-tuned parameter values estimated from the entire dataset, instead of just AKI stage 0. 
Additionally, Model G does not contain afferent/efferent resistance bounds. These estimations 
were done to ascertain if the model performs better after parameters are tuned with all data since 




pre-tuned in that they use baseline scalings of 1 for all NKI parameters before estimating GN 
parameters. This is to assess estimation of GN parameters with no knowledge of the patient 
beforehand (not starting from an NKI-personalized model) when only GN parameters are 
estimated. Additionally, Model I does not bound the afferent/efferent resistance. Finally, Models 
J and K are not -pre-tuned, but with the addition of all fluid reabsorption as a parameter to 
estimate for GN. This estimation was performed to see if including a more sensitive parameter 
improves the result in a not pre-tuned case. Estimation K further does not bound the 
afferent/efferent resistance. 
After simulating over all the GN patient data for all estimation models, the results were 
averaged and compared. This can be seen in Table 3.5. We see that all models are within the 
design criteria of GFR RMSE less than 18 mL/min and a UO RMSE less than 1 mL/min. 
Further, both RMSE values are much lower than the standard deviation of each respective signal. 
Note that the when the model is personalized to any patient, it achieves an average GFR and UO 
RMSE value of 42.3 and 1.81 mL/min respectively. As expected, this version of model performs 
significantly worse than the personalize models since parameters can vary greatly from person to 
person. It also demonstrates by a quantifiable amount, by how much personalizing the model to 
each patient improves upon the error. 
Table 3.5: Average estimated parameters and RMSE values for all 28 patients (36 data points 
per patient average) for GN parameter estimations. Multiple estimation models are 
presented for each patient. The "#$ scores for each estimation is presented and a %"#$ is 
computed. 
 A B C D E F G H I J K 
Number of 
Nephrons 0.495 0.467 0.478 0.675 0.687 0.492 0.53 0.635 0.511 0.743 0.557 
Glomerular 
Resistance 0.183 0.126 0.496 0.137 0.494 0.198 0.258 0.413 0.364 0.34 0.694 
Distal Sodium 





Resistance 1.013 0.887 0.524 2.421 2.307 0.911 1.033 1.888 0.963 2.737 1.064 
All Fluid 
Reabsorption - - - - - - - - - 0.982 0.985 
GFR RMSE 
(mL/min) 13.34 12.7 12.49 12.8 12.51 12.77 13.1 12.57 14.18 12.75 14.38 
UO RMSE 
(mL/min) 0.63 0.661 0.651 0.624 0.624 0.539 0.505 0.496 0.495 0.446 0.483 
!"# 115.3 114 113.4 113.5 113 108.2 108.2 106.3 108.5 110.3 115.8 
Δ!"# 9 7.7 7.1 7.2 6.7 1.9 1.9 0 2.2 4 9.6 
 
Models A and B have almost identical parameters, with afferent/efferent resistance 
different by only 0.13. This implies that the true minimum was indeed within the physiological 
bounds of the expected afferent/efferent resistance since convergence to this point was achieved 
with and without the bounds. Compared to one another, the Δ*pq of Models A-E are all within 4 
and essentially difficult to distinguish which model is better. Models A-C have physiologically 
sound afferent/efferent resistances in the range of 0.88 to 1.21. The models without bounded 
nephron number or glomerular resistance achieve values higher than in the NKI case, which is 
not physiologically feasible, unless the NKI estimate was an underestimate. For Model C, GN 
glomerular resistance values reported were higher than in the NKI case, Table 3.3. This is 
unexpected because it would be assumed that resistance would be lower in the diseased case 
[66]. This is possibly due to clinical intervention (such as dialysis) data impacting results where 
inputs and outputs being recorded would essentially reflect a model of the dialysis machine and 
not the patient’s kidney. For Model E, interestingly, the number of nephrons and glomerular 
resistance values estimated were the same as those values from the respective estimation Models 
C and D where the respective parameter was not bounded. The *pq difference between Models 





Model F achieves very similar results to the pre-tuned case, as all parameters are within 
10% of these values. The UO RMSE value is actually more accurately calculated, but GFR 
RMSE is approximately the same. Without the afferent/efferent resistance bounds in Model G, 
the parameter values achieved are all still within 10% implying that the true minimum was still 
within the afferent/efferent resistance bounds. The Δ*pq is very low between the Models F and 
G as expected since they converge to similar parameters. The Δ*pq is also low compared to all 
estimations. 
Comparing Model B and H, GFR and UO RMSE values are similar across pre-tuned and 
non-tuned estimates. The number of nephrons and glomerular resistance are overestimated in the 
not pre-tuned case since they are much higher than in the NKI case. This is again, not possible 
since nephrons can only die, and resistance can only decrease. Distal sodium reabsorption values 
are similar in both cases. Since afferent/efferent resistance is not bounded in Models B and H, 
the value is not physiologically correct in the not pre-tuned case but falls into expected range of 
0.88-1.21 in the pre-tuned case, giving credence to the pre-tuned case. 
Including afferent/efferent resistance bounds in Model H, keeps all parameters within 
physiological bounds, but increases the GFR RMSE as compared to Model I. This implies that 
the true minimum was outside the range of the physiologically sound parameter values for the 
afferent/efferent resistances. This is most likely due to all sodium reabsorption and tubular 
resistance values not matching the patient as they have not been tuned with NKI data first. 
In Models J and K, we achieve the lowest UO RMSE values, but the afferent/efferent 
resistance is very high. This suggests that including all fluid reabsorption allowed for better UO 
corrections, but at the cost of other parameter values as well. The highest of all nephron numbers 




GFR RMSE increases, but UO RMSE stays about the same, and the nephron number decreases, 
and the glomerular resistance increases. This is most likely due to these parameters 
compensating for the decreased afferent/efferent resistance allowing for a higher GFR now. 
According to the *pq and the difference in *pq values, the pre-tuned model with 
parameters from all the data is the best version of pre-tuned estimations (Model G). This model 
also has feasible parameter values. Presumably this is because the parameters for NKI were 
tuned on the AKI data and hence the AKI parameters fit the AKI data better. Since this model 
also does not bound the afferent/efferent resistance, it allows for anomalies occurring in real 
patients to be captured. Adding fluid reabsorption with afferent/efferent resistance, Model J, 
raises the *pq difference almost above 10. Essentially the AIC determined this is a worse 
estimation method, overfitting the data. 
Using Model G, we now estimated parameter values and corresponding RMSE values 
using a random 70% of each patient’s data for each patient estimation. Then, RMSE values were 
calculated using the unseen 30% of each patient data. After conducting this estimation, we found 
that all parameter values estimated were within 15% percent difference with the exception of the 
afferent/efferent resistance. The GFR and UO RMSEs for the unseen testing data was 17.8647 
and 0.5190 mL/min respectively. While GFR RMSE is higher in the test data, we are still within 
the design requirements of being less than 18 mL/min. 
3.3.6 Parameter Estimation Comorbidity Analysis 
We further sought to study the impact of comorbidities on our estimation results. 
Specifically, we compared parameter estimates and RMSE values for NKI patients with and 
without certain comorbidities. We wanted to understand effect of comorbidities on estimation 




We considered comorbidities of patients with at least 25% positive (with comorbidity) or 
negative (without comorbidity). The number of patients with each comorbidity can be seen in 
Table 3.6. 
Table 3.6:  Number of positive and negative patients for each comorbidity. 
Comorbidity Number of Patients Positive Negative 
Congestive Heart Failure 8 20 
Cardiac Arrhythmias 10 18 
Valvular Disease 12 16 
Rheumatoid Arthritis 10 18 
Coagulopathy 12 16 
 
The estimates should be more accurate for the disease that are negative since the model 
does not need to account for them. In cases where estimation performed worse in the negative 
group, we explored the physiology for potential unmodeled mechanisms associated with the 
comorbidity that could explain (or be responsible for) the worse estimates. The RMSE values 
and estimated scalings are presented in Fig. 3.8, separated by comorbidity. 
 
(a) 
GFR RMSE vs Comorbidities



























Fig. 3.8: Average GFR and UO RMSE values and parameter estimation values for NKI 
patients, divided by comorbidity.  
 
For congestive heart failure (CHF) patients, RMSE is slightly worse for UO for positive 
CHF patients, but better for GFR. This could potentially be solved by adding less weight onto the 
UO output in the estimation (see section 3.2.7). CHF will affect blood flow into the kidneys [80], 
UO RMSE vs Comorbidities

















































































that is captured by the model as an input. The negative CHF case had a much lower glomerular 
resistance to correct for UO but overcorrected for GFR. Glomerular resistance was higher for 
CHF patients, as expected since CHF can be caused by increasing vascular pressure. 
For cardiac arrhythmias (CA) patients, RMSE is worse for GFR and UO for positive 
case, as expected. It has been shown that CA can lead to proteinuria. The effects of protein 
filtration and the associated osmotic pressure needs to be included to capture this [81]. The 
model is capturing some proteinuria through the increased glomerular resistance, a way to 
compensate for the actually decreasing oncotic pressure. The model would need to include or 
estimate the oncotic pressure to better describe CA patients. 
For valvular disease patients, RMSE is worse for GFR and UO for positive case, as 
expected. The associated valvular calcification can lead to calcium-phosphorus product, vascular 
calcification, hypercalcemia, and hyperphosphatemia [82]. Including more solutes into the model 
would capture the effect of hypercalcemia for instance. Without these solutes, we cannot model 
the effect of this disease. Similar to CHF, we see glomerular resistance much higher in valvular 
disease patients for the same reasons. 
For rheumatoid arthritis (RA) patients, RMSE is worse for UO for positive rheumatoid 
arthritis patients, but better for GFR. RA is linked to kidney disease via inflammation and 
medications [83]. Inflammation is included in the model via affected reabsorption and vascular 
resistance. NSAIDs (non-steroidal anti-inflammatory drugs) can reduce kidney function and 
likely the estimation correction for this in GFR outweighed the correction in UO. Presumably 
with a decreased weight on UO outputs, the estimate could more closely fit the diseased case 
better. The inflammation from RA can lead to nephron death, as we see by the lower average 




For coagulopathy patients, unexpectedly, the RMSE for UO and GFR for positive 
coagulopathy patients is better than negative patients. Coagulopathy can damage endothelial 
cells and hence reduce reabsorption [84]. It is unclear, however, why estimation performs better 
in the case of positive coagulopathy. We do see a slight decrease in fluid reabsorption for 
positive coagulopathy cases as expected. 
3.4 Conclusion 
In this chapter, we have shown the feasibility of personalizing the previously developed 
human kidney model. We began by developing an estimation methodology that included which 
parameters to estimate for NKI (no-kidney-injury) and GN (glomerulonephritis) patients and 
incorporating a Levenberg-Marquardt optimization method. From here, we analyzed the 
robustness of the estimation to noise and manually tuned hypertension parameters. We found that 
the doubling of output noise has a linear effect on estimation RMSE values for NKI and GN 
patients. In manually tuning the hypertension parameters to either baseline or diseased values, we 
found that GFR RMSE and UO RMSE values as high as 2 mL/min and 0.2 mL/min for NKI and 
GN patients. 
In validating the estimation against real NKI patients, our average RMSE values across all 
patients were 13.55 and 0.78 mL/min respectively for GFR and UO. These RMSE values are better 
than what is currently available for estimating GFR and UO values. Further, after personalizing 
the model, unlike the current state of medicine, GFR and UO can now be calculated for varying 
MAP and sodium level inputs. The NKI estimation results also matched the reported trend 
differences between demographics. The results also showed an increase in axial resistance with 
age, height, and weight. This was conjectured to be due to an increase in sclerotic nephrons with 




conducted on GN patient data as well and showed best performances with 12.7 and 0.44 mL/min 
GFR and UO RMSE values. The parameters estimated were within the expected physiological 
bounds for glomerulonephritis patients. Further, different models for estimation were compared 
that included varying pre-tuned data, parameter bounds and number of parameters to estimate. 
According to a calculated *pq score, using pre-tuned GN parameter values from all available data, 
along with an unbounded afferent/efferent resistance yielded the best results. 
Finally, we studied how comorbidities affect the NKI patient estimation results. We 
determined that cardiac arrhythmias, valvular disease, and rheumatoid arthritis all negatively 
impacted the estimation results. In such cases, for varying physiological phenomena that are not 
included in the current model, the estimation failed to fit well to these patients’ data. 
Improvements to the model can include adding more solutes and allowing for varied oncotic 





Chapter 4: Rat Proximal Tubule Model - Development, Validation, 
& Analysis 
4.1 Introduction 
The kidneys are a collection of many small tubules called nephrons working in 
conjunction to filter the blood. In this chapter, we seek to accomplish our secondary objective, 
simulating targeted therapies in the kidney. We present a model of nephron fluid and solute 
transport that is used to test a diabetic therapy where the expression of the sodium-hydrogen 
transporter (NHE3) in the proximal tubule is reduced to prevent hyperfiltration – an 
overfiltration of sodium and fluid at the glomerulus. This therapy involves partial or complete 
inhibition of the NHE3 transporter in order to combat the hyperfiltration associated with 
diabetes. The theory behind NHE3 therapy is to limit the amount of sodium reabsorbed in the 
proximal tubule by shunting this transporter. Fluid reabsorption is more or less equivalent to 
sodium reabsorption in this segment due to the osmotic effects of sodium reabsorption and 
hence, dampening sodium reabsorption will also dampen fluid reabsorption. The hyperfiltration 
will cause sodium concentrations to rise in the proximal tubule. Since the NHE3 transporter is 
responsible for the majroity of sodium reabsorption in the proximal tubule, this therapy targets 
this area. This relatively new therapy is not widely administered yet, but discussed at length by 
Packer in [85]. In this work, we contribute to the research studying the feasibility of this therapy. 
We do so by simulating the effects in a physiological model and observing how it affects fluid 
and solute reabsorption. 
We developed a rodent physiological model to gain a deeper understanding of the renal 




transporter equations into a model that would allow us to undersatnd and simulate the NHE3 
therapy. Namely, we include glucose and all reactive solutes (bicarbonate, hydrogen, etc.). The 
effects of this therapy are primarily in the proximal tubule and hence we expand and focus on a 
proximal tubule model based on the human model previously developed. The proximal tubule is 
the most important functional portion of the nephron. In this portion, the majority of reabsorption 
takes place, including almost all of the filtered glucose. From an intimate understanding of the 
biology we develop the equations that express the transport phenomena within and between 
different energy domains. 
Once the model is developed, we use the necessary parameters to simulate the model in 
healthy conditions, giving us time-varying values for all model variables. We then conduct a 
parameter sensivity analysis where we observe the system response to changes in the NHE3 
expression. Model responses are compared to other literature models and experiments. 
Several kidney models have been developed over the years [86]–[100]. Many of them, 
[85]–[92], specifically focus on the proximal tubule portion of the nephron. The developed 
models are either partial differential equations (PDEs) in space and time, or steady-state 
differential equations in space only. These models are used to study variable behavior along the 
tubule or adjacent cells of the tubule. 
With the exception of the models of Weinstein et al. [101] and Layton and Layton [16], 
most models include only water, salt, potassium, and urea [102]. Such models are useful for 
understanding basic fluid balance within the kidneys, however, their shortcomings arise when a 
disease is intimately tied to an unmodeled solute. For instance, diseases relating to bicarbonate 




affect glucose will indirectly affect bicarbonate concentrations as well. We, hence, include these 
important solutes for assessing kidney health into our model. 
Models can afford less rigor in their equations when they are simulated only in healthy, 
steady-state conditions. However, for the purposes of the development of this model, it is 
essential to ensure that all equations are physiologically accurate within and beyond the bounds 
of healthy variable values. Therefore, models that lack sufficiently normo- and patho-
physiologically accurate equations would not be sufficient for our purposes. While [16] includes 
more accurate glucose transport equations, active pump transporter phenomena require more 
accurate descriptions via equations that account for the competitive binding of solutes. Thomas 
and Dagher [103], include more accurate, kinetically defined equations, however, their model is 
developed for steady-state. 
Aside from the recent model, [16], models are developed for rats. In order to characterize 
human diseases, models must be adjusted for humans. In Layton and Layton’s adjustments from 
rodents to humans, they scaled radii and lengths of the tubules, and adjusted parameters to fit 
their model to desired measured solute concentrations in urine output. Here, with more 
information about rat parameters available, we constrain ourselves to a rat-based model. This 
will allow us to validate and test scenarios for the experimental data that exists. 
Renal models often also make and implement several assumptions about the flow of 
solutes throughout. For our model to operate outside of the healthy bounds and in time, it 
becomes even more necessary to eliminate these assumptions. A few models, include a short-
circuit epithelial assumption [101], [16] that there is no net current entering or leaving the 




not constrain us into requiring this assumption since we do not need this boundary condition 
constraint. 
In terms of disease and therapy analysis, Layton et al.’s model in [104] and [94] is used 
to study sodium-glucose (SGLT) related therapy for a diabetic kidney. Further Layton, Vallon, 
and Edwards investigated impaired NHE3 and SGLT inhibition on sodium transport and oxygen 
consumption in steady-state [92]. Our model will be used to further this analysis focusing on the 
effects of NHE3 expression change from complete knockout to double the normal expression in 
healthy and diabetic states. We will study the effects on the reabsorption of fluid, sodium, 
glucose, potassium, chloride, ammonium, and bicarbonate since these are too invasive to 
measure and shed light on overall kidney health. We will also investigate the system’s dynamic 
response to salt and glucose loading as NHE3 expression is altered. Since the model is a 
differential-algebraic equation, we will also investigate solving methods for this type of model, 
as well as the stability. 
4.2 Methods 
4.2.1 Model Structure 
In the model, we tessellate the proximal tubule, based on physiological transport 
differences, into two sections: the proximal convoluted tubule (PCT) and the proximal straight 
tubule (PST). Similar to Christensen et al. [105], we consider the PCT to be the first 70% (0.7 
cm) of the proximal tubule in length and the PST to be the last 30% (0.3 cm). Each section is 
further divided into three nodes: the tubule, the epithelial cell (EC), and the interspace between 
the cells (IS). The source to the system, where filtrate enters the proximal tubule, is Bowman’s 




and the descending limb of Henle (LDN). Flow throughout the system is shown in Fig. 4.1, 
where arrow direction indicates positive flow. 
 
Fig. 4.1: Node locations in proximal tubule. The source node is Bowman’s space (&'). The 
sink/reference nodes are the descending limb of Henle (()*), the upper interstitial fluid 
(+,3), and lower interstitial fluid (+,4). The nodes include the proximal convoluted tubule 
(-./), the proximal straight tubule (-'/), the adjacent epithelial cells (0.567 and 0.587) and 
adjacent interspaces between the cells (+'567 and +'587). Arrow directions indicate positive 
flow. 
At an arbitrary node +, the time-varying variables we include are hydraulic pressure, 
/!(ö), in mmHg, concentration, @!(ö), in mmol/mL, and electric potential, •!(ö), in mV. 
Between arbitrary nodes + and ,, the flow of fluid and solutes is respectively given by, 
-!2"(ö), in mL/s, and ?!2"(ö), in mmol/s. Volume at any node is given by integrating the fluid 














node is given by integrating the solute flow, ¡!(ö) = ∫ ?!(ö)âö in mmol, where ?! is the net 
solute flow into node +. The solutes included in the model are: Naa, Ka, Cl2, glucose (Gl), urea 
(Ur), an impermeant protein (Imp2) with valence z = −1, HCOO2, HDCOO, COD, HPO5D2, HDPO52, 
NHO, NH5a, Ha, HCOD2, HDCOD, an impermeant buffer (Buff2) with valence Õ = −1, and a 
protonated impermeant buffer (HBuff) with valence Õ = 0. 
4.2.2 Energy Domains 
In order to solve, in time, for each variable, we use continuity and compatibility relations 
to derive a system of equations using the aforementioned variables. At every node, there is 
energy storage and dissipation represented by capacitors and resistors. Energy storage and 
dissipation can come in several forms: hydraulic, chemical, and electrical, each defining an 
energy domain. There can be a transfer of energy between energy domains called transduction. 
This transduction is assumed to be lossless such that no energy is lost during the transfer. We use 
conservation of mass (continuity) at each node to develop the system of equations. This is 
implemented as a conservation of flow equations at all nodes. Energy storage, dissipation, and 
transduction are further described below, and constitute the full set of equations of motion for the 
system.  
4.2.3 Energy Storage 
At any node +, the volume of fluid is given by the net fluid flow into that node, such that, 
upon differentiating, we have 
 $̇!(ö) = -!(ö), (4.1) 
where -!(ö) is the net flow into node +. The pressure and volume relationship for within the 




 $!(ö) = 5E!:!,>D ⋅ (1 + œ!(/!(ö) − /yz))D, (4.2) 
where E! is the tubule length, :!,> is the tubule unstretched radius, œ! is the tubule compliance, 
and /yz is the interstitial fluid pressure (IF> for PCT and IFL for PST). Equation (4.2) takes into 
account the cross-sectional area, physical volume, specific gravity, and rigidity of the node’s 
walls. The pressure in the adjacent cells is assumed equal to the tubule [90]. The volume in the 
interspace is held constant to 3.8´10-5 mL and 1.6´10-5 mL for the convoluted and straight 
portions, respectively with the physiologically sound assumption that they do not collapse. 
At any node, the concentration is given by @!(ö) ≡ ¡!(ö)/$!(ö), where ¡! is the mass 
of the solute at location + and $! is the volume of the fluid at location + that carries the solutes. 
Concentration accumulation at any location in the system is a storage of potential energy. To 
describe the concentration changes at a given location in time, we must differentiate this 
equation, noting that all variables vary in time. From here we have: 
 ¡̇!(ö) = @̇!(ö) ⋅ $!(ö) + @!(ö) ⋅ $̇!(ö). (4.3) 
Equations (4.1) and (4.3) are used at each node, for the hydraulic and chemical domains 
of each solute, in order to derive the equations of motion (ODEs). 
4.2.4 Energy Dissipation 
Dissipative flow in the hydraulic domain is due to energy loss from the flow of fluid 
down a pressure gradient due to frictional effects. In order to characterize this phenomenon, we 
consider, for each flow from location + to ,, a hydraulic resistance, 1!2"# . This resistance is a 
material property of the vessel and the fluid. In axial flow, this resistance captures the thickness 
of the tubule, and any other viscous factors impeding the fluid flow. In transverse flow, this 




Some branches between nodes are impermeable to water without aquaporins (transport 
protein specific to water). For these branches, the resistance parameter captures both the 
resistance that the fluid experiences flowing through an aquaporin and the number of aquaporins. 
Dissipative flow is described as the difference in pressures divided by the resistance, in an 
idealized manner, as follows: 




Dissipative flow in the chemical domain is energy loss from the solute flowing down its 
concentration gradient. We characterize this energy dissipation by a diffusive resistance, 1!2"r . 
This parameter is commonly referred to as permeability in the literature that is 1/1!2"r . This 
resistance is a material property of the solute and the vessel. As in the hydraulic domain, we 
express this flow as the difference in concentrations divided by the resistance as follows: 




This equation is in fact Fick’s law of diffusion. 
4.2.5 Energy Transduction 
Energy transduction in the model occurs through several transport mechanisms. These 
include osmosis, advection, drift, co-transporters, solute generation, and active pumps. 
Osmosis. Energy transduced from the chemical to the hydraulic domains is a function of 
all the solute concentration gradients and material properties of the membrane and solutes. The 
induced fluid flow from this energy transfer is called osmotic flow and is obtained from van ‘t 
Hoff’s law. Equation (4.6) shows the concentration differences converted to osmotic fluid flow 










c@!S (ö) − @"S (ö)d, (4.6) 
where W is the number of solutes, 1!2"#  is the hydraulic resistance, and u!2"S  is the reflection 
coefficient of solute ó. The reflection coefficient ranges from 0 to 1 and represents the percentage 
of solutes reflected back from the membrane, i.e., not allowed to pass through the membrane. 
Impermeant solutes (including the impermeant protein, unprotonated and protonated buffer 
solutes) have reflection coefficients of 1 because they cannot move through membranes. Osmotic 
pressure due to proteins is commonly referred to as oncotic pressure and written as 5!2" = 1— ⋅
u!2"S c@!S (ö) − @"S (ö)d for protein solutes. Combining the hydraulic dissipative flow, (4.4), with 








c@!S (ö) − @"S (ö)d. (4.7) 
Advection. Advection, sometimes referred to as convection, is the movement of solutes 
due to the bulk flow of the fluid. This type of flow is due to a transduction of energy from the 
hydraulic domain (hydraulic and osmotic pressure differences) to the chemical domain 
(concentration difference). This flow is simplified as an average velocity of the fluid, which is 
carrying solutes, times an average cross-sectional area between two nodes. We multiply the fluid 
flow by the logarithmic mean of the concentration between nodes + and , in the following way 
according to [107]: 
 ?!2"+ (ö) = (1 + u!2")@“!"(ö)-!2"(ö), (4.8) 
where @“!" is the logarithmic mean of solute concentrations at node + and ,,  u!2" is the 




Drift. All solutes that are ions are subject to flow induced by the electric potential 
difference between nodes. This flow is called drift and is characterized, along with diffusion, in 
the Nernst-Planck equation [108]. The drift portion of the Nernst-Planck equation serves as the 
electrical to chemical transducer in our formulation. In this case, the electric potential difference 
across nodes moves solutes from one node to another. The equation is: 
 ?!2"| (ö) =
ÕU@̅!"(ö)
1—1!2"r
O•!(ö) − •"(ö)P, (4.9) 
where Õ is the valence of the solute, U is Faraday’s constant, and @̅!" is the arithmetic mean of 
the concentrations in nodes + and ,. 
Co-Transporters. Co-transport flow, mediated by proteins, uses energy from the 
electrochemical gradient of one solute to move others. We include the following transporters: 
Naa: Gl, Naa: HDPO52, Ka: Cl2, Naa: HCOO2, Naa: Ha, Cl2: HCOO2, Cl2: HCOD2, and 
Naa: Cl2: HCOO2. In the PCT, the Naa: Gl transporter is known as SGLT2, and in the PST, it is 
known as SGLT1. The Naa: Ha transporter is known as NHE3 in both segments. For transporter 
flow (with the exception of the Naa: Ha transporter, described below), we use the non-
equilibrium thermodynamic formulation implemented by Weinstein et al. [90], given by 
 ä}2h(ö) = (‘!2"Ñ}2h ⋅ Ñ}2h)Δ’}2h(ö), (4.10) 
 Δ’}2h(ö) = 1— ln
◊}(ö)
◊h(ö)
+ ÿUO•!(ö) − •"(ö)P, (4.11) 
for W solutes, where ‘!2" is the transporter permeability coefficient, Ñ}2h is an W × 1 vector of 
stoichiometric ratios of each solute in the transport reaction, Δ’}2h is the vector of 
electrochemical differences for all solutes. Negative ratios within Ñ}2h indicate solutes moving 
in opposite directions. For the Naa: Ha transporter we use the kinetic equations derived in [89], 




Active Pumps. Active pumps utilize energy from adenosine triphosphate (ATP) to move 
solutes. There are two active pumps in the proximal tubule, the Naa: Ka pump and the hydrogen 
pump. We use the probabilistic derivation, described by Layton and Edwards [13], for the 
Naa: Ka pump (but include competitive binding between Ka and NH5a as done in [90]) such that 
solute flows are given by 
 ?!2"R, -
4(ö) = ?!2"R,~- ⋅ Ÿ,-4O (ö) ⋅ ŸN4D (ö), (4.12) 
 ?!2"R,C
4(ö) = −23 ⋅ ?!2"
R, -4(ö) − ?!2"
R, Ä)4(ö), (4.13) 
 ?!2"





where ?!2"R,~- is the maximal sodium flow, Ÿ,-4, and  ŸC4 are intermediary variables as described 
by Layton and Edwards [13]. For the hydrogen pump, we use the empirical relation from Strieter 




1 + CÅ563⋅(Ñ56374 (m)2Ñ8)
, (4.15) 
where ⁄!2"Ä
4  is the electrochemical difference of hydrogen between nodes, ?!2"#,~- is the maximal 
flow, €!2" is the steepness of the flow, and ⁄> is the point of half-maximal activity. 
Generation. Solute generation from hydrogen transfer is the final type of flow modeled. 
A conservation of total buffer (such that the flow generated from one solute of a pair must equal 
the negative flow generated from the other solute of the same pair) for each pair is shown in the 
following equations for an arbitrary node + 
 ?!
&,ÄBÜ)&6(ö) + ?!
&,Ä&BÜ)6(ö) = 0, (4.16) 
 ?!




 ?!&, Ä((ö) + ?!
&, Ä)4(ö) = 3!
,Ä)4 , (4.18) 
 ?!
&,ÄáÜ(6(ö) + ?!&,Ä&áÜ((ö) + ?!&,áÜ& = 0, (4.19) 
 ?!&,áÜ&(ö) = $!(ö) ⋅ c≥#@!áÜ&(ö) − ≥r@!Ä&áÜ((ö)d, (4.20) 
where 3!
,Ä)4 is the constant ammoniagenesis generative flow (nonzero in the cells), ≥# is the 
hydration rate constant and ≥r is the dehydration rate constant, both needed assuming the 
interconversion between HDCOO and COD is not instantaneous. There is also a conservation of 





&,ÄáÜ(6 + ?!&,Aàââ(ö) − ?!
&, Ä)4(ö). (4.21) 
4.2.6 Algebraic Constraints 
For the impermeant protein, Imp2, there is no flow into or out of each node and therefore 
?!(ö) = 0, effectively a constant mass. The sum of the masses of the impermeant buffer pairs, 
Buff2 and HBuff, is also held constant. 
All hydrogen transfer chemical reactions are considered instantaneous (with the 
exception of the reaction with COD) and therefore 
 9|nAàââ









ÄáÜ&6 ⋅ @!Ä&áÜ&(ö) = @!
ÄáÜ&6(ö) ⋅ @!Ä
4(ö), (4.24) 
 9|n,Ä( ⋅ @!
,Ä)4(ö) = @!,Ä((ö) ⋅ @!Ä
4(ö), (4.25) 
 9|n
ÄáÜ(6 ⋅ @!Ä&áÜ((ö) = @!
ÄáÜ(6(ö) ⋅ @!Ä
4(ö), (4.26) 
given each reaction’s equilibrium constant, 9. These reactions occur on a scale orders of 




only in reactions that are faster than one second and hence assuming the reactions above are 
instantaneous is sound. 
The electrical capacitance values within the system are much smaller than all other 
parameters, which leads to numerical solver issues. In order to address this issue, we enforce the 
electroneutrality compatibility constraint. It has been shown that the electroneutrality constraint 
is a very good approximation of the stiff system that would be developed using the above 
equations as long as the time steps of interest remain above nanoseconds, and the distances of 
interest remain above nanometers [109]. As we are considering above seconds and millimeters, 
then we are not in violation of using the electroneutrality condition. We use the electroneutrality 
condition in place of the short-circuit assumption where the net current is set to zero as well. The 





@!S (ö) = 0. (4.27) 
The constraint equations, (4.22) – (4.27), are all algebraic equations containing variables that 
appear differentially in other equations of this system. This leads to a system of differential-
algebraic equations (DAEs). Typically, these systems are difficult to solve due to the challenge 
of finding consistent initial conditions and solver method choice. The method we use for solving 
this system will be discussed in a later section. 
4.2.7 System of Equations 
The full list of equations comprises over 500 equations and is not reproduced here. 
However, the code for generating all equations using the symbolic toolbox in MATLAB® is 




dynamic model. A linear graph is a visual tool that can concisely display all dynamics of a 
complex system to allow for a systematic formulation of the system’s dynamic equations [26]. 
We develop a linear graph comprising all domains with transducers linking them together. At 
each node, the flows are determined for all domains. By way of example, the sodium solute 
transport linear sub-graph is presented in Fig. 4.3. Any variables subscripted with 0 are 
considered known constant reference values. Arrows are illustrated in the positive defined 
direction; however, flow may occur in either direction. By using conservation of mass (analog to 
Kirchhoff’s Current Law), the flows entering must equal the sum of all flows leaving, being 
stored, or being generated. 
As an example, consider the 6q— node in the sodium linear graph. We have 13 flows 































































Flows In: There are three flows entering this node, they include the diffusive, advective, 
and drift flows ((4.5), (4.8), (4.9)) from 4‹ into the 6q—. The sum of these flows can be 
described as: 
 ?*ä:ST, -
4(ö) = ?%ã2*ä:r, -
4 (ö) + ?%ã2*ä:+, -
4 (ö) + ?%ã2*ä:|, -
4 (ö). (4.28) 
Flows Out: There are three paths for sodium to flow out of the 6q— node; these are flows 
into the Iq*ä:, the p‹*ä:, and/or the 6‹—. There are three paths for sodium transport into the 
Iq*ã:: the sodium-glucose symporter (SGLT2), the sodium-hydrogen antiporter, and the 
sodium- dihydrogen phosphate symporter. There are three paths for sodium transport into the 
p‹*ä:: diffusion, advection, and drift flows. Finally, there are three paths for sodium transport 





MR2,-4:Jç, -4(ö) + ?*ä:2@ä9:;
+R2,-4:Ä4, -4(ö) + ?*ä:2@ä9:;
MR2,-4:Ä&*é)6, -4(ö)
+ ?*ä:2èã9:;
r, -4 (ö) + ?*ä:2èã9:;
+, -4 (ö) + ?*ä:2èã9:;
|, -4 (ö) + ?*ä:2*ã:r, -
4 (ö)
+ ?*ä:2*ã:+, -
4 (ö) + ?*ä:2*ã:|, -
4 (ö). 
(4.29) 
Flows Stored: Since there is water in the PCT, there is additional energy stored that is: 
 @̇*ä:,-
4(ö) ⋅ $*ä:(ö) + @*ä:,-
4(ö) ⋅ $̇*ä:(ö) = ¡̇*ä:,-
4(ö). (4.30) 
Flows Generated: Since sodium is a nonreactive solute, there are no flows being 
generated and therefore: 
 ?*ä:
&, -4(ö) = 0. (4.31) 
Differential Equation: Combining all of these flows from (4.27) – (4.31), we have the 






4(ö) = ?*ä:{!m, -
4(ö) + @̇*ä:,-
4(ö) ⋅ $*ä:(ö) + @*ä:,-
4(ö) ⋅ $̇*ä:(ö). (4.32) 
4.2.8 References & Parameters 
Concentrations from a Ringer’s solution (an isotonic solution relative to interstitial fluid), 
were used as the source and sink values at BS, IF>, and IFL. For the LDN node, reference values 
were set to 30/70 ⋅ (}*ã: + }*ã: − }*ä:) for pressures and concentration variables }. Reference 
pressure and voltage values needed at BS, LDN, IF> and IFL nodes were also from [90]. 
Reference volumes are not needed for sources or sinks, as they do not appear in any equation. 
The parameters for axial flow of fluid were calculated using the Hagen-Poiseuille 






where E!̅" is the average length between nodes, :̅!" is the average radius between nodes, and í is 
the blood viscosity, assumed to be 6.4´10-6 mmHg⋅s. A constant flow source of 35 nL/min into 
the PCT was used, with no diffusive solute resistance into the PCT, only advective flow. 
For axial solute flow, all reflection coefficients were set to 0 since there are no 
membranes to impede the flow of these solutes axially. For the diffusive resistance along the 
tubule, diffusion coefficient values in an aqueous, well stirred water solution were found from 
[110] and [111] and then adapted to our system by multiplying by the cross-sectional area of the 








where 1›r is the diffusion coefficient from the literature for the solute and fi is the temperature 
adjustment factor for solutes (in this case, the adjustment for 37℃ is fi = 1.339) used to account 
for change in the diffusion coefficient based on temperature. All remaining parameters were 
adapted from [90] to fit a lumped model with our model units. A complete list of all parameters 





Table 4.1:  Model constants and parameters. 
Constants 
Ideal Gas Constant ! mL⋅mmHg / K / mmol 62.3637 
Temperature # K 310.15 
Faraday’s Constant $ C/mmol 96.485 
Blood Viscosity % mmHg⋅s 6.4´10-6 
Hydration Constant &! 1/s 1.45´103 
Dehydration Constant &" 1/s 4.96´105 
NH#: NH$
% Equilibrium Constant *&'




+ Equilibrium Constant *&'
),-"#$ - 1.58´10-7 
HCO*
+
: H*CO* Equilibrium Constant *&'
).-#$ - 1.74´10-4 
Buff
+
: HBuff Equilibrium Constant *&'
/011$ - 3.16´10-8 
HCO#
+
: H*CO# Equilibrium Constant *&'
).-!$ - 2.69´10-4 
 Pressure [mmHg] and Volume [mL] Relations Ammonia Generation 1
23%& 
[mmol/s] 
2456$ [mmol] 27899$ +237899 [mmol] 
456 7:;< = 0.7< ⋅ 0.00106* ⋅ ?1 + 0.03 ⋅ A7:;< − C=>'DE
*
 0 0 0 
F5?@A 7B;()* = 7:;< 3.9´10-10 3.30´10-7 3.30´10-7 
GH?@A I=C()* = 3.8´10
-5 0 0 0 
4H6 7B;(+* = 7:C< 0 0 0 
F5?DA 7:C< = 0.3< ⋅ 0.00106* ⋅ ?1 + 0.03 ⋅ A7:C< − C=>,D
*
E 1.6´10-10 1.41´10-7 1.41´10-7 
GH?DA I=C(+* = 1.6´10
-5 0 0 0 
from 456 F5?@A F5?@A 4H6 F5?DA F5?DA  
to F5?@A GH?@A GJE F5?DA GH?DA GJF 
Co-Transporter Permeabilities [mmol2/J/s] (Additional Na!: H!(NH"!) parameters in [89]) Ratios 
KL
%































+ 0 1.39´10-8 3.85´10-10 0 5.94´10-9 1.65´10-10 1 -1 2 









%) 0 1.19´10-7 3.3´10-9 0 5.09´10-8 1.41´10-9 - - 
P






Table 4.1 (Continued):  Model constants and parameters. A resistance of infinity is equivalent to setting the given flow to 0. 
from WH 456 4H6 456 456 F5?@A F5?@A GH?@A 4H6 4H6 F5?DA F5?DA GH?DA 
to 456 4H6 XYK F5?@A GH?@A GH?@A GJE GJE F5?DA GH?DA GH?DA GJF GJF 
Reflection Coefficients Z 
KL
% 0	 0	 0	 1	 0.75	 1	 1	 0	 1	 0.75	 1	 1	 0	
T
% 0	 0	 0	 1	 0.6	 1	 1	 0	 1	 0.6	 1	 1	 0	
5N
+ 0	 0	 0	 1	 0.3	 1	 1	 0	 1	 0.3	 1	 1	 0	
MN 0	 0	 0	 1	 1	 1	 1	 0	 1	 1	 1	 1	 0	
[\ 0	 0	 0	 0.95	 0.7	 0.95	 0.95	 0	 0.95	 0.7	 0.95	 0.95	 0	
G]^
+ 0	 0	 0	 1	 1	 1	 1	 1	 1	 1	 1	 1	 1	
P5QI
+ 0	 0	 0	 1	 0.9	 1	 1	 0	 1	 0.9	 1	 1	 0	
PG5QI 0	 0	 0	 1	 0.9	 1	 1	 0	 1	 0.9	 1	 1	 0	
5QG 0	 0	 0	 1	 0.9	 1	 1	 0	 1	 0.9	 1	 1	 0	
P4QH
G+ 0	 0	 0	 1	 0.9	 1	 1	 0	 1	 0.9	 1	 1	 0	
PG4QH
+ 0	 0	 0	 1	 0.9	 1	 1	 0	 1	 0.9	 1	 1	 0	
KPI 0	 0	 0	 0.5	 0.3	 0.5	 0.5	 0	 0.5	 0.3	 0.5	 0.5	 0	
KPH
% 0	 0	 0	 1	 0.6	 1	 1	 0	 1	 0.6	 1	 1	 0	
P
% 0	 0	 0	 1	 0.2	 1	 1	 0	 1	 0.2	 1	 1	 0	
P5QG
+ 0	 0	 0	 1	 0.3	 1	 1	 0	 1	 0.3	 1	 1	 0	
PG5QG 0	 0	 0	 0.95	 0.7	 0.95	 0.95	 0	 0.95	 0.7	 0.95	 0.95	 0	
W_``
+ 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	
PW_`` 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	 0	
Resistances aJ and aK – [s⋅mmHg/mL] and [s/mL] 
PGQ - 3.34´106 1.50´106 2.44´108 8.80´108 2.44´108 8.80´109 2.93´107 5.70´108 2.05´109 5.70´108 2.05´1010 6.84´107 
KL
% ¥ 5.72´109 2.57´109 ¥ 7.00´105 6.48´108 2.33´1010 1.82´105 ¥ 1.63´106 1.51´109 5.44´1010 4.24´105 
T
% ¥ 3.88´109 1.75´109 1.01´107 6.27´105 1.26´106 4.55´107 1.30´105 2.36´107 1.46´106 2.95´106 1.06´108 3.03´105 
5N
+ ¥ 3.75´109 1.69´109 ¥ 9.09´105 ¥ ¥ 1.52´105 ¥ 2.12´106 ¥ ¥ 3.54´105 
MN ¥ 1.14E´1010 5.11´109 ¥ 1.14´107 3.37´105 1.21´107 3.03´105 ¥ 2.65´107 7.86´105 2.83´107 7.07´105 
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4.2.9 Diabetic Conditions 
We will be investigating the proposed NHE3 (sodium-hydrogen transporter) therapy from 
the literature [85]. This therapy will reduce the NHE3 transporter expression in the proximal 
tubule in order to reduce reabsorption of fluid and sodium and hence hyperfiltration. 
Hyperfiltration is a side effect of diabetes in the kidneys, where excess fluid and sodium are 
filtered at the glomerulus. We consider a transporter scaling value of 1 (or 100%) as the baseline, 
healthy value for this transporter. The transporter scaling will represent the density (expression) 
of the protein transporters along the tubule available for solute transport. This NHE3 therapy will 
reduce (or impair) the transporter scaling under 100%. Complete knockout of this transporter 
will result in a scaling of 0 (of 0%). Since insulin therapy is known to stimulate the NHE3 
transporter this will result in a scaling above 100% (or overactive). Hence, we will also 
investigate the effects of an increased NHE3 transporter scaling up to 200% (or a doubling). 
In order to simulate a diabetic kidney, we make several changes to the system parameters 
and reference concentrations. Initial conditions for the model will be those obtained from solving 
the system at the equilibrium steady-state point. Changes excluding those made to the NHE3 
transporter and sodium-potassium pump, have also been implemented by Layton, Vallon, and 
Edwards [104] in order to simulate a diabetic kidney. We begin by increasing glucose reference 
concentrations at the BS, IF!, and IF" nodes fivefold. This is due to the increased concentration 
of glucose in the bloodstream due to the inability to metabolize it properly and we simulate this 
phenomenon via this increase in glucose concentration. In diabetes there is also an associated 
increase in the nephron tubule diameter. This is implemented via a decrease in %#$%&#'%
(  and 
%#'%&)*+
(  by 2.07 times and increase in solute diffusive resistance along the tubule, %#$%&#'%
,  
and %#'%&)*+




increased GFR (glomerular filtration rate). This is simulated by decreasing %-'&#$%
(  and 
%-'&#$%
, 	for all solutes by 1.5 times, which hence increases the fluid flow via (4.4) and (4.6).  
Since glucose levels in the bloodstream of a diabetic are increased, there is a natural increase in 
glucose transporter expression in the PCT to attempt to mitigate this. The sodium-glucose 
transporter in the PCT, SGLT2, is increased by 38% and the sodium-glucose transporter in the 
PST, SGLT1, is decreased by 33% such that more glucose is reabsorbed in the PCT, and less is 
reabsorbed in the PST. Further, we increase NHE3 expression by 40% as described in [112]. 
Finally, we decrease the sodium-potassium pump expression by 10% as described in [113]. 
4.2.10 Differential-Algebraic Equation Background 
The index of a differential-algebraic equation (DAE) can be viewed as a measure of the 
difficulty to solve the system of equations. An index zero system is equivalent to a set of 
traditional differential equations, in that there are no algebraic constraints. An index one system 
is one with at least one algebraic constraint, in addition to the differential equations, that can be 
removed via algebraic substitution. Hence, algebraic equations of just algebraic variables that are 
never differentiated within the system (such as the hydraulic flow equation in (4.4)) can be 
removed via substitution and do not cause a DAE system above index one. Higher index 
systems, greater than or equal to two, are known to be a source of numerical issues [114]. One 
definition for index of a system begins with considering a system defined as +(-, -̇, /) = 0. From 
here, the number of times + must be differentiated with respect to / (the independent variable) 
such that the system can then be rewritten as a standard ordinary differential equation (ODE) of 
the form -̇ = 3(/, -) is the index of the system [115]. Typically, this process of differentiation is 
not used to solve the actual problem since additional constraints arise from this process, but it 




Jacobian of the system with respect to the differential variables, -̇. The singularities arise from 
rows of zeros in the Jacobian due to the fact that the algebraic constraints do not involve any 
differential variables. 
Specifically, in modeling the kidneys, one such algebraic constraint that induces a DAE 
is the pressure-volume relations in (4.2) and the constant interspace volume. These constraints 
can be removed from the system via substitution though. If we consider a general continuity 
equation at a node with arbitrary flow variables 4 and a node variable 5. Assuming there are 6 ≥
0 flows 4. into node 5, 8 ≥ 0 flows 4/ out of node 5, 9 ≥ 0 flows 40 energy transfer flows into 
node 5, and one energy storage capacitive element. All flow equations for 4 in our system are 
algebraic. Because of this, all intermediary variables 4 can be expressed in terms of the node 
variables, reducing the number of equations necessary to solve the system from 6 +8 + ; + 1 to 
1. Equations we derive based on pressure and concentration continuity, (4.2), are in fact at most 
index one systems, that can be solved via substitution because they involve purely algebraic 
variables. 
Another equation that arises in modeling the kidneys and causes a DAE is the 
electroneutrality constraint (4.27). The capacitances within the system, as described by Layton 
and Edwards [13], are often assumed to be zero (negligible) since they are very small compared 
to other parameters in the system. The order of magnitude difference in parameter values creates 
a stiff system that is difficult to solve. To avoid this, differential equations with capacitance are 
replaced with electroneutrality constraints. Since the electroneutrality constraints are algebraic 
and involve solute concentrations (which appear differentially in other equations such as (4.3)), 
this creates a DAE. Hence, a DAE can actually be viewed as a stiff system pushed to the limit 




instantaneously in time. Gray et al. [115] note that when electric potential appears in several 
differential equations in the system (via the drift (4.9) and co-transporter equations (4.11)), but 
does not explicitly appear in the constraint equation, the DAE is an index two system. This can 
easily be seen in our system since an equation with =̇ would require one differentiation of all 
continuity equations (4.3), subsequently generating a second order system for all concentrations, 
thereby requiring two differentiations of the electroneutrality constraint (4.27). This fact that two 
differentiations would be needed to be reduce the index of the system to 0 indicates that the 
system is an index two DAE. 
Finally, the rate law equations for the protonation/deprotonation (adding or losing a 
hydrogen proton) of buffer pair solutes cause a DAE when modeling the kidneys. The time scale 
for these reactions is far greater than the time scale for other modes of transport for fluid and 
solutes in the kidney. Because of this, these equations are approximated by algebraic rate law 
equations which imply an instantaneous binding/unbinding of hydrogen, (4.22)-(4.26). The 
reaction involving H1CO2 and CO1 however, is orders of magnitude slower than the other buffer 
pairs and therefore is characterized by rate constants, @( and @,, and does not appear as an 
instantaneous reaction. 
4.2.11 Differential-Algebraic Equation Solving Methods 
In terms of solving a DAE, as described earlier, given constraints of only algebraic 
variables, at most an index one DAE, we can use simple algebraic substitution to remove these 
variables and generate a typical index 0 system of differential equations. For higher index 
problems, the solution is not as simple. 
One of the main challenges in solving DAE systems is finding consistent initial 




the hidden constraints. Hidden constraints are those which arise from differentiations of the 
algebraic constraints. 
Several approaches exist for reducing the index of a set of DAEs.  The algorithm that we 
employed is the Pantelides algorithm, because of its effectiveness in solving systems with 
minimal, algebraic constraints. This algorithm determines the minimum set of equations needed 
to find consistent initial conditions. This is done by introducing new variables and equations for 
the differential variables. Further, with this algorithm we are able to find a set of consistent initial 
conditions. As described in [114], this algorithm introduces auxiliary variables (derivatives of 
existing variables) along with additional equations to reduce the index of the system without 
altering the solution set. In general, this algorithm can prove useful in problems where the 
structural index is less than the true index. The structural index is the number of times an 
individual equation need be differentiated to reduce the index using the Pantelides algorithm 
[116]. 
With the reduced system of equation and initial conditions from applying the Pantelides 
algorithm, we can use backward differentiation formulas (BDF) to solve the new system in time. 
The simplest form of BDF is the implicit Euler method where we replace the derivatives with a 
backward difference 
 + A/., -.,
-. − -.&"
ℎ
D = 0, (4.35) 
Where + is the system, - are the states, / is time, 6 is the discrete step in time, and ℎ is the solver 
stepsize such that ℎ = /. − /.&". From here, we use Newton’s method to solve the system at 
each time step. By employing backward differentiation, we are in effect solving for the 
differential variables and the algebraic variables simultaneously. This ensures that the algebraic 




complex. According to [114], there are several variations of this approach, but it is reported that 
this method is largely the most successful in terms of solving accuracy and stability. For our 
system we are able to successfully reduce the system index and find consistent initial conditions 
using the Pantelides algorithm. From there we solve the system using a BDF formulation 
implemented in the MATLAB® function ode15i. This is the implicit solver that is best suited 
for DAE systems. The initial conditions were those values found from solving the system at 
equilibrium where time derivative terms are set to zero. Using the MATLAB® function decic 
(decide initial conditions), and these initial conditions then serve as starting points. We are then 
able to converge to exact consistent initial conditions that are subsequently used in simulation. 
4.2.12 Differential-Algebraic Equation Stability 
When assessing the stability of our DAE system, we can consider local stability in the 
region around an equilibrium point of the linearized system. Our system has an implicit DAE 
structure, that can be explicitly expressed with two, one, or zero derivative terms per equation. 
First, we remove constraint equations that do not involve differential variables via substitution, 
this reduces the system from 126 equations and variables down to 118 (42 of which are algebraic 
constraints). Our 76 differential equations are derived from (4.1) and (4.3) in terms of 
concentrations and volumes for all nodes. We can substitute (4.1) into (4.3) and then explicitly 
solve for the derivatives of volume and concentrations in the form 
 EḞ = −3(/, F), (4.36) 
where F is a vector of volumes and concentrations at all nodes, and E is a singular matrix with 
the first 76 rows and columns equivalent to the identity matrix and the last 42 rows all zeros. 




terms and are hence all zeros. From here, we solve for an equilibrium point where Ḟ = G, called 
FH. Finally, we can linearize our system via the following standard linear approximation, 
 EḞ = I ⋅ (F − FH), (4.37) 
where I is the standard Jacobian of the right side of (4.36) with respect to F, evaluated at F = FH. 
Next, we must discuss the mathematical pencil of this system. For a DAE of the form 
(4.37), the pencil is given by KE − I and is said to be singular if det(KE − I) = 0 for all K ∈ ℂ, 
and regular otherwise. For a singular E, there will be either infinite or finite eigenvalues of the 
pencil. A system of the form (4.37) is solvable if and only if the pencil is regular [117]. Given a 
regular pencil, and consistent initial conditions, according to [118], we can extend the regular 
linear methods of eigenvalue analysis to determine local stability of the system. Namely, we can 
find the eigenvalues of the pencil and consider the real part of the eigenvalues to determine 
stability. Since E is singular and has infinite or finite eigenvalues, we are interested in the real 
part of the finite eigenvalues for stability analysis, which is included in the results. 
4.3 Results & Discussion 
Complex systems with a multitude of states are typically difficult to validate, as many of 
the states (unknown variables) cannot be observed. However, guidelines to validate such a 
system have been articulated. For instance, according to Summers [119], since dynamic data of 
the proximal tubule is not measured (due to invasiveness and difficulty), our validation process is 
founded on ensuring that steady-state and parameter values are within acceptable ranges, the 
transient response within physiological ranges, and that the model is internally consistent 
(internal stability and robustness to changes in inputs). We validate the model by comparing 
model steady-state values to those in the literature and from other models. Then, we compare the 




conditions where the NHE3 transporter is impaired or overactive. Finally, we analyze the 
systems’ dynamic response to NHE3 therapy of varying degrees in the presence and absence of 
salt and glucose loading. 
4.3.1 Model Validation 
Using baseline healthy initial conditions, the steady-state results of the simulation, for 
pressures and concentrations along the tubule, are presented in Fig. 4.3. Here we show steady-
state values as circles at different spatial locations. The lines between circles, represent a linear 
interpolation between nodes. The steady-state response in Fig. 4.3 closely matches those in the 
literature. The model outputs were compared to several measurements from real data. Sodium 
concentration in the proximal convoluted tubule was 139 mEq/L compared to 144 from the 
literature [120], [121]. Potassium concentrations in the proximal convoluted tubule were 5.9 
mEq/L compared to 4.4 [15] and 3.8 [122] from the literature. While higher than the literature 
values, we are more in line with the 6.04 mEq/L reported in [90]. Chloride concentrations in the 
proximal convoluted tubule were 125 mEq/L compared to 135 [15] and 110 [122] from the 
literature. This gives good credence to the model’s healthy simulations. The simulation outputs 
were further compared to Weinstein et al.’s simulations for the proximal tubule [90]. From this 
comparison, our model outputs were all within 10%, with pH values within the healthy range of 
6.98 and 7.46 throughout the proximal tubule and adjacent cells and interspaces. Further, 
according to [123], in mice, the SGLT2 transporter is responsible for the majority of glucose 
reabsorption in the proximal tubule. This was validated with the model by observing that 
1.7 × 10&3 mmoles/s of glucose were transported across the SLGT2 transporter, and 




In Fig. 4.3, the pressure decreases along the tubule from BS to PCT since net fluid volume 
decreases as well. We notice that the concentration of sodium at each of the modeled tubule 
locations (PCT and PST) is fairly constant, as expected since sodium and water are reabsorbed in 
equal amounts in the proximal tubule, as is known and described by the glomerulotubular 
balance [5]. The concentrations of potassium and chloride both rise to approximately 1.15 and 
1.2 times their respective initial values along the tubule, as also shown in [90]. The glucose 
concentration has a large decrease at the tubule, which is expected in a healthy case because the 
majority of glucose is reabsorbed from the PCT [5]. The urea concentration rises 20-40% 
between each nephron segment, as expected because urea reabsorption is minimal (due to the 
lack of dedicated transporters and high diffusive resistances and reflection coefficients) and 
because volume decreases steadily along the tubule leading to a larger ratio of urea mass to fluid 
volume, i.e., concentration. In the proximal tubule (PCT and PST), where the majority of 
bicarbonate reabsorption occurs, bicarbonate concentrations indeed decrease by roughly 40-50% 
in the proximal tubule (both PCT and PST)  [5]. Formate (HCO1&) concentrations rise at the 
proximal convoluted tubule, as bicarbonate concentrations decrease, and decrease at the PST and 





Fig. 4.3: Healthy simulation results along the proximal tubule. Pressures and concentrations 
normalized by Bowman’s space (!") inlet values. 
The model was also simulated under the diabetic conditions, as previously outlined in 0. 
As compared to healthy tubule concentrations in Fig. 4.3, the diabetic tubule concentrations of 
glucose in the PCT increased by approximately five times the baseline. This is no doubt due to 
the increased glucose concentrations entering each nephron overwhelming the glucose 
reabsorption transporters. However, under healthy conditions, with an increase in glucose 
concentration five times, glucose concentration in the PCT was only 4.8% times that of inlet 
concentration, as compared to 7.2% higher for diabetic conditions. This implies that the diabetic 
conditions further inhibit the reabsorption of glucose in the PCT. As discussed in [104], the 
diabetic state of the kidney will lead to increased glucose concentration throughout and an uptake 
































in glucose reabsorption in the latter parts of the nephron. This is in fact what we are observing 
with a higher 7.2% increase in glucose concentration in the PCT. 
We sought to compare model outputs to those reported in the literature for studies 
conducted on rats with similar NHE3 density via drugs or selective breeding. The NHE3 
transporter density was changed to 20%, 60%, and 150% and then compared to those from rats in 
Table 4.2. Reabsorption flows were calculated as the net flow into the interstitial fluid from cells 
and interspaces such that for a given solute ;, the reabsorption is given by 




6 , (4.38) 
and similarly, for the fluid reabsorption. Li et al. [124] reported a decrease in bicarbonate and 
fluid reabsorption with impaired NHE3 expression. The model demonstrates this as well but 
shows a larger decrease in both reabsorptions at 20% NHE3 density. For pH changes, Li et al. 
[124] and Girardi et al. [125] report different pH responses. Our model predicts (within 2% of 
measured values) an increase in pH with decreasing density and a decrease in pH with increasing 
density, as described by Girardi et al. [125]. 
Table 4.2: Simulation outputs of bicarbonate and fluid reabsorption, and pH in the 
convoluted proximal tubule compared to experiments in the literature. 
NHE3 Density Source V:;
<=>'
(
 WX?=@ Y:; 
20% 
[124] 64.41% 98.64% 72.82% 
Model 35.05% 104.66% 33.70% 
60% 
[125] 69.57% 103.57% - 
Model 92.02% 102.25% 75.57% 
150% 
[125] 115.38% 98.21% - 
Model 97.85% 97.85% 114.53% 
 
4.3.2 Diabetic & NHE3 Therapy Analysis 
In Fig. 4.4, we see steady-state concentrations of sodium, potassium, glucose, and 




with no therapy, (B) diabetic kidney with no therapy, (C) diabetic kidney with 50% NHE3 
density, and (D) diabetic kidney with complete NHE3 knockout (0% density). We note that pH 
stays relatively constant with changes to NHE3 in the diabetic case for all nodes. As reported by 
Li et al. [124] and Girardi et al. [125], there is not a significant change in pH in the convoluted 
proximal tubule with changes in NHE3 in the healthy case. There is however a slight increase in 
pH in the PCT and PST nodes with 50% NHE3 density (C), as compared to (B). As reported by 
Onishi et al. [126], NHE3 knockout mice had higher urine pH and this can be seen via the higher 
pH of our simulation. A similar behavior was reported for increased bicarbonate urine 
concentrations with NHE3 knockout [126], which is shown in the simulation via increased 
[#'%
A8B)( in Fig. 4.4 scenario (B) compared to scenarios (C) and (D). In the no-therapy diabetic 
case (B), [+C
*
, at all tubular and cellular nodes, increases as compared to the healthy case (A). 
During complete NHE3 knockout (D), [+C
*
 at all nodes is restored to values closer to those in 
the healthy case, (A). This is a good indication that sodium concentrations throughout the 





Fig. 4.4: Simulation results for healthy and diabetic kidneys in response to NHE3 therapy 
with varying degrees of density changes from 0% to 200%. Concentrations of sodium, 
potassium, glucose, and bicarbonate, and pH at all six nodes (proximal convoluted and 
straight tubules, and adjacent cells and interspaces). (A) is healthy kidney with no therapy, 
(B) is diabetic kidney with no therapy, (C) is diabetic kidney with 50% NHE3 density, and 
(D) is diabetic kidney with complete NHE3 knockout (0% density). 
In Fig. 4.5, we see dynamic results of fluid, bicarbonate, glucose, ammonium, sodium, 
chloride, and potassium reabsorption in both healthy and diabetic cases with NHE3 therapy 
administered via the timing of a sigmoidal change as seen in Fig. 4.6. NHE3 transporter density 
is changed by varying degrees in each separate simulation. We ran this simulation in order to 
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be altered during the therapy. This will then allow us to observe what level of NHE3 knockout 
would be necessary in order to correct the reabsorption flows for diabetics. The sigmoid equation 
used to modify the transporter density is the following, 
 Density =
1 − a
1 + #"!&D/1!!!! + 1, (4.39) 
where a is the final value of the transporter density. As reported in [126], sodium, bicarbonate, 
and ammonium reabsorption are decreased by NHE3 knockout which can be seen in the 
simulation results, detailing a dramatic decrease in reabsorption of all three solutes. As described 
in [126], tubular hyper-reabsorption can lead to hyperfiltration at the glomerulus due to a 
reduction in NaCl in the distal parts of the tubule activating the tubuloglomerular feedback 
mechanism. One benefit of the NHE3 knockout therapy is the reduction in fluid reabsorption and 
further reduction in NaCl reabsorption in the proximal tubule as can be seen in the model 
simulations. This reduction in reabsorption will maintain higher concentrations of NaCl in the 
distal parts of the nephron avoiding hyperfiltration. As also described in [92], sodium 





Fig. 4.5: Simulation results for healthy and diabetic kidneys in response to NHE3 therapy 
with varying degrees of density from 0% to 200%. Dynamic results of fluid, bicarbonate, 
glucose, ammonium, sodium, chloride, and potassium reabsorption in both healthy and 
diabetic cases with NHE3 therapy administered via a sigmoidal change as seen in Figure 3 in 





























































































Fig. 4.6: Dotted line – solute reference changes in !", $%&, '(!, and '(". This curve is how 
reference solute concentrations are changed in time during loading. Solid line – NHE3 
density parameter change for therapy. This curve is the sigmoidal change of this parameter 
from a value of 1 to ) = +. The equation is given by %,-./01 = "#$"%&!"#$/&"""" + 3. 
Fig. 4.5 also shows that a decrease in NHE3 density to 50% of the baseline moves the 
sodium reabsorption values of the diabetic kidney closer in line with those of the healthy kidney 
without therapy. As described in [85], a positive effect of NHE3 reduction would decrease 
sodium retention and we see the therapy achieving that. Similarly, fluid reabsorption of the 
diabetic kidney at 50% NHE3, is also brought closer to fluid reabsorption in the healthy case. It 
was also described by Packer [85], that insulin therapy has the effect of stimulating the NHE3 
transporter and subsequently sodium retention. This can also be seen in the simulation results as 
an increase in NHE3 expression leads to increased sodium reabsorption. As per Girardi [125], 
sodium reabsorption is proportional to NHE3 impairment. Our model shows that flow rate is 













































affected more by a decrease of NHE3 than by an increase, whereas Girardi shows a more linear 
relationship. Similar to the findings in [92], we report a decrease in bicarbonate and chloride 
reabsorption from NHE3 knockout. In a healthy or diabetic state, NHE3 impairment does not 
linearly affect changes in bicarbonate and chloride reabsorption though. Further, bicarbonate 
reabsorption is less sensitive to changes below 50% density than chloride reabsorption. This is 
most likely due to bicarbonate co-transporter reabsorption no longer reaching the full limit 
possible because sodium concentration has been sufficiently reduced [92]. 
Li et al. [124] have reported that, in the healthy case, ammonium reabsorption is largely 
unaffected by changes to NHE3 expression. We see a similar behavior in the simulation results 
of Fig. 4.5 where ammonium reabsorption does not change by more than 30% with NHE3 
knockout. In the diabetic case, ammonium reabsorption is slightly more affected by NHE3 
expression changes. Ammonium reabsorption is in line with healthy ammonium reabsorption for 
a nondiabetic kidney with 50% NHE3 density. These results for ammonium reabsorption 
validate that the model replicates the expected ammonium reabsorption with NHE3 knockout 
and shows the positive effects of a 50% NHE3 density that can be achieved via the NHE3 
therapy [124]. 
Finally, we note in Fig. 4.5 a dramatic increase in glucose reabsorption in the diabetic 
case as expected since glucose concentrations are higher entering Bowman’s space. We do also 
observe that glucose reabsorption is much more affected by changes to the NHE3 expression in 
the diabetic case versus the healthy case, similarly to ammonium. This makes sense since the 
saturated sodium-glucose transporters that are transporting glucose across the epithelium, at a 





4.3.3 Salt & Sugar Loading Analysis 
We now have a model capable of simulating a variety of real-world scenarios important 
for diabetics. Hence, we studied the effects of salt and sugar loading. This was done to simulate a 
real-world scenario where a diabetic ingests a high amount of salt and sugar over several days. 
During this same period, a dose reducing the NHE3 transporter density was administered. We 
sought to understand how this combined loading and therapy affects the reabsorption, and hence 
hyperfiltration in the proximal tubule. To simulate this, we varied the reference concentrations in 
Bowman’s space, the descending limb of Henle, and the interstitial fluid of sodium, chloride, and 
glucose by the curve shown in Fig. 4.6 from 1 to 1.25 times baseline values. These effects were 
studied for a healthy kidney without therapy, a healthy kidney with NHE3 therapy according to 
Fig. 4.6 where the final value is 0.5 instead of 0, and the same conditions for a diabetic kidney. 
These results are presented in Fig. 4.7 where we show the effect of administering NHE3 therapy 






Fig. 4.7: Model dynamic response to sodium, glucose, and chloride loading according to 
Figure 3 from 1 to 1.25 times and therapy inducing 50% NHE3 density according to Figure 3 
where the final value is 0.5 instead of 0. Fluid, bicarbonate, glucose, ammonium, sodium, 
chloride, and potassium reabsorption in both healthy and diabetic cases with and without 
the aforementioned therapy. 
It is apparent that the glucose reabsorption greatly increases in the diabetic case 
irrespective of therapy administration. This is expected as glucose concentration has greatly 
increased in the diabetic kidney and the NaF: Gl  transporter responsible for the majority of the 
glucose reabsorption is unable to transport all the glucose back into the blood due to the 
increased load from diabetic conditions and from the loading test. We also see in Fig. 4.7 that the 
NHE3 density impairment to 50% therapy does not alter glucose reabsorption by a significant 
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attenuate hyperglycemia associated with diabetes. The NHE3 therapy has a large effect on the 
ammonium reabsorption in the diabetic kidney, bringing it closer to healthy levels. 
Importantly, fluid, potassium, and ammonium reabsorption for the diabetic kidney with 
therapy administered moves the reabsorption of all solutes more closely in line with that of a 
healthy kidney. This is an important effect of the therapy where fluid retention that typically 
occurs in the case of the diabetic kidney is reduced. For bicarbonate reabsorption, this increased 
reabsorption can disrupt blood pH levels in the case of the diabetic kidney. Bicarbonate is an 
essential solute for maintaining this pH balance in the kidneys. The pH balance in the kidneys 
can have adverse whole body consequences if disrupted [1]. We observe in Fig. 4.7 that the 
NHE3 therapy does in fact increase bicarbonate reabsorption to levels further beyond those of a 
diabetic kidney during this loading. 
Sodium and chloride reabsorption are largely unaffected by the NHE3 therapy, Fig. 4.7, 
administered presumably due to the high loading of both solutes. Though we do note that the 
NHE3 therapy in both cases moves reabsorption of both solutes closer to the values seen in the 
healthy kidney during loading. 
Taking into account aforementioned results, fluid, potassium, glucose, ammonium, 
sodium, and chloride reabsorption are positively affected by NHE3 expression reduction to 50% 
density in the case of salt and sugar loading. Certain diabetic therapies such as insulin, according 
to Packer [85], can lead to an increase in NHE3 expression. This increased expression can have 
adverse effects on all reabsorptions aforementioned, namely fluid retention that is associated 




4.3.4 Stability Analysis 
In order to check if the pencil (E, I), is regular, it suffices to show the existence of one K 
such that det(KE − I) ≠ 0. For our system we arbitrary found K = 5 × 10&"G from an 
exhaustive search, to make det(KE − I) ≠ 0. For this value, the determinant of the pencil is 
−2.4 × 10"1 and hence the pencil is regular. 
We next looked at the eigenvalues of the pencil, from (4.37), for the linearized version of 
the model. We have 70 eigenvalues. Considering just the real parts of these finite eigenvalues, 64 
are negative and 6 are zero. This implies that the system is marginally stable based on the 
solution to the differential equation including sinusoidal components [13]. Further, it implies that 
a bounded input will necessarily produce a bounded output within a given region of oscillation. 
This is important because it implies that the proximal tubule reabsorption will not be life-
threatening during changes to inputs from the glomerulus, within a neighborhood around the 
equilibrium point, as is true in real life since the proximal tubule reabsorptions returns to 
equilibrium with many perturbations throughout the day. 
In a paper by Weinstein and Sontag [101], the authors note that in healthy kidney 
function, there are routinely swings in proximal tubule fluid flow and proportional changes in 
sodium reabsorption. This is known as the glomerulotubular balance and it was investigated in 
[101], how transporter regulation may account for this balance and subsequent stability of the 
system. It was determined in [101] that transporter parameter modulation is a function of cell 
volume, electrical potential, and interspace pressure acts to stabilize cell volume, sodium flux, 
and cell pH. The proposed feedback via transporter modulation in [101] is left as a hypothesis to 




In the presence of known autoregulation mechanisms in the kidney, such as the myogenic 
response, the tubuloglomerular feedback, and the renin-angiotensin mechanism, fluid flow into 
the proximal tubule is contained within a tight range. In [101], it is suggested that there is an 
intrinsic autoregulation within the proximal tubule. Therefore, it is not expected for the proximal 
tubule to be asymptotically stable to all bounded inputs since these autoregulation systems are 
required for a healthy kidney.  
4.4 Conclusion 
In this chapter, we developed a mathematical model that captures the transport dynamics 
of the proximal tubule, the most active portion of the nephron. We have developed a novel 
modular mathematical dynamic model based on physiological first principles that was subjected 
to different validation steps. We first replicated trends and steady-state results from experiments 
and other models in the literature and found our model to be in good standing. Further, we have 
investigated the effects of sodium-hydrogen transporter (NHE3) therapy in the case of healthy 
and diabetic kidneys. We see in our simulation results that a reduction of NHE3 expression to 
50% both in baseline input and loading of salt and glucose cases, partially restores diabetic 
kidney fluid, sodium, ammonium, potassium, and chloride reabsorption to values that coincide 
with a healthy kidney under identical conditions. This model can be a tool for testing NHE3 
therapy on a population of diabetic patients, or on an individual diabetic patient, after 
personalization. 
Again, the goal of NHE3 therapy for a diabetic kidney is to reduce hyper-reabsorption 
and subsequently glomerular hyperfiltration that can lead to diabetic nephropathy. With reduced 
sodium and chloride reabsorption from NHE3 suppression, the tubuloglomerular feedback 




Therefore, in terms of reducing hyperfiltration, the NHE3 effects demonstrated by the model, 
reduce sodium and chloride reabsorption in the proximal tubule thereby preventing 
hyperfiltration. 
The model, a differential-algebraic set of equations (DAEs), was linearized and the 
stability around the equilibrium point was analyzed, showing marginal stability. Solving a 
complex DAE is similar to solving a stiff system and the complexities of solving this system 
were also discussed. 
The model presented was developed using a first principles approach based on renal 
physiology. It improves upon the current literature of proximal tubule models in its development 
strategy, dynamic simulation, inclusion of 17 solutes, and removal of assumptions about solute 
transport and pressure-volume constraints. This model, after validation, can be used to 
understand kidney diseases. We can simulate the time-varying response of the proximal tubule to 
therapy and capture the dynamics of diseases, as demonstrated in our clinical scenario 





Chapter 5: Rat Proximal Tubule Model - Parameter Estimation & 
Disease Classification 
5.1 Introduction 
A physiological model of a complex system allows for the understanding of variables and 
parameters most of which are unobservable. Variables are states of the system, like pressure, 
concentration, and flow. Parameters characterize physical properties of a system and typically 
appear as coefficients of the variables in system’s equations; they are a window into system 
health. In the proximal tubule of the kidney there are several vital transporters that determine 
overall kidney health. We make use of the previously validated lumped, ordinary differential 
equation model from the previous chapter, of the nephron proximal tubule model with 
parameters that describe these vital transporters. In the current chapter, we focus on the 
NaF: HCO2& (sodium-bicarbonate), KF: Cl& (potassium-chloride), NaF: HF (sodium-hydrogen), 
and Cl&: HCO2& (chloride-bicarbonate) co-transporters in an effort to determine their expression 
(density). These transporters are important because the largest flow rates of sodium, bicarbonate, 
chloride, and potassium occur across these co-transporters as compared with any others in the 
proximal tubule [90]. Therefore, alterations in the expressions of these co-transporters will 
greatly affect kidney function. 
Parameter estimation is the process of using measured input and output variables in order 
to compute the parameters. Estimating parameters is important for determining diseases, where 
altered parameters are indicative of the state of the system. The process can also be used to 
personalize a model to a specific patient. A personalized model can then be used to test therapy 




parameter estimation. It leverages prior information in the estimation to improve the confidence 
of each estimation. This technique is well suited for clinical applications, where patient 
demographic and comorbidity information are readily available and can be incorporated into the 
prior information for a Bayesian estimation. As described by Spielgelhalter [128] a Bayesian 
approach is best for providing additional tools for disease classification where the prior 
prevalence (probability) of such disease is known. Considering the patient population as 
stochastic, with a Gaussian distribution, it makes sense to use this type of probabilistic approach 
for disease classification. With a vast majority of patient medical records being stored and 
aggregated, there is an abundance of prior information for different patient populations. Because 
of this, any estimation technique that can make use of this information lends itself nicely to the 
cause. Several papers have utilized parameter estimation techniques for the kidneys and 
specifically the proximal tubule [43]–[47] via least-squares or nonlinear least-squares. These 
papers were focused on either estimating resistances, capacitances, or transporter parameters for 
kinetic models of a single co-transporter. Estimations were carried out with healthy data, 
spontaneously hypertensive data, or data after glucose loading in rats. Our goal is to study which 
model outputs are needed as estimation inputs in order to achieve high accuracy estimation of 
parameters of the four aforementioned co-transporters. We analyze how proximal tubule 
variables, such as the pressure, electric potential, or concentrations of sodium, potassium, 
chloride, glucose, urea, and bicarbonate, are affected when several co-transporter densities are 
changed simultaneously. 
Using Bayesian estimation, we are able to estimate these transporter densities using 
measurable model outputs including the aforementioned pressure, electric potential, and solute 




pressures and concentrations in the epithelial cells and interspaces corresponding to the perturbed 
transporter density via simulation. The estimation results are validated using data that was 
collected from rats with normal, decreased, and increased NaF: HF transporter expressions. 
Using the measured bicarbonate concentration and pH levels from the experiments, we estimate 
the parameters of all four co-transporters for all cases of NaF: HF expression and report the 
difference between the estimated and the true values. Further, we evaluate estimation results by 
comparing fluid, sodium, bicarbonate, and glucose reabsorption from model outputs using the 
true parameter density (as measured) and model outputs using estimated parameter densities. To 
study variable response to changes in transporter density, we begin by conducting a sensitivity 
analysis that can also identify suitable inputs for the Bayesian estimation. Using the inputs 
highlighted from the sensitivity analysis, we then conduct several estimations, with model-
generated noisy data, for different transporter expressions. We again evaluate the performance of 
the estimation by comparing reabsorption flow rates of those corresponding to true parameters 
and those corresponding to estimated parameters. High accuracy was determined by minimal 
error between parameter estimations as compared to true co-transporter parameter expression 
and minimal error between estimation derived reabsorption flow rates compared to true 
reabsorption flow rates. 
5.2 Methods 
5.2.1 Model Structure 
In the model, we divide the proximal tubule, based on physiological transport differences, 
into two sections: the proximal convoluted tubule (PCT) and the proximal straight tubule (PST). 
Similar to Christensen et al. [105], we consider the PCT to be the first 70% (0.7 cm) of the 




tessellated into three nodes: tubule, epithelial cell (EC), and interspace between the cells (IS). The 
source to the system (where filtrate enters the proximal tubule) is Bowman’s space (BS) and the 
sinks are the interstitial fluid (IF) and the descending limb of Henle (LDN). Flow throughout the 
system is shown in Fig. 4.1, where arrow directions indicate positive flow. 
At an arbitrary node m, the time-varying variables we consider are hydraulic pressure, 
nH(/), in mmHg, concentration, [H(/), in mmol/mL, and electric potential, =H(/), in mV. 
Between arbitrary nodes m and o, the flow of fluid and solutes is given by pH&I(/), in mL/s, 
and UH&I(/), in mmol/s, respectively. Volume at any node is given by integrating the fluid flow, 
qH(/) = ∫ pH(/)s/ in mL, where pH is the net flow into node m. Similarly, mass at any node is 
given by integrating the solute flow, 8H(/) = ∫ UH(/)s/ in mmol, where UH is the net solute flow 
into node m. The solutes included in the model are those that are also included in [90]: NaF, KF, 
Cl&, glucose (Gl), urea (Ur), an impermeant protein (Imp&) with valence z = −1, HCO2&, H1CO2, 
CO1, HPOJ1&, H1POJ&, NH2, NHJF, HF, HCO1&, H1CO1, an impermeant buffer (Buff&) with 
valence z = −1, and a protonated impermeant buffer (HBuff) with valence z = 0. These solutes 
are included because they comprise the solute constituents of the co-transporters and associated 
buffer pair solutes. The full set of equations is comprised of those previously derived in (4.1) – 
(4.27). 
5.2.2 References & Parameters 
Concentrations from a Ringer’s solution (an isotonic solution relative to interstitial fluid) 
were used as the source and sink values at BS, IF!, and IF". For the LDN node, concentrations 
were set to concentrations in the PST, plus the difference between the values at the PCT and PST 
divided by the ratio of their lengths. We use the lengths instead of the volumes since the cross-




secreted back into the nephron, this is a fair assumption that concentrations would decrease in the 
LDN. Reference pressure and voltage values needed at BS, IF! and IF", and LDN nodes were 
from [90]. Reference volumes are not needed for sources or sinks, as they do not appear in any 
equation. 
The parameters for axial fluid flow were calculated using the Hagen-Poiseuille relation, 





where |H̅I is the average length between nodes, Ä̅HI is the average radius between nodes, and ~ is 
the blood viscosity, assumed to be 6.4´10-6 mmHg⋅s. Inlet flow from BS was set to 35 nL/min 
and solute flow from BS to PCT was restricted to only advective flow since the diffusive flow 
here is negligible. 
For axial solute flow, all reflection coefficients were set to 0 since there are no 
membranes to impede the flow of these solutes axially. For the diffusive resistance along the 
tubule, diffusion coefficient values in an aqueous, well stirred water solution were found from 
[110] and [111] and then adapted to our system by multiplying by the cross-sectional area of the 





where %Å, is the diffusion coefficient and Ç is the temperature adjustment factor for the solutes 
(in this case, the adjustment for 37℃ is Ç = 1.339) used to account for change in the diffusion 
coefficient based on temperature. 
All remaining parameters were adapted from [90] to fit a lumped model with our model units. A 
complete list of all parameters can be found in Table 4.1 with the co-transporter parameters for 




Table 5.1: Co-transporter permeabilities [mmol2/J/s] and stoichiometric ratios. 
from to ÑÖ&: XÑÜK
& áàF: XF âF: ÑÖ& áàF: XÑÜK& 
äÑã åÑ?=@ 7.92×10-10 1.09×10-9 0 0 
åÑ?=@ çé?=@ 0 0 1.98×10-9 1.98×10-9 
åÑ?=@ çèL 0 0 5.50×10-11 5.5×10-11 
äéã åÑ?M@ 3.39×10-10 4.67×10-10 0 0 
åÑ?M@ çé?M@ 0 0 8.48×10-10 8.48×10-10 
åÑ?M@ çèN 0 0 2.36×10-11 2.36×10-11 
Ratios 1:-1 1:-1 1:1 1:3 
 
5.2.3 Bayesian Estimation 
Since we have developed the rat proximal tubule model using a first-principal approach, 
the parameter values have physical meaning, such as transporter expression or hydraulic 
resistance of tubules. Bayesian estimation is a parameter estimation technique that uses prior (a-
priori) knowledge of parameter values in order to better estimate (or predict) these parameters 
[16]. Typically, medicine is evidenced-based, where physicians integrate: clinical experience, 
patient values, and the best available research information [129]. Using Bayesian estimation for 
parameter estimation in our application essentially comprises all parts of this definition for 
evidence-based medicine: clinical experience (prior prevalence and population information), 
patient values (input and output signals), and the best available research information (the 
mechanistic model). By utilizing all three of these components we are able to accurately estimate 
patient parameter values and subsequent diseases. 
The process of this parameter estimation consists of finding a probability distribution of 
each parameter to be estimated given the values of input and output variables. We can then use a 
maximum-a-posteriori (MAP) estimator to select the parameter values that have the highest 
probability as the final estimated parameter value for all parameters estimated. Another 




based on parameter values. Essentially, we are also estimating a confidence via a distribution for 
each estimate and hence a confidence that a particular patient has a particular disease. 
We are specifically interested in estimating scaling values multiplying the result of (4.10) 
for the NaF: HCO2&, KF: Cl&, NaF: HF, and Cl&: HCO2& co-transporters. These transporters are 
important because the largest flow rates of sodium, bicarbonate, chloride, and potassium occur 
across these co-transporters as compared with  any others in the proximal tubule [90]. These 
scaling values represent the density/expression of each co-transporter. A value less than one 
represents an under-expressed transporter, while a value of one represents a healthy transporter, 
and a value greater than one represents an over-expressed transporter. An over-expressed or 
under-expressed transporter can lead to a decrease or increase in solute reabsorptions throughout 
the proximal tubule that can result in solute concentrations that are dangerously low or high.  The 
4 × 1 vector of scaling (density) parameters of the NaF: HCO2&, KF: Cl&, NaF: HF, and Cl&: HCO2& 
co-transporters that we aim to estimate is ê. Here, we are assuming that every parameter is 
stochastic and varies between a range of 0 to 2. Again, this approach makes sense because 
patient parameter values are typically stochastic and normally distributed across the population. 
Our prior information about these parameters will be derived from population statistics. The 
ë × í matrix of model outputs in time is given by  
 ì(/) = î(/, ê), (5.3) 
where ë is the number of measurements at time /, í is the number of outputs, and î is the model 
of the system. The collected measurements will inevitably be corrupted by noise and since the 
model cannot perfectly describe the physics, we introduce the ë × í matrix of noisy 
measurement outputs, 




where ñ is a matrix of white Gaussian noise on each model output (estimation input). The 
estimation is used to obtain a value of ê,  êó, from the available measurements, ï. This is done by 





where 9(ê|ï) is the conditional (a-posteriori) probability of ê values given the available 
measurements ï, 9(ï|ê) is the joint conditional probability of ï, given ê values, 9(ê) is the 
combined (product) a-priori probability density function (pdf) of each parameter, and 9(ï) is the 
joint pdf of the measurements. We are interested in solving for 9(ê|ï) which will inform us of 
the probability of the patient having certain parameter values given the patient measurements. 
The 9(ï|ê) term is the likelihood function, and a measure of the probability of achieving patient 
measurements given a set of parameter values. When evaluating 9(ê), we make use of the prior 
information known about the population and parameter values. Finally, the term 9(ï), having no 
functional dependence on ê, is not strictly necessary for evaluating (5.5), but instead used to 
scale the results based on the probability of achieving the given measurement values. 
  The MAP estimation for a single ô is defined as  
 ôöOP# = argmax
Q
9(ô|ù). (5.6) 
For multiple parameters, ê is a vector, and the MAP estimated parameter vector value êó for each 
is defined as the argmax of the marginalization of 9(ê|ï) for each a-posteriori pdf. The 
marginalization is defined as the sum over all possible values of the parameters, more 
specifically, the multiple summations over every other parameter other than the specific element 
of ê. For the ;th element of êó, this is discretely defined by 











where ΔôR is the discrete distance between neighboring possible values for ôR (and similarly for 
ôS and ôT). The a-priori pdfs for each of the four transport scaling parameters were chosen as 
normal distributions with a mean of 1 and standard deviation of 0.2. This value of standard 
deviation was chosen since it is half the value of what is determined to be a diseased transporter 
in [125]. In practice, these values may be different depending on prior patient knowledge. Some 
prior patient knowledge includes patient demographics and information about other 
comorbidities. 
The conditional probability, 9(ï|ê), is the product of conditional probabilities, 9(¢|ê), 
for each estimation input, where ¢ is an ë × 1 vector of measurements in time for that input. 
Practically speaking, 9(¢|ê) is a matrix evaluated for all combination of allowable, ê, defined as 
ê = ê£ values, as dictated by the domain of 9(ê). One element of the conditional probability, 
9§¢•ê = ê£¶, for a given value of ê = ê£ and one estimation input signal is defined as 
 9§¢•ê = ê£¶ =
exp ß−12 (¢ − ®)
U ⋅ ©V&" ⋅ (¢ − ®)™
´(2)W|©V|
, (5.8) 
where ©V = ¨I1 ⋅ ≠ is the covariance matrix of the measurement noise with standard deviation 
¨I, |©V| is the determinant of the covariance matrix, and ® is a vector of the estimation inputs 
calculated from the model given ê = ê£. We define a matrix Æ comprising model outputs, in 
time, for all discrete combinations of ê values allowable. From Æ, for a given ê£, we select the 
vector of estimation inputs ®, corresponding to ê£. For example, for a four element ê vector, with 
10 possible values for each element, Æ will be a 5-dimensional matrix with 10 elements along the 
first four dimensions and ë along the last. In selecting the ë × 1 vector ®, we select the 
elements of Æ, along the first four dimensions corresponding to the value of ê£.	The matrix Æ, is 




in the calculation. However, this term need only be calculated once, prior to any parameter 
estimations. Hence, evaluating 9(¢|ê), for a specific patient, is a simple substitution of ¢ values 
prior to the parameter estimation using Bayesian theorem in (5.5) and evaluate for all possible 
parameter value combinations. 
Given that the term 9(ï|ê) ⋅ 9(ê) = 9(ï, ê) is the joint pdf of 9(ï, ê), we can compute 
9(ï) as the following 
 9(ï) = Ø9(ï, ê)
Q
sô = Ø9(ï|ê) ⋅ 9(ê)
Q
sô. (5.9) 
With all three terms in Bayes’ theorem, we can then calculate 9(ê|ï) using (5.5). To find 
each component of ê, we can marginalize the pdf 9(ê|ï), as described above, and then calculate 
the MAP value for each a-posteriori pdf using (5.6). 
5.3 Results & Discussion 
We validate the estimation results using data from real rats. We will use the inputs 
available from the study as estimation inputs. Next, we conduct a sensitivity analysis to select 
which inputs (when available) allow for better estimation. Finally, we generate simulation data 
for various diseased states and conduct several estimations to investigate how input signals, 
degree of noise, and number of data points per signal provided affect the estimations. 
Specifically, we will consider the results in terms of correct parameter estimations as well as 
percent error for reabsorption flows (model-predicted variables using the estimated parameters).  
5.3.1 Parameter Estimation Validation 
In this section, we apply Bayesian estimation to the model to estimate co-transporter 
parameters and hence validate the performance of the estimation technique by estimating co-




which co-transporters have altered or unaltered expressions. Further, we analyze how the model 
outputs using the estimated parameter values compare to the true model outputs. 
Girardi et al. [125] investigated the effect of parathyroid hormones on the expression of 
the NaF: HF transporter in the proximal tubule of rats. Rats without altered NaF: HF transporters 
were compared to those with decreased and increased NaF: HF transporter densities. After eight 
days, bicarbonate concentrations and pH levels were measured and compared to the measured 
baselines. A western blot analysis was conducted to determine the expression change of the 
NaF: HF transporter. We used our model and estimation technique to determine the expression of 
each of the four co-transporters, NaF: HCO2&, KF: Cl&, NaF: HF, and Cl&: HCO2&, and the degree 
of disease, namely the new density of the transporters. 
The estimation results are shown in Fig. 5.1. All parameter estimations consisted of two 
measurements at two time points, an initial healthy value for [#$%
X$Y)( 	and pH#$% and a final value 
8 days after disease insult. Fig. 5.1a shows the estimation results for a healthy NaF: HF 
transporter, Fig. 5.1b shows the estimation results from rats with impaired NaF: HF transporter 
density to 60% of the baseline, and Fig. 5.1c shows the estimation results from rats with a  
NaF: HF transporter density 150% of the baseline. Each estimation was conducted 100 times and 








0 0.5 1 1.5 2


















0 0.5 1 1.5 2

















0 0.5 1 1.5 2

















0 0.5 1 1.5 2


















0 0.5 1 1.5 2




















0 0.5 1 1.5 2




















0 0.5 1 1.5 2



















0 0.5 1 1.5 2

























Fig. 5.1: Bayesian estimation results for three cases of &4%: 6% transporter health. Prior 
probability density function for each parameter shown in dashed line, true parameter 
density shown in blue, and estimation probability shown in solid black line. Maximum a-
posteriori estimate is highest point on the a-posteriori probability curve. (a)  All transporters 
healthy. (b) Impaired &4%: 6% transporter to 60% baseline density, with all other transporters 
healthy. (c) Overactive &4%: 6% transporter to 150% baseline density, with all other 
transporters healthy. All data from rats from [125]. 
In Fig. 5.1a (the healthy case), the estimation’s MAP values, as shown by highest point 
on the posterior curve, for each transporter density are correct as compared to the true value 
(vertical line). In other words, the estimation MAP values match the true values. Further, the a-
posteriori probability of each transporter density (after estimation) has a higher peak at the 
estimated value as compared to the a-priori distribution. This implies that the estimation 
likelihood for those parameters’ values is higher with the given measurements. 
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In Fig. 5.1b, for the impaired NaF: HF transporter case, the a-posteriori pdf for the 
NaF: HCO2& , KF: Cl&, and Cl&: HCO2& estimates are all within 10% of the true scaling and 
indicative of healthy functioning co-transporters. The MAP value for NaF: HF was correctly 
estimated to be 60%. Hence, the estimation has correctly identified three transporters as healthy, 
and the NaF: HF transporter as diseased. We note that the MAP value for the NaF: HFtransporter 
is very near the second most probable value of 70% (as determined by the vertical height). This 
means that the estimation has determined that the NaF: HF density is most likely either 60% or 
70%. In both cases, the estimation would still have correctly identified the NaF: HF transporter 
as diseased, as indicated by estimated transporter density lower than 20% the baseline. This 20% 
threshold for declaring a transporter diseased is based on the standard deviation used for the a-
priori pdf curves. In practice, this value may differ and is up to the physician to decide. 
In Fig. 5.1c, for the case of increased density, we once again see the NaF: HCO2& , 
KF: Cl&, and Cl&: HCO2& transporters are estimated to be within 10% of the true scaling and 
indicative of healthy function co-transporters. The NaF: HF transporter density in the overactive 
case has a MAP value of 120%. This 120% value is indicative of a disease. Similarly, to the 
impaired case, there are in fact two estimation values with similar likelihood for this transporter, 
120% and 110%. The true value was 150% and the estimation has underestimated the NaF: HF 
density. However, at the MAP value, the estimation results still imply a diseased NaF: HF 
transporter, with all other transporters healthy. 
Further, we compared the reabsorption flow model outputs of fluid, sodium, glucose, and 
bicarbonate since drastic changes in the reabsorption of these constituents can greatly affect the 
health of the kidney [5]. Since the MAP estimation for the healthy case proved to be correct for 




since all parameter values are identical to the baseline. For the case of impaired NaF: HF 
transporters, using estimated MAP parameters, fluid and sodium reabsorption flows were within 
7.5% and 7.1% respectively, of the true reabsorption flows as determined by the true transporter 
densities. Glucose reabsorption was within 0.11% of the true value and bicarbonate reabsorption 
was within 4.97% of the true value. This indicates that although the estimated (MAP) transporter 
density values are slightly different from the true values, the model with estimated parameter 
values yields fairly accurate model outputs as compared to the true system outputs. For increased 
expression of NaF: HF transporters, it was calculated that fluid and sodium reabsorption were 
within 9.2% and 8.8% respectively, of the true reabsorption, glucose reabsorption was within 
0.5%, and bicarbonate reabsorption was within 4.98%. This again indicates that although the 
estimated (MAP) transporter density values are different from the true values, all reabsorption 
flows of the model using the corresponding parameters are within 10% of the true reabsorption 
flow values. These estimations have therefore been shown to be capable of estimating diseased 
co-transporter parameters, as well as reabsorption flows within 10% of the true reabsorption 
values. 
5.3.2 Sensitivity Analysis 
Our goal is to understand which variables are likely to change given an alteration in the 
co-transporter expression/density. This will allow us to conclude which variables are good 
indicators of altered co-transporter expressions. We conducted a sensitivity analysis by 
individually varying all four of the transporter density parameters from 0 to 2 times their baseline 
values in increments of 0.1 and then recorded the variable value changes with respect to their 
baselines. These parameter ranges have real, physical meaning and hence are physiologically 




baseline. We calculated a Σ value to quantify how sensitive a particular variable, +, is to a 
change in a particular parameter, 9, based on the change of both the parameter and variable value 
from their baseline values as 







The results of this sensitivity analysis for all variables in the proximal convoluted tubule are in 
Fig. 5.2, where the sensitivity values for each variable have been normalized such that the largest 
sensitivity is 1 by dividing by the largest sensitivity values to easily compare variable 
sensitivities to the parameter changes. For each system variable, there are four bars, representing 
the sensitivity value of that variable to each of the four co-transporters. We specifically analyzed 
values in the convoluted portion of the tubule instead of the straight portion since these values 
are more easily measured. In order for a variable to be a good candidate for use in the estimation, 
it should be highly (uniquely) sensitive to one parameter and not another. Consider example 
transporters A and B and variables 1 and 2. If variable 1 is highly sensitive to transporters A and 
B, then deviations of variable 1 from the baseline do not imply which transporter has changed. 
However, if variable 2 is highly sensitive to only transporter A, then a deviation from baseline in 
variable 2 is likely due to a change in transporter A, and not transporter B.  
In Fig. 5.2 we see that formic acid (H1CO1) concentration is highly sensitive to all 
transporter densities, as expected since formic acid is pivotal in maintaining the electrically 
neutral environment and alteration of any transporter changes the movement of charged particles, 
and hence electroneutrality [130]. This implies that estimation using formic acid measurements 
would not be indicative of which transporters are healthy and which are diseased. We expected, 
and indeed, sodium concentration shows very low sensitivity in response to changes in 




transporter density since a large amount of sodium is transported across both of these 
transporters. This indicates that relatively unchanged sodium concentrations in the PCT imply 
unchanged NaF: HCO2& and NaF: HF transporters, and possible changes to Cl&: HCO2& transporter 
density. Glucose is highly sensitive to the NaF: HCO2& and NaF: HF transporters. Since the 
majority of glucose is reabsorbed via co-transport with sodium [5], it follows that glucose would 
share sensitivity to the same transporters as sodium. Sensitivity to changes in the  Cl&: HCO2& 
transporter is relatively low across all variables compared to the other transporters with the 
exception of hydrogen phosphate (HPOJ1) concentration. Potassium concentration in, Fig. 5.2, 
shows increased sensitivity to the KF: Cl& transporter as opposed to the Cl&: HCO2& transporter, 
whereas chloride concentration shows increased sensitivity to the Cl&: HCO2& transporter as 
opposed to the KF: Cl& transporter. This can be useful during estimation as changes in either 
concentration can imply a change in a given transporter. 
 
Fig. 5.2: Sensitivity (7 = |9:;/9;:|	 for variable : and parameter ;) plot where each 
transporter density parameter was varied from 0 to 2 independently in increments of 0.1 and 
averaged. A 7 was calculated for all variables in the >?@, for each transporter. The 


















5.3.3 Parameter Estimation Analysis 
In order to analyze how estimation accuracy and performance change in the presence of 
varied number of inputs, number of data points of inputs (resolution), and amount of noise, we 
conducted several parameter estimations with varied configurations. Data used for the estimation 
was generated by the model with noise superimposed on the signals after generation. We tested 
estimations with 2, 10, 21, and 41 data points. Data points were down-sampled evenly in time for 
cases with less than the baseline number of data points. For cases of more than 2 data points, the 
data captures the dynamic changes in variables during transition from the beginning healthy 
values to the final diseased values. For noise, we tested 5%, 10%, and 20% of the signal range. 
Finally, we tested 11 different combinations of estimation input signals (Table 5.2) based on 
conclusions from the sensitivity analysis. All configurations included sodium and potassium with 
the addition of other variables, except for the last configuration, which used pH and bicarbonate 
concentrations in the proximal convoluted tubule, to mirror the available inputs from [125].  
Table 5.2: Co-transporter parameter estimation input configurations. 
Proximal Convoluted Tubule Estimation Inputs for each Configuration 
NaF, KF 
NaF, KF, Cl& 
NaF, KF, Gl 
NaF, KF, Ur 
NaF, KF, n 
NaF, KF, = 
NaF, KF, HPOJ1& 
NaF, KF, H1CO1 
NaF, KF, HCO2& 
NaF, KF, pH 
pH, HCO2& 
 
The results of these estimations, for 5% (low) signal range noise and 21 data points, are 




transporters for all four co-transporters. The error results for all of these combination simulations 
were averaged together. Fig. 5.3a shows the density percent error for each co-transporter 
averaged over all simulations. Fig. 5.3b shows the reabsorption flow percent error calculated 
using the MAP of the estimated co-transporter parameters, averaged over all simulations. Fig. 
5.3c shows the averages of Fig. 5.3a and Fig. 5.3b across all four transporters and all four 
reabsorption flows, respectively. Unsurprisingly the estimation results for varying data points 
and noise (regardless of inputs) demonstrated that more data points and lower noise resulted in 
better estimations, with average density percent error increasing by approximately 20% for each 
























Fig. 5.3: Percentage errors for several estimations: (a) average estimated error in co-
transporter density across all estimations, (b) average reabsorption error using estimation co-
transporter densities, (c) average co-transporter density error over all co-transporters and all 
estimations and average reabsorption error across all reabsorption flows and estimations. 
We note from Fig. 5.3a that the highest errors exist when estimating the density of the 
Cl&: HCO2& co-transporter. However, where we included chloride as an estimation input, the 
density error of Cl&: HCO2& significantly decreased, as expected since chloride is one of the 








































HCO2&, or pH. Adding voltage improves accuracy since bicarbonate is the main anion transported 
in the proximal convoluted tubule and hence directly affects the electric potential throughout [5]. 
According to the sensitivity analysis, HPOJ1 showed the highest sensitivity to changes in 
Cl&: HCO2& density and therefore it is logical that including this concentration as an estimation 
input would improve estimation performance. The addition of HCO2& as well makes sense, since 
it is one of the solutes transported via the Cl&: HCO2& transporter. The other transporters are 
estimated with similar percent errors across all estimation configurations, with the exception of 
using only pH and HCO2& as estimation inputs. This implies that these estimation inputs do not 
provide enough information for the estimation to correctly determine transporter densities, with 
the exception of the NaF: HF transporter, as also demonstrated by the validation in 5.3.1.  
In Fig. 5.3b we see that glucose reabsorption is more accurate when either  Cl&or HCO2&	 
are included with  NaF and KF as estimation inputs, as opposed to without. Reabsorption of 
HCO2& is estimated within 1% percent error from the true reabsorption in all estimation cases. 
This implies that reabsorption of HCO2& is less sensitive to the parameter changes estimated in  
Fig. 5.3a. Fluid and NaF reabsorption errors are similar for all estimation configurations. This 
makes sense since fluid and NaF are typically absorbed in equal parts as per the 
glomerulotubular balance [5].  
From Fig. 5.3c, we note that better average accuracy (across all four co-transporters and 
across all four considered reabsorption flows) according to both transporter density error and 
reabsorption flow error occurs when including Cl&, urea, pressure, voltage, HPOJ1, or pH. 
Accuracy was unchanged by including glucose or H1CO1. Based on the sensitivity analysis and 
the high sensitivity H1CO1 shows in response to changes in any transporter parameter, it was in 




HCO2& as estimation inputs significantly worsens accuracy of transporter density, as density 
percent error for the NaF: HCO2&, KF: Cl&, and Cl&: HCO2& co-transporters were all above 50%. 
This implies that estimations using just these two inputs will not necessarily estimate transporter 
density correctly but can still aid in determining reabsorption flow with the same accuracy as 
using concentrations of NaF and KF only. The best estimation of reabsorption flow included 
HCO2& and the best estimation of transporter density included Cl&. Including HPOJ1 in the 
estimation greatly improved transporter density determination, particularly for the Cl&: HCO2& co-
transporter, reducing density percent error from over 60% to under 30%. This makes sense given 
the sensitivity analysis where HPOJ1 was the only solute with high sensitivity to the Cl&: HCO2& 
transporter compared to the other co-transporters.  
We further analyzed the estimation accuracy in terms of disease classification via an F1 
score, which is a measure of accuracy for classification algorithms. We classify a specific 
estimation into one of 16 possible combinations, where each of the four co-transporters is 
estimated to be in one of two states, healthy or diseased. The determination of diseased 
transporters was made via estimated density less than 0.8 times or greater than 1.2 times baseline, 
and healthy otherwise. Based on the estimation performance over several scenarios of all 
possible disease outcome combinations for the four independent co-transporters, we construct the 
confusion matrix, which is a matrix that presents predicted and true classifications via calculation 
of the precision and recall of the estimation, which are the measures of exactness and 
completeness of the estimation, respectively. The F1 score is the harmonic mean of precision and 
recall and quantifies the model performance in estimation. The F1 score is bound between 0 
(worst) and 1 (best) in terms of performance. For our simulation configurations, a plot of the 




from the results, much like the accuracy measures according to Fig. 5.3, the best performance of 
the estimation includes Cl&, HPOJ1, or HCO2&. This was predicted by the sensitivity analysis 
where all three concentrations showed varying sensitivity across each transporter density. We 
again note little to no improvement of disease classification with the addition of glucose or 
H1CO1. Similarly, from the sensitivity analysis, specifically for H1CO1, it was predicted that this 
solute would not help in estimation since its sensitivity to changes in transporter density is 
largely the same across all transporters. 
 
Fig. 5.4: F1 scores for each estimation configuration. Scores are averaged over all possible 
disease outcomes given four independent transporter densities, where a disease is classified 









The parameters estimated had already been preselected based on diseases we chose to 
study. In practice, an intuition is necessary for narrowing down potential diseased transporters 
and hence choosing the subsequent potentially injured parameters to estimate. Further, in the 
current estimation, invasive data within the proximal convoluted tubule is needed for estimation. 
It is possible to estimate proximal convoluted tubule variable values based on blood tests or urine 
samples, however, the model would need to be expanded, or the added assumption that no insults 
exist elsewhere in the kidney besides the potentially selected transporter parameters to be 
estimated would need to be included. 
5.4 Conclusion 
We have developed a lumped parameter model of the proximal tubule that has been 
validated and used in an analysis of co-transporter density estimation. Focusing on the 
NaF: HCO2&, KF: Cl&, NaF: HF, and Cl&: HCO2& co-transporters, we have shown how we apply a 
Bayesian estimation approach to estimate transporter density. Transporter density is directly 
related to the health of the kidneys since alterations in density can lead to irregular filtration. 
The Bayesian estimation approach (which leverages prior knowledge about parameter 
values) with our model was validated with real rat data to demonstrate the ability to estimate 
parameters corresponding to reabsorption flows within 10% of the true reabsorption flows. We 
then sought to investigate how estimation performance changes with varied input configurations, 
as determined by correct transporter density and corresponding reabsorption flows of fluid, 
sodium, glucose, and bicarbonate. We began with a sensitivity analysis that shed light on 
variables that are good candidates for estimation based on their sensitivity to transporter 




changes in Cl&: HCO2& transporter expression but highly sensitive to changes in NaF: HCO2& and 
NaF: HF transporter densities. 
Via several simulations with different estimation input configurations, we determined 
that overall estimation of transporter densities and subsequent reabsorption flows were improved 
with the inclusion of chloride or bicarbonate concentrations in addition to sodium and potassium 
concentrations. The percent density error of Cl&: HCO2& significantly decreased with the addition 
of voltage, HPOJ1, HCO2&, or pH. Formic acid, which demonstrated a more uniform sensitivity to 
co-transporter density, alterations also showed no improvement in estimation accuracy when 
included as an estimation input. This implies that measurements of formic acid will likely not 
improve estimation results. 
We have demonstrated, that with preselected co-transporters of interest, a parameter 
estimation is possible to determine which of these co-transporters are diseased and which are 
healthy. Further, we have determined, for the NaF: HCO2&, KF: Cl&, NaF: HF, and Cl&: HCO2& co-
transporters in the proximal tubule, which variable measurements are needed in order to 
successfully distinguish between healthy and diseased. Such an analysis on co-transporter 
interaction leads to a better understanding of how the proximal tubule and its subset of nodes 
operate. Further, the parameter estimation of co-transporter densities will eventually lead to more 





Chapter 6: Summary & Future Research 
 In this thesis, we have shown how physiological modeling can be used for 1) therapy 
testing via personalization and co-transporter therapy for diabetes, 2) disease classification of co-
transporter impairment, and 3) to develop a deeper understanding of renal physiology. The 
models developed demonstrate how a deeper understanding of renal physiology can be gleaned 
from a first-principle approach to modeling. Further, these models could be of great use to 
physicians as a tool to understand physiology, test potential therapies in a safe environment, and 
diagnosis and predict kidney diseases based on alterations to parameter values estimated using 
patient data. Two novel kidney models were presented, one from a rigorous, dynamic 
framework, and the other from a steady-state, whole body approach. 
 A steady-state human model was developed with the intention of investigating the 
relationship between mean arterial blood pressure and glomerular filtration rate (GFR). The 
model was validated against real patient data from the MIMIC database, a study involving 10 
mildly hypertensive and 10 severely hypertensive patients, and other models in the literature. It 
was shown that in severely hypertensive patients, the renal autoregulation and vasculature is 
affected. A sensitivity analysis varying these parameters was conducted to observe how GFR and 
sodium concentrations in the nephron are affected. We observed an inverse relationship between 
vascular resistance and GFR. We also noted a significant change in sodium concentration in the 
descending limb of Henle in response to changes of these parameters. 
 Next, the steady-state human model was used in a parameter estimation case study where, 
with prior knowledge of the patient disease, we estimated certain parameters for patients having 
glomerulonephritis. After parameter estimation we validated the physiological soundness and 




patient. This opens to the door to a model where inputs and/or parameters can be varied, as they 
would in a therapy, to determine the optimal GFR and UO necessary to achieve healthy kidney 
function. 
 In the development of the dynamic proximal tubule model, we first validated our model 
outputs versus those in the literature. From here, we investigated the effects of sodium-hydrogen 
transporter (NHE3) therapy in the case of healthy and diabetic kidneys. We saw that a reduction 
of NHE3 expression by 50% both in 1) baseline input and loading of salt and 2) glucose cases, 
partially restores fluid, sodium, ammonium, potassium, and chloride reabsorption to values that 
coincide with a healthy kidney under identical conditions. This is the first step in validation of 
this therapy and one that demonstrates the feasibility, via a model, of reducing hyperfiltration. 
 Finally, we used this model to investigate disease differentiation via parameter 
estimation. Using a Bayesian estimation approach, we first validated the model’s capability to 
differentiate between diseased transporters using real rat data. Then, using simulated data and a 
sensitivity analysis, we showed that overall estimation of transporter density and subsequent 
reabsorption flow was improved with the inclusion of chloride and bicarbonate concentrations in 
addition to sodium and chloride concentrations in the proximal tubule. 
 The work presented here prompts several areas where physiological modeling and 
healthcare can be further improved. Specifically, the work in each chapter can be extended in the 
following ways: 
 Chapter 2: The human, steady-state model presented in Chapter 2 can be extended into a 
dynamic system by including capacitance values for all hydraulic nodes, and time varying 
feedback. This extension would allow for the model to be utilized in experiments that require 




progressing glomerulonephritis) The model in its steady-state formulation can also be extended 
to differentiate between juxtamedullary and cortical nephrons. Further, the interplay between 
neighboring nephrons can also be modeled. 
 Chapter 3: The extension to the parameter estimation work done in this chapter include: 
estimation of unlabeled data, further validation with different populations, and improvements to 
the estimation algorithm developed and implemented. Rather than estimating parameters with 
prior knowledge of the patient disease, the model can be used to estimate potentially affected 
parameters without knowledge of the patient disease. This poses a more difficult problem since 
the parameters likely to change depending on the given disease vary significantly from disease to 
disease. Validation with different population sets will highlight needed areas of improvement in 
the model and estimation. Further, the estimation technique used, can be improved with increases 
to speed and accuracy. 
 Chapter 4: The model presented in Chapter 4 was a highly detailed, lumped dynamic 
proximal tubule model. This model can be used to investigate other potential therapies. Different 
diseased states can be replicated with the model, while then implementing therapies. The model 
can also be expanded to include the remaining parts of the nephron, the peritubular capillaries 
that surround the nephron, renal autoregulation, and nephron-to-nephron interaction developing a 
network of nephrons that represents the entire kidney. Acute renal diseases in the ICU would 
benefit from such an extension. 
 Chapter 5: In terms of parameter estimation using the model developed in Chapter 5, 
further research can include expansion to other diseases that affect the proximal tubule 
transporters. This would include estimations of more than four transporter parameters. The 




physiological effect where transporter parameter values can change in the presence of other 
damaged or hyperactive transporters. 
In general, the kidney models developed in this thesis can also be linked and connected to 
other physiological models. For instance, the previously developed heart and lung models 
described in [130]–[132], included the kidneys as a single node with a single resistance value. 
However, this node can be replaced with the human kidney modeled developed here. This would 
require further adjustments though as the kidneys are not an isolated organ only interacting with 
other organs via the input/output channels of the vasculature. Instead, the kidneys and lungs, in 
particular, maintain a delicate acid/base balance that must be properly represented. Also, the full 
effects of the renin-angiotensin mechanism on the body must also be included. 
With an ever more accurate model of the human body, the applications are limitless in 
healthcare. Such a model can aid in the deeper understanding on human physiology and in the 
workflow of physicians. Rather than just providing information on decisions related to one 
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